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Summary 
 
Gene transcription begins with the assembly of RNA polymerase (Pol) II and its initiation 
factors on promoter DNA. Pol II then initiates mRNA synthesis and exchanges initiation 
factors for elongation factors, which are required for chromatin passage and RNA processing. 
During transcription elongation nascent RNA is synthesized in a processive manner. Usually, 
Pol II transcription termination occurs within a region downstream of the polyadenylation 
(pA) site. In the course of the mRNA transcription cycle the phosphorylation pattern of the C-
terminal repeat domain (CTD) of the largest subunit of Pol II changes. The CTD in yeast 
consists of 26 heptapeptide repeats of the consensus sequence Y1-S2-P3-T4-S5-P6-S7. For 
selected genes it was shown that the CTD gets phosphorylated on Ser5 residues during 
initiation and early elongation by site-specific CTD kinases. In the course of transcription 
elongation Ser2 phosphorylation levels increase, leading to the recruitment of elongation and 
termination factors. Recently, it was shown that the CTD can also be phosphorylated on Ser7 
and Thr4 residues. However, it was not known whether transcription is carried out by a 
general Pol II transcription complex that functions at all active genes and whether the 
composition of this complex changes uniformly during the mRNA transcription cycle. 
Furthermore, it remained to be determined whether the CTD phosphorylation cycle occurs 
genome-wide, whether the CTD gets also phosphorylated on Tyr1 residues in proliferating 
yeast and, if so, whether this modification has a functional role. 
This work provides strong evidence for a general transcription complex that mediates 
transcription and mRNA processing at all Pol II genes in proliferating yeast. The genome-
wide occupancy profiles for Pol II, its phosphorylated forms, its elongation factors and 
components of the Pol II initiation and termination machinery were determined by an 
optimized ChIP-chip protocol. The data reveals that Pol II and its associated transcription 
factors co-localize at all active genes. The data also shows that the CTD phosphorylation 
cycle occurs genome-wide, and includes Tyr1-phosphorylation. The results obtained in this 
work converge on the following model. In the course of a uniform initiation-elongation 
transition Pol II exchanges initiation factors for elongation factors that is completed 150 
nucleotides (nt) downstream of the transcription start site. The resulting elongation complex is 
composed of all elongation factors and shows high levels of Ser7 and Ser5 phosphorylation 
on the CTD. In the course of transcription elongation Ser7 and Ser5 phosphorylation decrease 
and Tyr1 as well as Ser2 phosphorylation levels increase. Whereas Tyr1 phosphorylation 
starts to decrease ~180 nt upstream of the pA site, Ser2 phosphorylation levels remain high. 
Low occupancy levels of Tyr1 phosphorylation and high levels of Ser2 phosphorylation 
triggers the recruitment of termination factors such as Pcf11 and Rtt103 to transcribing Pol II, 
at a narrow region downstream of the pA site. Tyr1 and Ser2 phosphorylation thus play a role 
in the uniform two-step elongation-termination transition, where several elongation factors are 
exchanged for termination factors. Additionally, this work shows that apart from the Pol II 
CTD, nascent RNA and the C-terminal region of the highly conserved Pol II transcription 
elongation factor Spt5 contribute to the recruitment of factors at defined regions of genes 
during the mRNA transcription cycle. 
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I. General Introduction 
1. Gene transcription systems in eukaryotes 
Gene transcription represents one of the most fundamental processes of life. During gene 
transcription a nascent RNA molecule is synthesized from a DNA template by DNA 
dependent RNA polymerases (317). Gene transcription in a eukaryotic cell is carried out by 
four different DNA dependent RNA polymerases Pol I, Pol II, Pol III and the mitochondrial 
RNA polymerase (mitoPol) (11, 57).  
Pol I, Pol II and Pol III are multi-subunit nuclear enzymes that consist of 14 (589 kDa), 12 
(514 kDa) and 17 (693 kDa) subunits, respectively (57). Pol I synthesizes ribosomal RNA 
(rRNA) and its activity accounts for up to 60% of all nuclear transcription and rRNA accounts 
for up to 80% of all cellular RNA (141). Pol II produces messenger RNA (mRNA), small 
nuclear RNAs (snRNAs), small nucleolar RNAs (snoRNAs) (57), cryptic unstable transcripts 
(CUTs, (330)), stable unannotated transcripts (SUTs, (330)), Xrn1-sensitive unstable 
transcripts (XUTs, (307)) and other non-coding RNAs (16). Pol II transcribes up to 85% of 
the yeast genome (64, 219). Consistently, Pol II occupies large parts of the yeast genome 
(136, 287). Pol III synthesizes transfer RNAs (tRNAs), 5S rRNA, the spliceosomal U6 
snRNA and the signal recognition particle 7SL RNA (323). A recent transcriptome analysis 
extended the repertoire of transcripts that can be synthesized by Pol III, including several 
undescribed non-coding RNAs (227). 
Until recently it was thought that Pol I, Pol II and Pol III independently transcribe distinct sets 
of genes. However, a genome-wide study recently revealed that Pol II associates with several 
Pol III transcribed genes in human cells (256). In addition, factors such as TFIIS that are 
normally associated with Pol II transcription (45), are also detected at Pol III genes (96). Pol 
II transcription factors including Fcp1 (84), Spt5 (270) and the Paf1 complex (340) also play a 
role in Pol I transcription. All these observations argue for a substantial crosstalk between all 
three nuclear transcription systems.      
A typical eukaryotic cell contains a forth transcription system that is located in the 
mitochondrion (11). Transcription of the mitochondrial genome is carried out by a single-
subunit DNA dependent RNA polymerase, the mitoPol, that is distantly related to the RNA 
polymerase of the bacteriophage T7 (262). The mitoPol produces polycistronic transcripts that 
are subsequently cleaved to generate individual mRNAs, tRNAs and rRNAs (11). A recent 
analysis of the human mitochondrial transcriptome revealed unexpected complexity in the 
expression and processing of mitochondrial RNA, including the identification of several new 
transcripts (204).   
Recently, a fourth and fifth multi-subunit RNA polymerase, Pol IV and Pol V, was discovered 
in plants. Both enzymes are not essential for cell viability and play a role in small RNA-
mediated gene silencing pathways in plants (242).    
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2. Gene transcription by RNA polymerase (Pol) II 
2.1 The Pol II transcription cycle 
The Pol II transcription cycle can be divided into different main phases: initiation, elongation, 
termination and re-initiation (Figure 2) (114, 220). However, the transitions between the 
different phases are fluent. During initiation Pol II is recruited to the gene promoter and 
associates with the general transcription initiation factors TFIIA, TFIIB, TFIID, TFIIE, TFIIF 
and TFIIH to form the preinitiation complex (PIC) (114). A recent quantitative proteomics 
analysis of the yeast PIC revealed new subunits, including Sub1 and RPA, indicating that the 
PIC is a more complicated assembly than originally thought (278). At the promoter region Pol 
II also associates with the Mediator complex. The Mediator complex from yeast is 1.4 MDa 
multiprotein complex that comprises 25 subunits (33). The Mediator represents a coactivator 
complex that integrates signals from activators bound upstream of the core promoter into the 
initiation complex (313). 
After opening of the DNA duplex, transcription initiates and the nascent RNA molecule is 
synthesized (114). The early steps of RNA synthesis do not proceed smoothly. Early 
transcription up to the +8 position is accompanied by several rounds of abortive initiation, 
leading to the production of many tiny transcripts (196). Past this region stability in the 
synthesis of the transcript is obtained and Pol II leaves the promoter region, known as 
promoter clearance or promoter escape (196).  
Pol II enters into the early elongation state. During the last couple of years evidence for early 
transcription elongation has accumulated to be highly regulated (220). Genome-wide 
localization analyses of Pol II in higher eukaryotes, primarily in Drosophila and humans, 
revealed peak occupancy levels 20 to 50 nucleotides downstream of the TSS (257). Whether 
this occupancy peak corresponds to promoter proximally pausing as originally thought, or 
whether it is due to premature termination is currently under debate (288). With the help of 
dedicated factors, such as of P-TEFb kinase in higher eukaryotes, Pol II enters into the 
productive elongation phase where nascent RNA is synthesized by a stable elongation 
complex in a processive manner (220). Additional aspects of transcription elongation are 
described in section III 1.1. 
At the pA site the transcript is cleaved, but Pol II transcribes past this site (169). At a region 
downstream of the pA site Pol II falls off the DNA template and transcription terminates. 
Further aspects of transcription termination are detailed in section IV 1.3 and V 1.2. 
After transcription termination a new round of transcription can be started either by initiation 
or by re-initiation (169). Whereas initiation requires the recruitment of the complete 
transcription machinery to the gene promoter, re-initiation occurs via a different pathway 
(336). After the first round of transcription a subset of the transcription machinery, including 
TFIID, TFIIE, TFIIF and the Mediator complex, remain at the promoter, thus facilitating the 
following rounds of Pol II transcription (336). 
It is currently under debate whether the Pol II transcription cycle occurs on a linear DNA 
template where the promoter and terminator regions are physically separated, or whether it 
takes place on a DNA template where the promoter and terminator regions are close to each 
other via gene looping (115).    
  I. General Introduction 
 
   3 
2.2 Pol II transcription in a chromatin environment 
The simple model of the Pol II transcription cycle outlined above is helpful for getting an idea 
of how Pol II transcription may works, but it has ignored that transcription occurs in the 
context of chromatin in vivo. Therefore the model needs to be extended.   
Pol II transcription takes place on chromatin DNA. The primary structure of chromatin is the 
10 nm fiber that appears as “beads on a string” in electron micrographs (228, 258). The 
“beads” correspond to the nucleosome particles that are connected by linker DNA. The 
nucleosome consists of an octamer of histone proteins (two H2A-H2B dimers and one H3-H4 
tetramer) and 146 base pairs of DNA that is wrapped around the histone octamer (191). 
Genome-wide studies in various organisms have shown that genomes are usually densely 
occupied by nucleosomes (138, 175, 335). Nucleosomes limit the access to regulatory DNA 
sequences, such as gene promoters, and thus can inhibit transcription (258). Before the 
preinitiation complex can be assembled and Pol II transcription be initiated, promoter DNA 
has to be made accessible. Gene-specific activators and repressors work in conjunction with 
protein complexes that remodel and modify chromatin structure in a way that regulatory 
sequences become either accessible or inaccessible (310). Therefore regulation of chromatin 
structure is intrinsically tied to the regulation of Pol II transcription initiation.        
Furthermore, nucleosomes represent a physical barrier to transcribing Pol II. How Pol II 
overcomes this barrier is described in section III 1.1.   
 
 
2.3 The Pol II C-terminal repeat domain (CTD) 
2.3.1 Basic aspects 
Although Pol I, Pol II and Pol III are similar in structure and subunit configuration, Pol II 
possesses a unique tail-like CTD that is part of its largest subunit Rpb1 (57). The CTD is 
flexibly linked to the catalytic core, near the RNA exit pore of the enzyme (58). The CTD 
seems to be largely flexible, but it shows some tendency to form β-turns (201, 202). In an 
extended β-turn conformation the yeast CTD would be ~650 Å long and thus could in 
principle reach any location on the surface of Pol II, which is ~150 Å in diameter (Figure 1) 
(202). 
The CTD consists of heptapeptide repeats of the consensus sequence Y1-S2-P3-T4-S5-P6-S7. 
However, the sequence can vary considerably from this consensus motif (42, 291). The 
number of repeats depends on the organism and is 26 and 52 in yeast and humans, 
respectively (42).  In yeast at least eight repeats are required for cell viability (321). The 
functional unit of the CTD lies within heptapeptide pairs as was shown by site-directed 
mutagenesis in yeast (289). Mutagenesis approaches also revealed that residues Tyr1, Ser2 
and Ser5 are essential for cell viability in yeast, whereas residues Thr4 and Ser7 are not (290, 
321). 
The Pol II CTD primarily functions as a general platform to recruit proteins involved in 
transcription, mRNA processing and histone modifications (37). Direct protein-CTD 
interactions ensure that all of these processes occur cotranscriptionally (237). Post-
translational CTD modifications which change during the transcription cycle, allow that the 
various factors associate with the CTD at the appropriate location. 
  I. General Introduction 
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Figure 1: Elongating Pol II and the relative length of the CTD. The complete 12-subunit yeast Pol II is shown as a ribbon 
diagram. The subunits are indicated in different colors. DNA is in blue and nascent RNA is in red. The extended CTD and 
the Linker region are illustrated in black and green, respectively. The direction of transcribing Pol II is indicated by an arrow. 
(modified from  (202))     
 
 
 
2.3.2 The CTD phosphorylation cycle  
For selected genes it was shown that the Pol II CTD undergoes dynamic phosphorylation and 
dephosphorylation during the transcription cycle (Figure 2) (37). The early studies performed 
in yeast revealed Ser2 and Ser5 to be the main phosphorylation sites within the CTD 
heptapeptide repeat (162, 272). These studies also show that (i) Ser5 phosphorylation levels 
peak at the beginning of the transcribed region, (ii) Ser2 phosphorylation increases during 
transcription with maximum levels at the 3’ end of the transcribed region and (iii) that the 
CTD is dephosphorylated at the end of gene transcription (162, 272). These observations led 
to the idea that a CTD phosphorylation cycle exists that is associated with the transcription 
cycle (Figure 2) (162).  
Following the discovery of these CTD modifications, kinases and phosphatases were 
identified that target Ser5 or Ser2, respectively (161). At that time first proteins were 
described that preferentially interact with certain CTD phosphorylation patterns. For example, 
the yeast mRNA capping enzyme was shown to bind directly to Ser5 phosphorylated CTD 
thus explaining the early recruitment of this enzyme to actively transcribed genes (82). The 
discovery of several other proteins that directly bind to particular phosphorylated forms of the 
Pol II CTD (Pol II phospho-isoforms) led to the concept of the “CTD code” (36, 79). 
According to this concept the different CTD phospho-isoforms that predominate at each stage 
of the transcription cycle recruit a particular set of transcription, mRNA processing and 
histone-modifying factors (36, 79).          
Recently, Ser7 phosphorylation (157) and more recently Thr4 phosphorylation (128) of the 
CTD was described in yeast and mammals, and thus extending the CTD code. Whether the 
Pol II CTD phosphorylation cycle is true on a genome-wide level, whether other types of 
CTD phosphorylations occur and how Ser7 phosphorylation levels change during the 
transcription cycle are only some of the questions addressed in this work. 
Apart from posphorylation other covalent CTD modifications were described, including 
glycosylation (147), and more recently methylation (279) and acetylation (Melanie Ott, 
University of California, San Francisco, personal communication).  
Additional details of CTD modifications and of how the CTD code is read are described in 
section III 1.2 and IV 1.1-1.2.   
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Figure 2: Coordination of the Pol II transcription cycle by CTD phosphorylation. The main stages of the 
Pol II transcription cycle are indicated by a black circle. The TSS and the pA site are also shown. Regions of the 
transcription cycle where the Pol II CTD is phosphorylated on Ser5 and Ser2 residues are indicated in red and 
blue, respectively. The stronger the color saturation, the stronger is the expected CTD phosphorylation level. The 
region where the Pol II CTD is thought to be unphosphorylated is illustrated as a dashed gray line. A selection of 
factors that were shown to interact with particular CTD phosphorylation patterns or with unphosphorylated CTD 
(Mediator complex) is given. Whereas the guanylyltransferase subunit of the mRNA capping enzyme Ceg1, the 
histone methyltransferase Set1 and the termination factor Nrd1 directly interact with Ser5-phosphorylated CTD, 
the termination factors Pcf11 and Rtt103 as well as the Pol II elongation factor Spt6 preferentially bind to Ser2-
phosphorylated CTD. Please note that although the Ser5-phosphorylation is predominantly observed during 
initiation and early elongation, low levels also occur throughout elongation and past the pA site. This results in 
an extended region in which Ser5- and Ser2-phosphorylation overlap. The peptidyprolyl-cis/trans-isomerase 
Pin1 and the histone methyltransferase Set2 preferentially interact with CTD that is phosphorylated on Ser5 and 
Ser2 and thus can “read” the doubly phosphorylated CTD.  
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3 Towards systems biology 
3.1 A new era of biological research has started 
The availability of DNA sequences of complete genomes as well as technological advances 
enables researches for the first time to address biological questions at a global and systems 
level. Until the mid 1990s almost all biological research was focused on the detailed study of 
individual components, such as single genes and particular proteins (281). This approach 
changed in the mid 1990s by the development of several large-scale studies that for the first 
time allowed the analyses of a large number of components systematically and simultaneously 
(281). The majority of these projects were pioneered in Saccharomyces cerevisiae (S. 
cerevisiae) since its genome was one of the first sequenced and due to its facile genetics 
(172). A selection of early and state-of-the-art systems-wide approaches is given in Table 1 
and 2.  
 
Table 1: Systems-wide approaches used in yeast and other organisms. The method, its goal as well as the 
corresponding reference(s) are given. Please see also Table 2 for complementary genome-wide techniques.  
Method and goal Reference(s) 
Gene expression analysis with DNA microarrays (steady state mRNA levels) (71, 177) 
Systematic gene knockouts  (99, 327) 
Subcellular protein localization (129) 
Protein profiling by mass spectrometry (protein levels) (65, 241, 316) 
Protein-protein interactions by coupling affinity purification with mass spectrometry (93, 126, 132, 
166, 306, 334) 
Genetic interactions (53, 232, 304, 
305) 
Mapping of post-translational modifications by mass spectrometry (47, 85, 95, 106, 
173, 250) 
Genomic Run-On (GRO) to measure rates of mRNA synthesis (91) 
Transcriptome profiling with DNA microarrays and high-throughput sequencing (64, 76, 219, 
231) 
Ribosome profiling (131) 
Dynamic transcriptome analysis (DTA) to measure rates of mRNA synthesis and decay (205) 
 
 
 
3.2 ChIP-chip: a powerful systems-wide approach 
3.2.1 A short history 
Chromatin immunoprecipitation (ChIP) followed by DNA microarray (chip) hybridization is 
a very powerful technique to determine DNA binding sites of a protein of interest genome-
wide (116). The technique was developed in the laboratories of Patrick O. Brown (Stanford 
University, Stanford, California), Michael Snyder (Yale University, New Haven; now: 
Stanford University) and Richard A. Young (Whitehead Institute for Biomedical Research, 
Cambridge, Massachusetts), and the protocols were published in the years 2000 and 2001 
(134, 260). The technique was originally developed for S. cerevisiae and was made possible 
by several breakthroughs (Figure 3). 
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Figure 3: Towards ChIP-chip in yeast. The different milestones on the way to setting up a ChIP-chip protocol as well as a 
timeline are indicated. 
  
 
One major breakthrough was the availability of the DNA sequence of the yeast genome in 
1996 (51). The DNA sequence information together with new developments in parallel 
chemical synthesis led to the fabrication of high-density microarrays (64, 87, 269). The first 
microarray covering a complete eukaryotic genome (S. cerevisiae) appeared in 1997 (177). 
Apart from the developments leading to DNA microarrays, another milestone was the 
establishment of a reproducible ChIP protocol. The first ChIP protocols appeared in 1984 and 
1985 and were used to investigate the DNA binding of bacterial RNA polymerase 
(Escherichia coli) and of RNA polymerase II of Drosophila melanogaster in vivo, 
respectively (101, 102). In the early ChIP protocol, protein-DNA crosslinking was performed 
with UV light. However, UV light was replaced by formaldehyde as a fixative soon. 
Formaldehyde is cheap, simple to apply, penetrates biological samples very rapidly, the 
crosslinks are heat-reversible and in contrast to UV fixation, formaldehyde crosslinking can 
be used to localize chromatin associated proteins that do not directly bind to DNA (282). In 
the following years the ChIP protocol was improved and adapted to other model organisms 
(67). In 1993 the first ChIP study was performed in yeast, investigating the relationship 
between transcriptional silencing and histone acetylation levels (35). The development of a 
reproducible ChIP protocol and of microarray technology, together with other experimental 
and technological advances, such as whole genome amplification methods, finally resulted in 
ChIP-chip. Although the ChIP-chip protocol was originally applied to investigate protein-
DNA interactions in yeast, it is now adapted to many organisms, ranging from bacteria to 
humans (116).          
 
 
3.2.2 Key steps of the technique 
From an experimental point of view ChIP-chip consists of two main parts, chromatin 
immunoprecipitation (ChIP) and microarray (chip) hybridization (including the preparatory 
steps). Whereas the first part of the protocol necessitates classical biochemical approaches 
that can vary considerably among different laboratories, the second part is rather standardized 
and includes several ready-to-use kits, depending on the microarray platform. 
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According to a standard ChIP protocol formaldehyde is used to generate protein-DNA, 
protein-RNA and protein-protein crosslinks between molecules that are in close proximity in 
vivo (9). The chromatin is prepared and fragmented usually by sonication. The average DNA 
fragment length is in the range of 200 to 500 base pairs (bp) and is important for the spatial 
resolution of DNA binding events. Parts of the chromatin sample are kept as “input” sample, 
the remaining sample is immunoprecipitated by an antibody either directed against the protein 
of interest or a particular modification (such as acetylation, methylation and phosphorylation) 
or against a certain epitope-tag (“IP” sample). This leads to a selective enrichment of DNA 
sequences that directly or indirectly (via other proteins or RNA) crosslink with the protein of 
interest. After the reversal of crosslinks the amount of a particular DNA sequence in the “IP” 
and “input” samples are determined by quantitative PCR (qPCR). 
A single ChIP experiment does not provide enough DNA for labeling and hybridization to an 
array and thus has to be amplified. Several protocols are available that allow linear DNA 
amplification in a standardized manner (226). After amplification the DNA is labeled, for 
instance by incorporation of a biotinylated nucleotide analog and then loaded onto the array.  
Different array platforms are currently available including the single-color array platform of 
Affymetrix (Santa Clara, USA) and the two-color array systems of Agilent (Palo Alto, USA) 
and NimbleGen (Madison, USA). Whereas in case of single-color arrays the IP and input 
sample is hybridized on different arrays, the two-color array systems permit the hybridization 
of the differently labeled IP and input sample on the same array. However, experiments with 
two-color arrays necessitate dye-swap replications, in which each hybridization is performed 
twice, with the dye assignment reversed in the second hybridization in order to reduce 
systematic color biases (136, 332).       
For ChIP-chip analyses high-density tiling arrays are usually used that cover the complete 
genome. For model organisms with smaller genome sizes such as yeast (12 Mb) the whole 
genome is covered on a single array. For example, the S. cerevisiae Tiling 1.0R Array of 
Affymetrix comprises over 3.2 million 25-mer probes tiled at an average resolution of 5 bp 
across the yeast genome. However, for organisms with large genomes such as humans (3,300 
Mb) the whole genome is covered by several arrays (seven in case of Human Tiling 2.0R 
Array, Affymetrix). A new generation of arrays contains isothermal probes, meaning probes 
that are adjusted in length (45- to 75-mer, NimbleGen) to keep the same melting temperature 
across the entire probe set. This new development should lead to more uniform results. 
 
 
 
3.2.3 Strengths and limitations of the technique 
ChIP-chip is a very powerful technique to investigate protein-genome interactions in vivo. 
Standard ChIP-chip protocols are available for various organisms, ranging from bacteria to 
humans. Protocols are convenient, fast and can be automatized. In addition, ChIP-chip yields 
highly reproducible and high-resolution data. Until now, the method led to many 
groundbreaking studies that changed our view of how the expression of genes is regulated. 
For example, ChIP-chip led to the dissection of transcription regulatory networks (117, 179), 
revealed the importance of post-initiation gene regulatory mechanisms (196, 217, 339) and 
also set the ground for a global understanding of the histone code hypothesis (110, 120, 244).       
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Despite its enormous power ChIP-chip is also associated with some limitations. Firstly, 
standard ChIP-chip experiments provide no information of how the protein associates with 
chromatin. Questions like “what other proteins and modifications are required for binding of a 
protein of interest?” cannot be addressed directly by the standard procedure. Secondly, ChIP-
chip cannot distinguish whether a protein of interest binds DNA directly or associates with 
DNA indirectly via protein-protein or protein-RNA interactions. Thirdly, it does not provide 
any information about the function of the protein of interest bound to particular genomic 
regions. Fourthly, the crosslinking efficiency of formaldehyde can vary between different 
proteins (283). Fifthly, a ChIP-grade antibody is not available against all proteins of interest. 
The specificity and affinity of the antibody as well as the epitope accessibility are other 
important issues in this context (78, 116). Sixthly, the final spatial resolution of DNA binding 
events of a certain protein of interest is limited. The resolution mainly depends on the average 
chromatin fragment size that is reached by sonication before the IP is performed. Despite 
extensive optimization trials, DNA average fragment sizes lower than 200 bp could not be 
realized (83). Seventhly, ChIP-chip consists of several experimental modules that usually 
include various kits and DNA microarrays, and thus is a quite expensive technique. Finally, 
ChIP-chip leads to huge data sets whose analyses require advanced bioinformatics expertise 
and tools.    
 
 
3.2.4 New innovative approaches 
Since the availability of the protocol more than a decade ago, ChIP-chip was the method of 
choice to study protein-genome interactions for several years. In November 2011 the literature 
database Pubmed listed 597 publications that contain the term “ChIP-chip” either in their title 
or abstract, or both. However, the literature search also shows that the numbers of 
publications that contain results of ChIP-chip studies are currently on the decline (Figure 4). 
The reason for that trend is that new innovative approaches are gaining ground. An overview 
of these new powerful techniques is given in Table 2. Among these alternative approaches, 
ChIP-seq turned out to be very powerful. The technique was developed in the laboratories of 
Michael Snyder (Yale University, New Haven, now: Stanford University) and of Steven Jones 
(British Columbia Cancer Agency Genome Science Center, Vancouver), and the protocol was 
published in 2007 (263). Although the first part of the protocol (ChIP) is very similar to ChIP-
chip, the second part is quite different. Instead of hybridizing the amplified 
immunoprecipitated DNA to microarrays, the DNA is sequenced. This development was 
made possible by next-generation high-throughput sequencing technologies that allow 
massively parallel sequencing (324). Comparisons of the data obtained by either ChIP-chip or 
ChIP-seq have revealed high correlations (125). However, comparisons also have shown that 
ChIP-seq generally produces occupancy profiles with higher spatial resolution, dynamic range 
and genomic coverage (125). Another advantage of ChIP-seq is that its applicability is not 
limited by the availability of an organism-specific microarray and thus can be used to analyze 
virtually any species. These advantages together with the fact that the costs for sequencing are 
declining (223) have led to the rapid adaptation of this technique (Figure 4). Since 2010, 
ChIP-seq led to more publications than ChIP-chip (Figure 4). 
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Apart from ChIP-seq other innovative approaches became available during the last years (or 
will become available soon) which allow the systems-wide analysis of protein-DNA and 
protein-nascent RNA interactions as well as long-range chromatin interactions (Table 2). A 
spectacular improvement of the ChIP-seq method, called ChIP-exo, will become available 
soon. The protocol was developed in the laboratory of Franklin Pugh (Pennsylvania State 
University, Pennsylvania) and includes exonuclease digestion of DNA that is not directly 
contacted by the protein of interest (107). This increases the spatial resolution dramatically 
and also improves the signal-to-noise ratio and thus the sensitivity of the former ChIP-seq 
approach. This method will allow the mapping of transcription factor binding site at single 
nucleotide resolution.  
Another powerful technique that allows the mapping of protein-nascent RNA interactions at 
single nucleotide resolution is NET-seq. This approach was developed in the laboratory of 
Jonathan Weissman (University of California, San Franscisco) and the protocol was published 
earlier this year (49). NET-seq is based on deep sequencing of 3’ ends of nascent transcripts 
that are associated with the protein of interest. The technique was used to analyze Pol II 
transcription in yeast and provided strong evidence for pervasive polymerase pausing 
throughout the body of transcripts (49).  
A very innovative approach that allows the analysis of chromatin interactions across an entire 
genome is Hi-C. This approach was developed in the laboratory of Job Dekker (University of 
Massachusetts Medical School, Worcester) and published in 2009 (183). This method couples 
proximity-based ligation and massively parallel sequencing, and was used to investigate the 
three-dimensional architecture of the human genome (183). Other state-of-the-art genome-
wide approaches are listed in Table 2. 
 
 
 
 
 
 
 
Figure 4: ChIP-seq is gaining 
ground. The absolute numbers of 
publications containing the term “ChIP-
chip” (gray bars) or “ChIP-seq” (violet 
bars) either in the title or abstract of 
publications listed on Pubmed 
(http://www.ncbi.nlm.nih.gov/pubmed) 
in November 2011. Although first 
ChIP-chip studies were already 
published in 2000 and 2001, the term 
“ChIP-chip” was neither part of the title 
nor of the abstract of these publications 
and thus were not considered in this 
analysis. 
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Table 2: State-of-the-art genomic tools to analyze protein-DNA, protein-nascent RNA and long-range 
chromatin interactions. This toolbox can be used to dissect Pol II gene transcription from a genome-wide 
perspective. The name of the method, its main goal and the reference are given. Please see also Table 1. 
Method Goal Reference 
4C-seq Genome-wide interactions of one selected locus (68, 97, 329) 
ChIP-exo Mapping of protein-genome interactions at single-nucleotide 
resolution  
Not yet published 
(Pugh laboratory) 
ChIP-seq High-resolution mapping of protein-genome interactions (263) 
Competition-ChIP Measurement of transcription factor binding dynamics Not yet published 
(Lieb laboratory) 
DamID Mapping of protein-genome interactions  (66, 229) 
DNase-ChIP Mapping of nucleosome-depleted DNA regions (59) 
DNase-seq High-resolution mapping of nucleosome-depleted regions (284, 285) 
FAIRE-seq Alternative to DNase-seq to map open chromatin regions (92, 104) 
GRO-seq Mapping of transcriptionally engaged Pol II (56) 
Hi-C Mapping of genome-wide chromatin interactions (183) 
NET-seq Protein-nascent transcriptome interactions at single-
nucleotide resolution 
(49) 
Nucleosome mapping Genome-wide mapping of nucleosome binding sites (27, 138, 180, 
335) 
PAR-CLIP High-resolution mapping of protein-transcriptome 
interactions 
(113) 
Permanganate genomic 
footprinting 
Mapping of transcriptionally engaged Pol II in Drosophila 
and vertebrate cells 
(100) 
RIP-seq Mapping of protein-transcriptome interactions (342) 
Sono-seq Mapping of open chromatin regions (12) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  II. Materials and General methods 
 
   12 
 
II. Materials and General methods 
 
1. Materials 
1.1 Bacterial and yeast strains 
 
Table 3: E. coli strains 
Strain Description Source 
XL-1 Blue Rec1A; endA1; gyrA96; thi-1; hsdR17; supE44; relA1; lac[F’ 
proAB lacIqZ∆M15Tn10(Tetr)] 
Stratagene 
BL21-CodonPlus 
(DE3)RIL 
B; F-; ompT; hasdS(rB, mB); dcm+; Tetr; gal λ(DE3); endA; 
The [argU, ileY, leuW, Camr] 
Stratagene 
 
 
 
Table 4: S. cerevisiae strains 
Strain Description Source 
BY4741  
(wild-type) 
MATa; his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 Open Biosystems 
Wild-type-pRS316 BY4741; pRS316 [URA3] This work 
S288C MATα; SUC2 gal2 mal mel flo1 flo8-1 hap1 ho bio1 bio6 Euroscarf 
Bur1-TAP BY4741; BUR1::TAP::HIS3MX6 Open Biosystems 
Cet1-TAP BY4741; CET1::TAP::HIS3MX6 Open Biosystems 
Clp1-TAP BY4741; CLP1::TAP::HIS3MX6 Open Biosystems 
Ctk1-TAP BY4741; CTK1::TAP::HIS3MX6 Open Biosystems 
Elf1-TAP BY4741; ELF1::TAP::HIS3MX6 Open Biosystems 
Hrp1-TAP BY4741; HRP1::TAP::HIS3MX6 Open Biosystems 
Kin28-TAP BY4741; KIN28::TAP::HIS3MX6 Open Biosystems 
Paf1-TAP BY4741; PAF1::TAP::HIS3MX6 Open Biosystems 
Pap1-TAP BY4741; PAP1::TAP::HIS3MX6 Open Biosystems 
Pcf11-TAP BY4741; PCF11::TAP::HIS3MX6 Open Biosystems 
Pcf11-TAP Ssu72-
degron 
BY4741; PCF11::TAP::HIS3MX6; 
SSU72promoter∆::CUP1promoter::degron::kanMX; 
This work 
Rna14-TAP BY4741; RNA14::TAP::HIS3MX6 Open Biosystems 
Rna15-TAP BY4741; RNA15::TAP::HIS3MX6 Open Biosystems 
Rpb3-TAP BY4741; RPB3::TAP::HIS3MX6 Open Biosystems 
Spn1-TAP BY4741; SPN1::TAP::HIS3MX6 Open Biosystems 
Spn1-TAP Elf1-3HA BY4741; SPN1::TAP::HIS3MX6; ELF1::3HA::KANMX6 This work 
Spt4-TAP BY4741; SPT4::TAP::HIS3MX6 Open Biosystems 
Spt5-TAP BY4741; SPT5::TAP::HIS3MX6 Open Biosystems 
Spt6-TAP BY4741; SPT6::TAP::HIS3MX6 Open Biosystems 
Spt6∆C-TAP FY119 (isogenic to S288C); MATα; his4-912 lys2-128 leu2-1 
ura3-52 trp1-63 
Stefan Dengl (70) 
Spt16-TAP BY4741; SPT16::TAP::HIS3MX6 Open Biosystems 
TFIIB-TAP BY4741; SUA7::TAP::HIS3MX6 Open Biosystems 
TFIIS C-TAP BY4741; DST1::TAP::HIS3MX6 Open Biosystems 
TFIIS N-TAP BY4741; DST1::TAP; N-terminal TAP-tag This work 
Tfg1-TAP BY4741; TFG1::TAP::HIS3MX6 Open Biosystems 
Spt5 ∆CTR BY4741; SPT5Δ931-1063::KANMX6 This work 
Spt5 ∆CTR-pRS316 BY4741; SPT5Δ931-1063::KANMX6; pRS316 [URA3] This work 
Bur1-TAP Spt5 ∆CTR BY4741; BUR1::TAP::HIS3MX6; SPT5Δ931-1063::KANMX6 This work 
Cet1-TAP Spt5 ∆CTR BY4741; CET1::TAP::HIS3MX6; SPT5Δ931-1063::KANMX6 This work 
Clp1-TAP Spt5 ∆CTR BY4741; CLP1::TAP::HIS3MX6; SPT5Δ931-1063::KANMX6 This work 
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Ctk1-TAP Spt5 ∆CTR BY4741; CTK1::TAP::HIS3MX6; SPT5Δ931-1063::KANMX6 This work 
Elf1-TAP Spt5 ∆CTR BY4741; ELF1::TAP::HIS3MX6; SPT5Δ931-1063::KANMX6 This work 
Hrp1-TAP Spt5 ∆CTR BY4741; HRP1::TAP::HIS3MX6; SPT5Δ931-1063::KANMX6 This work 
Paf1-TAP Spt5 ∆CTR BY4741; PAF1::TAP::HIS3MX6; SPT5Δ931-1063::KANMX6 This work 
Pap1-TAP Spt5 ∆CTR BY4741; PAP1::TAP::HIS3MX6; SPT5Δ931-1063::KANMX6 This work 
Pcf11-TAP Spt5 
∆CTR 
BY4741; PCF11::TAP::HIS3MX6; SPT5Δ931-1063::KANMX6 This work 
Rna14-TAP Spt5 
∆CTR 
BY4741; RNA14::TAP::HIS3MX6; SPT5Δ931-1063::KANMX6 This work 
Rna15-TAP Spt5 
∆CTR 
BY4741; RNA15::TAP::HIS3MX6; SPT5Δ931-1063::KANMX6 This work 
Rpb3-TAP Spt5 ∆CTR BY4741; RPB3::TAP::HIS3MX6; SPT5Δ931-1063::KANMX6 This work 
Spn1-TAP Spt5 ∆CTR BY4741; SPN1::TAP::HIS3MX6; SPT5Δ931-1063::KANMX6 This work 
Spt4-TAP Spt5 ∆CTR BY4741; SPT4::TAP::HIS3MX6; SPT5Δ931-1063::KANMX6 This work 
Spt6-TAP Spt5 ∆CTR BY4741; SPT6::TAP::HIS3MX6; SPT5Δ931-1063::KANMX6 This work 
Spt16-TAP Spt5 
∆CTR 
BY4741; SPT16::TAP::HIS3MX6; SPT5Δ931-1063::KANMX6 This work 
 
 
 
1.2 Plasmids and primers 
Table 5: Plasmids 
Name Description Source 
pET15b T7; His-Tag 3’ of MCS; pBR322 origin; Ampr; Novagen 
pET28b(+) T7; T7-Tag; His-Tag 5’ and 3’ of MCS; pBR322 origin; 
f1 origin; Kanr; 
Novagen 
pGEX-3T GST-Tag; pBR322 origin; Ampr; GE Healthcare 
pGEX-4T-1 GST-Tag; pBR322 origin; Ampr;  GE Healthcare 
CIp10 Kl URA3; ColEI origin; Ampr; Heidi Feldmann; 
(215) 
pBS1539 Kl URA3; Ampr; TEV cleavage site; Euroscarf 
pFA6a-3HA-kanMX6 3HA::KanMX6; pBR322 origin; Ampr; Heidi Feldmann 
(190) 
pKL187 URA3; kanMX; CUP1 promoter; ts degron tag;  Euroscarf 
pRS316 URA3; CEN6; ARH4; pBR322 origin; f1 origin; Ampr;  ATCC; (277) 
 
 
 
Table 6: Primers used in this work 
Name DNA sequence Project 
109_Degron_Fw GTGTAAGGAATTCACTAGTTCATAAGCATATATACTTGTTT
TAATATATTATTAAGGCGCGCCAGATCTG 
Ssu72-degron 
103_Degron_Rev GATGCACAAACTGTGCAAAACTTCAAGTTTGAATTGCGAT
GACTAGGCATGGCACCCGCTCCAGCGCCTG 
Ssu72-degron 
110_ControlA_Fw ACTAGAGGGAGACTACGTAG 
 
Ssu72-degron 
104_ControlB_Rev TTCCAATATAGCTTTGCTAC 
 
Ssu72-degron 
111_ControlC_Fw CTGGTGCAGGCGCTGGAGCG 
 
Ssu72-degron 
105_ControlD_Rev CGCTCCAGCGCCTGCACCAG 
 
Ssu72-degron 
OligodT-anchor GACTCGAGTCGACATCGATTTTTTTTTTTTTTTTT 3’RACE 
Upstream primer 1 TATGAATTCTTCTGTTTTGGGTTTGGA 3’RACE 
Anchor primer 2 GACTCGAGTCGACATCGA 3’RACE 
Sequencing primer TAATACGACTCACTATAGGG For inserts, 
Table 4 (continued) 
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1 (forward) pET28b(+) 
Sequencing primer 
2 (reverse) 
GGGTTATGCTAGTTATTGC For inserts 
pET28b(+) 
RTh1 CTATTATTGATGCTTTGAAGACCTCCAG Readthrough 
assay 
RTh2 TGCCCAAAATAATAGACATACCCCATAA Readthrough 
assay 
RTh3 CAAGAAAGAAAAAGTACCATCCAGAG Readthrough 
assay 
RTh4 TTCATGTAAGTGTGTATCTTGAGTGTC Readthrough 
assay 
RTh5 CGTTCATGTAAGTGTGTATCTTGAGTG Readthrough 
assay 
RTh6 TACGTTCATGTAAGTGTGTATCTTGAG Readthrough 
assay 
66_Elf1-3HA_Fw 
 
GGCCAAGTTAAAAGAGGCAGAGGCGCCTTGGTAGATAGTG
ACGATGAATACCCATACGATGTTCCTGAC 
Spn1-TAP Elf1-
3HA 
68_Elf1-3HA_Rev 
 
AAATATATATGACCTAAGTAAATATGGTTTTTTCTCAGGAC
CGGATTATGGATGGCGGCGTTAGTATCG 
Spn1-TAP Elf1-
3HA 
68_Elf1-
3HA_control_Fw 
AGTGACACAGATGATGGTGAC 
 
Spn1-TAP Elf1-
3HA 
66_Elf1-
3HA_control_Rev 
ATTCGATACTGATGACGATG 
 
Spn1-TAP Elf1-
3HA 
DST1_URA_Fw TCAAGCAGCAGAACATTCACAGTGTAGTCAGTCCGCATAA
GAGCATTCATCATGGGCCGACTTGGCCAAGCCTAG 
TFIIS N-TAP 
DST1_URA_Rev CATTACTTTTGTTCTTTTCTAGATTCTTAACATGTACCAGTA
CTTCCTTACTATCTCTAGAAGGACCACCTTTGATTG 
TFIIS N-TAP 
DST1_TAP_Fw TCAAGCAGCAGAACATTCACAGTGTAGTCAGTCCGCATAA
GAGCATTCATCATGGGTCGACGGATCCCCGGGTT 
TFIIS N-TAP 
DST1_TAP_Rev CATTACTTTTGTTCTTTTCTAGATTCTTAACATGTACCAGTA
CTTCCTTACTATCCTGATGATTCGCGTCTACTTTCGGCG 
TFIIS N-TAP 
DST1_cont_Fw TAGCCTTTCTTGTATATCCCTC TFIIS N-TAP 
DST1_cont_Rev ATTCACGGACTCACCTACAG TFIIS N-TAP 
Spt5∆CTR_Fw AGCTGTAAATGCGCATGGAGGCTCAGGTGGTGGCGGTGTC
TAACGGATCCCCGGGTTAATTAAG 
Spt5 ∆CTR 
Spt5∆CTR_Rev TTGATTTCTTCTTGGGTGATATTGGTTCTCCTTTTGGTGACG
CATAGGCCACTAGTGGATC 
Spt5 ∆CTR 
∆CTR_cont1_Fw ACAACCGTGAGGGAGGTGAAG Spt5 ∆CTR 
∆CTR_cont2_Fw GTGAGGGAGGTGAAGGTA Spt5 ∆CTR 
∆CTR_cont3_Fw ATCATGCGTCAATCGTATGT Spt5 ∆CTR 
∆CTR_cont1_Rev TGCTCGCAGGTCTGCAGCGAG Spt5 ∆CTR 
∆CTR_cont2_Rev AATTCAACGCGTCTGTGA Spt5 ∆CTR 
∆CTR_cont3_Rev GGAAAGTGGCAGAAAGAAAG Spt5 ∆CTR 
TFIIB_Fw TGAAGGGGAAATCAATGGAG Strain Validation 
Openbio_Rev AACCCGGGGATCCGTCGACC Strain Validation 
Cet1_Fw CCCAGACAAGAGATTCCGTC Strain Validation 
Spt4_Fw TACCAGCTGAGGTTGTGGAG Strain Validation 
Paf1_Fw CAGATGCTGTTCATACTG Strain Validation 
Spt6_Fw TATCCAAGTGTTATCCAG Strain Validation 
Nrd1_Fw AAGACATGAGGCCGAAAATG Strain Validation 
Pap1_Fw ATACAAGGGGCAGTGACGAG Strain Validation 
Clp1_Fw AGGATTCGCTTTGATTACAG Strain Validation 
Hrp1_Fw TACAATCACCGTAGTGGTGG Strain Validation 
Rpb3_Fw CTCATGGGCCGTAATATTGG Strain Validation 
Kin28_Fw TGCTTATGACTTTGAGGGGC Strain Validation 
Tfg1_Fw ATCGCCCGTTAAAAAGGAAG Strain Validation 
Bur1_Fw GCTAAAACTGCGATTCCACC Strain Validation 
Spn1_Fw TTACCTGATGGGTCTCTGCC Strain Validation 
Pcf11_Fw AGCATTTGGACTGGCATTTC Strain Validation 
Spt16_Fw AGAGATTTGGGCTTCCAAGG Strain Validation 
Rtt103_Fw AACTGCAAAGCACACTGGAC Strain Validation 
Table 6 (continued) 
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Rna14_Fw AGGATTCGCAGATCAAAACC Strain Validation 
Rna15_Fw ATCGGGAGTTTCACAACAGC Strain Validation 
Ctk1_Fw TTGTGGCTGCCTCCTGGTGG Strain Validation 
Elf1_Fw TGTGGGCAGTCGTTCCAAAC Strain Validation 
 
All DNA primers were synthesized by Thermo Fisher Scientific GmbH Ulm, Germany. 
 
 
 
Table 7: qPCR primers used in this work 
Name DNA sequence 
ADH1_5'_Fw TTTCCTTCCTTCATTCACGCACA 
ADH1_5'_Rev TCAAGTAACTGGAAGGAAGGCCGTA 
ADH1_TSS_Fw TCCTTGTTTCTTTTTCTGCAC 
ADH1_TSS_Rev GAGATAGTTGATTGTATGCTTGG 
ADH1_ORF_Fw AGCCGCTCACATTCCTCAAG 
ADH1_ORF_Rev ACGGTGATACCAGCACACAAGA 
ADH1_pA_Fw AAAACGAAAATTCTTATTCTTGA 
ADH1_pA_Rev TACCTGAGAAAGCAACCTGA 
ADH1_3'_Fw CCTGTAGGTCAGGTTGCTTT 
ADH1_3'_Rev CGGTAGAGGTGTGGTCAA 
ACT1_5'_Fw AAACCAAACTCGCCTCTCT 
ACT1_5'_Rev GGAAGGAAAGGATCAAACAA 
ACT1_ORF_Fw TCAGAGCCCCAGAAGCTTTG 
ACT1_ORF_Rev TTGGTCAATACCGGCAGATTC 
ACT1_3'_Fw TTTATCCATTGGACCGTGTA 
ACT1_3'_Rev GGGCAATTGCATAAACCTAT 
ILV5_Prom_Fw ACCCAGTATTTTCCCTTTCC 
ILV5_Prom_Rev TTGTCTATATGTTTTTGTCTTGC 
ILV5_ORF_Fw CTATCAAGCCATTGTTGACC 
ILV5_ORF_Rev CTTGAAGACTGGGGAGAAAC 
ILV5_pA_Fw CCGAAACGCGAATAAATAAT 
ILV5_pA_Rev GTCCCGATGAGGACTTATACA 
PDC1_Prom_Fw TGCCCCTTTTTCTGTTAGAC 
PDC1_Prom_Rev AATAAGGTGGTGTTGAACGA 
PDC1_ORF_Fw CAAGACCAAGAACATTGTCG 
PDC1_ORF_Rev AAAGTGGCGTTTCTGATCTT 
PDC1_pA_Fw TACCATGGAAAGACCAGACA 
PDC1_pA_Rev CCCAGACTTAAGCCTAACCA 
PMA1_5'_Fw TGACTGATACATCATCCTCTT 
PMA1_5'_Rev TTGGCTGATGAGCTGAAACAGAA 
PMA1_ORF_Fw AAATCTTGGGTGTTATGCCATGT 
PMA1_ORF_Rev CCAAGTGTCTAGCTTCGCTAACAG  
PMA1_3'_Fw GGTTTCTCTGGATGGTACTTT 
PMA1_3'_Rev TGACTTGTGTGCGTTTCATA 
TEF1_Prom_Fw ACCACTTCAAAACACCCAAG 
TEF1_Prom_Rev ACGACACCCTAGAGGAAGAA 
TEF1_ORF_Fw TTGATTATTGCTGGTGGTGT 
TEF1_ORF_Rev TGTTCTCTGGTTTGACCATC 
TEF1_pA_Fw ATTTATCCCAGTCCGATTCA 
TEF1_pA_Rev CTGATGTGATTTCGACCATT 
Control(YER)_Fw TGCGTACAAAAAGTGTCAAGAGATT 
Control(YER)_Rev ATGCGCAAGAAGGTGCCTAT 
 
All qPCR primers were synthesized by Thermo Fisher Scientific GmbH Ulm, Germany. 
 
 
Table 6 (continued) 
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1.3 Antibodies 
Table 8: Monoclonal antibodies used in ChIP and ChIP-chip experiments 
Antibody Amount in ChIP Source 
1Y26 (Rpb3) 5 µl (lyophilized ascites dissolved in 100 µl ddH2O) NeoClone Biotechnology 
3D12 (Y1P) 50 µl (supernatant cell culture) Elisabeth Kremmer/Dirk Eick 
3E8 (S5P) 20 µl (supernatant cell culture) Elisabeth Kremmer/Dirk Eick 
3E10 (S2P) 25 µl (supernatant cell culture) Elisabeth Kremmer/Dirk Eick 
4E12 (S7P) 50 µl (supernatant cell culture) Elisabeth Kremmer/Dirk Eick 
 
 
Table 9: Antibodies used in Western blot experiments 
Antibody Stock solution Host Source 
3F10 (αHA-tag) 1:700 Rat Roche (11867423001) 
8WG16 (αPol II CTD) 1:2000 Mouse Santa Cruz (sc-56767) 
α-Tubulin 1:1000 Rat Santa Cruz (sc-69971) 
α-GST-tag 1:5000 Goat GE Healthcare (RPN1236) 
yN-20 (αSpt5) 1:400 Goat Santa Cruz (sc-26355) 
PAP (Peroxidase-Anti-
Peroxidase) 
1:2000 Rabbit SIGMA (P1291) 
α-Goat-HRP 1:3000 Donkey Santa Cruz (sc-2020) 
α-Mouse-HRP 1:3000 Goat Bio-Rad (170-6516) 
α-Rat-HRP 1:3000 Goat SIGMA (A9037) 
 
 
 
1.4  Media and supplements 
Table 10: Growth media 
Name Description Application 
LB 1% (w/v) tryptone; 0,5% (w/v) yeast extract; 0,5% (w/v) 
NaCl (+ 1,5% (w/v) agar for selective media plates); 
E. coli culture 
YPD 2% (w/v) petone; 2% (w/v) glucose; 1,5% (w/v) yeast 
extract (+ 1,8% (w/v) agar for solid media plates); 
Yeast culture 
YPDCu YPD with 0.16 mM CuSO4; Yeast culture 
5-FOA plates SC (-ura); 0.01% (w/v) uracil; 0.2% (w/v) 5-FOA; 2% (w/v) 
agar; 
Yeast culture 
SC -ura 0.69% (w/v) yeast nitrogen base; 0.077% (w/v) drop-out -
ura; 2% (w/v) glucose; (+ 2% (w/v) agar for solid media 
plates)  
Yeast culture 
 
 
Table 11: Growth media additives 
Supplement Description Working concentration 
Ampicillin Antibiotic 100 µg/ml 
Chloramphenicol (in 100% EtOH) Antibiotic 50 µg/ml 
Kanamycin Antibiotic 30 µg/ml 
Tetracycline (in 70% v/v EtOH) Antibiotic 12.5 µg/ml 
IPTG Isopropyl-β-D-thiogalactopyranosid 0.5 mM 
Geneticin (G418) Antibiotic 400 µg/ml 
6-Azauracil (6-AU) Pyrimidine analog 50-200 µg/ml 
Mycophenolic acid (MPA) Immunosuppressive drug 15-45 g/ml 
 
  II. Materials and General methods 
 
   17 
 
 
1.5  Buffers and solutions 
 
All standard buffers and solutions were prepared according to Sambrook & Russell, 2001. 
 
Table 12: General buffers, dyes and solutions 
Name Description Application 
1x PBS 2 mM KH2PO4; 4 mM Na2HPO4; 140 mM NaCl; 3 mM 
KCl; pH 7.4 (25°C); 
Protein purification 
1x SDS-PAGE loading 
Buffer 
 SDS-PAGE 
2x SDS-PAGE loading 
Buffer 
25 mM Tris-HCl, pH 7.0 at 25°C; 0.05% (w/v) 
Bromophenol blue; 0.5% (v/v) β-Mercaptoethanol; 7% 
(w/v) Dithiothreitol; 0.05% (w/v) Lauryl sulfate; 5% 
(v/v) Glycerol; 
SDS-PAGE 
6x Loading dye 
(Fermentas) 
1.5 g/L Bromphenol blue; 1.5 g/L Xylene cyanol; 50% 
(v/v) Glycerol; 
Agarose gels 
4x Stacking gel Buffer 0.5 M Tris-HCl; 0.4% (w/v) SDS; pH 6.8 at 25°C; SDS-PAGE 
4x Separation gel Buffer 3 M Tris-HCl; 0.4% (w/v) SDS; pH 8.9 at 25°C; SDS-PAGE 
SDS electrophoresis 
Buffer 
25 mM Tris-HCl; 0.1% (w/v) SDS; 250 mM Glycine; SDS-PAGE 
Gel staining solution 50% (v/v) Ethanol; 7% (v/v) Acetic acid; 0.125% (w/v) 
Coomassie Brilliant Blue R-250; 
Coomassie staining 
Gel destaining solution 5% (v/v) Ethanol; 7.5% (v/v) Acetic acid; Coomassie staining 
1x TBE 8.9 mM Tris-HCl; 8.9 mM Boric acid; 2 mM EDTA; pH 
8.0 at 25°C; 
Agarose gels 
TFB-1 Buffer 30 mM KOAc; 50 mM MnCl2; 100 mM RbCl; 10 mM 
CaCl2; 15% (v/v) Glycerol; pH 5.8 at 25°C; 
Chemically competent 
E. coli cells 
TFB-2 Buffer 10 mM MOPS, pH 7.0 at 25°C; 10 mM RbCl; 75 mM 
CaCl2; 15% (v/v) Glycerol; 
Chemically competent 
E. coli cells 
TELit 10 mM Tris-HCl, pH 8.0 at 25°C; 155 mM LiOAc; 1 
mM EDTA, pH 8.0; 
Chemically competent 
S. cerevisiae cells 
LitSorb 10 mM Tris-HCl, pH 8.0 at 25°C; 155 mM LiOAc; 1 
mM EDTA, pH 8.0; 18.2% (w/v) D-Sorbitol  
Chemically competent 
S. cerevisiae cells 
LitPEG 10 mM Tris-HCl, pH 8.0 at 25°C; 155 mM LiOAc; 1 
mM EDTA, pH 8.0; 40% (w/v) PEG 3350; 
Chemically competent 
S. cerevisiae cells 
Lyticase Buffer 1 M Sorbitol; 100 mM EDTA, pH 8.0; 14.3 mM β-
Mercaptoethanol; 
Preparation of genomic 
DNA 
Spheroblast wash Buffer 1 M Sorbitol; 100 mM EDTA, pH 8.0; Preparation of genomic 
DNA 
TE 50/100 Buffer 50 mM Tris-HCl, pH 7.5 at 4°C; 100 mM EDTA, pH 
8.0; 
Preparation of genomic 
DNA 
WB transfer Buffer 25 mM Tris; 192 mM Glycine; 20% (v/v) Ethanol; Western Blotting 
WB blocking Buffer 2% (w/v) milk powder in 1x PBS; Western Blotting 
Ab lysis Buffer 50 mM Tris-HCl, pH 8.0 at 4°C; 150 mM NaCl; 1% 
(w/v) NP-40; PI; 
Antibody validation 
Ab lysis Buffer 2 50 mM HEPES-KOH, pH 7.5 at 4°C; 150 mM NaCl; 1 
mM EDTA; 1% (w/v) Triton-X-100; 0.1% (w/v) 
sodium-deoxycholate); PI; PhoI; 
Antibody validation 
Laemmli Buffer 60 mM Tris-HCl, pH 6.8 at 25°C; 2% (w/v) SDS; 10% 
(w/v) Glycerol; 0.01% (w/v) Bromphenol blue; 10 mM 
EDTA; 1 mM PMSF; 100 mM DTT; 
Antibody validation 
5x Tyrosine kinase 
Buffer 
300 mM HEPES, pH 7.5 at 25°C; 15 mM MgCl2; 15 
mM MnCl2; 6 mM DTT; 15 mM Na3VO4; 12.5 µM PEG 
20,000; 
Antibody validation 
5x Serine kinase Buffer 250 mM HEPES, pH 7.9 at 25°C; 50 mM MgCl2; 500 
mM KCl; 5 mM DTT; 1 mM EGTA; 500 µM EDTA; 
Antibody validation 
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Table 13: Nrd1-, Pcf11-, and Rtt103-CID purification buffers 
Name Description 
Buffer A 50 mM Tris-HCl, pH 8.0 at 4°C; 300 mM NaCl; 10 mM β-Mercaptoethanol; PI; 
Buffer B 50 mM Tris-HCl, pH 8.0 at 4°C; 150 mM NaCl, 5 mM DTT; 
Buffer C 50 mM MES, pH 6.5 at 4°C; 50 mM NaCl, 1 mM DTT; 
Buffer D 50 mM HEPES, pH 7.5 at 4°C; 100 mM NaCl; 1 mM DTT; 
Buffer E 50 mM Tris-HCl, pH 8.0 at 4°C; 50 mM NaCl; 10 mM Imidazole; 10 mM β-
Mercaptoethanol;  
Buffer F 50 mM Tris-HCl, pH 8.0 at 4°C; 30 mM NaCl; 10 mM Imidazole; 1 mM DTT; 
Buffer G 50 mM Tris-HCl, pH 8.0 at 4°C; 30 mM NaCl; 1 mM DTT; 
Buffer H 50 mM HEPES, pH 7.0 at 4°C; 1 100 mM NaCl; 5 mM DTT;  
Buffer I 50 mM Tris-HCl, pH 8.0 at 4°C; 300 mM NaCl; 10 mM β-Mercaptoethanol; 10% 
(v/v) Glycerol; PI; 
Buffer J 50 mM Tris-HCl, pH 8.0 at 4°C; 50 mM NaCl; 1 mM EDTA; 1 mM DTT; 
Buffer K 50 mM Tris-HCl, pH 8.0 at 4°C; 200 mM NaCl; 1 mM EDTA; 1 mM DTT; 
Buffer L 50 mM Tris-HCl, pH 8.0 at 4°C; 500 mM NaCl; 5 mM DTT; PI; 
Buffer M 50 mM Tris-HCl, pH 8.0 at 4°C; 300 mM NaCl; 5 mM DTT; 
Buffer N 50 mM Tris-HCl, pH 8.0 at 4°C; 150 mM NaCl; 2 mM DTT; 
Buffer O 20 mM HEPES, pH 8.0 at 4°C; 25 mM KCl; 2 mM DTT; 
 
 
 
Table 14: Buffers for Fluorescence anisotropy measurements, Malachite green assay, GST pull-down 
assay and for Tandem Affinity Purification (TAP) 
Name Description 
FluA Buffer 20 mM HEPES, pH 8.0 at 20°C; 150 mM NaCl; 5 mM DTT; 
FluB Buffer FluA, but with 10 mM NaCl; 
Mal Buffer 50 mM Tris-HCl, pH 6.5 at 25°C; 200 mM NaCl; 1 mM EDTA; 1 mM DTT; 
GST lysis Buffer 50 mM Tris-HCl, pH 8.0 at 4°C; 150 mM NaCl; 1 mM DTT; PI; PhoI; 
TAP lysis Buffer 50 mM Tris-HCl, pH 7.5 at 4°C; 1.5 mM MgCl2; 100 mM NaCl; 0.15% NP-40; 
1 mM DTT; PI;  
TAP wash Buffer Identical to TAP lysis Buffer, but with 0.5 mM DTT and without PI; 
Calmodulin Buffer 1 50 mM Tris-HCl, pH 7.5 at 4°C; 4 mM CaCl2; 1.5 mM MgCl2; 100 mM NaCl; 
0.15% NP-40; 1 mM DTT; 
Calmodulin Buffer 2 50 mM Tris-HCl, pH 7.5 at 4°C; 2 mM CaCl2; 1.5 mM MgCl2; 100 mM NaCl; 
0.15% NP-40; 1 mM DTT; 
TAP elution Buffer 10 mM Tris-HCl, pH 8.0 at 20°C; 5 mM EGTA; 
 
 
 
Table 15: Buffers used in ChIP, RNase ChIP and ChIP-chip experiments. 
Name Description 
1x TBS 20 mM Tris‐HCl, pH 7.5 at 4°C; 150 mM NaCl; 
FA lysis Buffer 50 mM HEPES‐KOH, pH 7.5 at 4°C; 150 mM NaCl; 1 mM EDTA; 1% (v/v) 
Triton X‐100; 0.1% (v/v) Na deoxycholate; 0.1% (v/v) SDS; PI; PhoI*; 
FA lysis Buffer 2 Identical to FA lysis buffer, but with 500 mM NaCl instead of 150 mM NaCl 
ChIP wash Buffer 10 mM Tris‐HCl, pH 8.0 at 4°C; 0.25 M LiCl; 1 mM EDTA; 0.5% (v/v) 
NP‐40; 0.5% (v/v) Na deoxycholate; 
TE Buffer 10 mM Tris‐HCl, pH 7.4 at 4°C; 1 mM EDTA; 
ChIP elution Buffer 50 mM Tris‐HCl, pH 7.5 at 25°C; 10 mM EDTA; 1% (v/v) SDS; 
RNase storage Buffer 10 mM HEPES, pH 7.5 at 25°C; 20 mM NaCl; 0.1% (v/v) Triton X-100; 1 
mM EDTA; 50% (v/v) Glycerol; 
*Phosphatase inhibitors (PhoI) were only applied in ChIP and ChIP-chip experiments of Pol II phospho-isoforms 
and in Spt5 CTR-GST pull-down assays; 
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Table 16: Protease and phosphatase inhibitor mixes. 
Name Description 
Protease-inhibitor mix (PI) 1 mM Leupetin, 2 mM Pepstatin A, 100 mM Phenylmethylsulfonyl 
fluoride, 280 mM Benzamidine; 
Phosphatase-inhibitor mix (PhoI) 1 mM NaN3, 1 mM NaF, 0.4 mM Na3VO4; 
 
 
 
 
2. General methods 
2.1 Chromatin immunoprecipitation with quantitative PCR (ChIP-qPCR) 
2.1.1 ChIP with TAP-tagged proteins 
TAP-tagged yeast strains were usually obtained from Open Biosystems (Huntsville, USA; 
Yeast TAP-Tagged Collection) and were isogenic to BY4741 wild-type strain. All TAP-
strains used in this work are listed in Table 4. Before these yeast strains were applied to ChIP 
analysis, the strains were validated. Firstly, gene-specific PCR was performed to confirm that 
the DNA coding for the TAP-tag was at the correct genomic position. The DNA sequences of 
all control primers are given in Table 6. Secondly, Western blotting with anti-TAP (PAP, 
Sigma) antibody was performed to verify whether the tagged protein of interest was properly 
expressed. Western blot experiments were conducted as described in in section II 2.7. Thirdly, 
the growth of the various tagged yeast strains compared to non-tagged wild-type strain was 
monitored to rule out any influence of the epitope tag on yeast growth. This was done by 
serial dilutions of the various yeast strains on YPD plates at 30°C for two days. Only yeast 
strains which passed all quality controls were used for ChIP analysis. 
For ChIP-qPCR experiments yeast cultures were grown in 40 ml YPD medium at 30°C to 
mid-log phase (OD600 ~ 0.8), treated with 1% formaldehyde for 20 min at 20°C, and cross-
linking was quenched with 5 ml 3 M glycine for 10 min. Subsequent steps were performed at 
4°C with pre-cooled buffers (Table 15) containing protease inhibitors (PIs; Table 16). Cells 
were collected by centrifugation, washed twice with 1x TBS and twice with FA lysis Buffer. 
Cell pellets were flash-frozen in liquid nitrogen and stored at -80°C. Pellets were thawed, 
resuspended in 1 ml FA lysis Buffer, and disrupted by bead beating (Retsch) in the presence 
of 1 ml silica-zirconia beads for 30 min at 4°C. Lysis efficiency was typically >80% as 
determined by spectrophotometer measurements (BioPhotometer, Eppendorf). Chromatin was 
solubilized and fragmented via sonication with a BioruptorTM UCD-200 (Diagenode Inc.). 
Sonication was performed at intensity setting “high” (cycles of 0.5 min on and 0.5 min off) 
for 35 min with sample cooling on ice after 5, 15 and 25 min. 30 µl and 100 µl of fragmented 
chromatin samples were saved as input and for control of the average chromatin fragment size 
(described in section II 2.1.3), respectively. 700 µl of sample (IP sample) was 
immunoprecipitated with 20 µl IgG Sepharose beads at 4°C for 1 h. The IgG beads were 
directed against the Protein A content of the C-terminal TAP-tag. Immunoprecipitated 
chromatin was washed three times with FA lysis Buffer, twice with FA lysis Buffer 2, twice 
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with ChIP wash Buffer and once with TE Buffer. Immunoprecipitated chromatin was eluted 
for 10 min at 65 °C with ChIP elution Buffer. Eluted chromatin was digested with 
Proteinase K at 37°C for 2 h and the reversal of crosslinks was performed at 65°C over-night. 
DNA was purified with the QIAquick PCR Purification Kit (Qiagen) according to the 
manufacturer’s instructions. Thereby, DNA was eluted with 50 µl ddH2O and was further 
analyzed by quantitative PCR. 
All buffers and reagents used for ChIP are listed in Table 15 and 16, respectively. The RNase-
ChIP assay that allows the analysis of RNA-dependent binding of the protein of interest is 
described in section V 2.2. 
 
 
 
2.1.2 ChIP of Pol II phospho-isoforms 
ChIP analysis of the various Pol II phospho-isoforms was performed as described in the 
previous section, but with the following modifications. Firstly, ChIP experiments were 
conducted in the presence of phosphatase inhibitors (PhoIs; Table 16). Secondly, for 
chromatin immunoprecipitation a set of monoclonal antibodies with strong specificity and 
affinity for particular phosphorylated states of the Pol II CTD were applied (Table 8). These 
antibodies were generated and validated in the laboratories of Dirk Eick and Elisabeth 
Kremmer (Helmholtz Zentrum München). The amount of antibody that was used for 
immunoprecipitation of chromatin was optimized as is described in (199). 
700 µl of chromatin sample was immunoprecipitated with the optimized amount of the 
respective monoclonal antibody (see Table 8) at 4°C over-night on a rotating wheel. 25 μl of 
Protein A and Protein G Sepharose beads (GE Healthcare) were added and incubated at 4°C 
for 1.5 h on a rotating wheel. Immunoprecipitated chromatin was treated as described in the 
previous section. 
 
 
 
2.1.3 Control of average chromatin fragment size 
100 µl of chromatin solution was used to determine the average DNA fragment size that was 
reached by sonication. 92 µl of TE Buffer and 8 µl of Proteinase K (20 mg/ml) was added to 
the chromatin sample and incubated at 37°C for 2 h and at 65°C over-night. Next, 20 µl of 
LiCl (4 M), 1 µl Glycogen and 120 µl Phenol was added, mixed and centrifuged at 13,000 
rpm for 10 min (20°C). The supernatant was mixed with 400 µl of pre-cooled Ethanol and 
incubated at -20°C for 5 h. The immunoprecipitated DNA (and RNA) was pelletized by 
centrifugation at 13,000 rpm for 20 min (4°C). The pellet was resuspended in 20 µl TE Buffer 
and RNA was removed by RNAse treatment. 10 µl of RNase A/T1 mix (2 mg/ml RNase A, 
5000 U/ml RNase T1) were added and incubated at 37°C for 1 h. The resulting DNA sample 
was electrophoretically separated on a 1.5% agarose gel (see section II 2.8). The average 
DNA fragment size was usually ~250 nucleotides (nt).  
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2.1.4 Quantitative PCR (qPCR) 
For ChIP experiments, input and immunoprecipitated (IP) samples were assayed by qPCR to 
assess the extent of protein occupancy at different genomic regions.  
However, before ChIP DNA was analyzed by qPCR, primers were designed and the PCR 
efficiencies of the corresponding primer pairs were determined. DNA primers used for qPCR 
experiments were 18 to 24 nt long and were designed with the OligoPerfectTM Designer 
(Invitrogen). The length of the amplified qPCR product was between 60 and 70 nt. The PCR 
efficiency was determined by quantitative PCR (as described below) with the same primer 
pair applied to at least four different dilutions of a DNA template (usually DNA that was 
fragmented by sonication). Based on the resulting standard curve, the PCR efficiency was 
calculated with the Bio‐Rad CFX Manager software version 1.1 according to the 
manufacturer’s instructions. Only primer pairs with a PCR efficiency of ≥ 90% were used in 
ChIP-qPCR experiments. A list of all qPCR primers used in this work is given in Table 7. 
PCR reactions for the analysis of ChIP DNA as well as for validation of qPCR primer pairs 
contained 1 μl DNA template, 2 μl of 10 μM primer pairs and 12.5 μl iTaq SYBR Green 
Supermix (Bio‐Rad). Quantitative PCR was performed on a Bio‐Rad CFX96 Real‐Time 
System (Bio‐Rad Laboratories) using a 3 min denaturing step at 95°C, followed by 49 cycles 
of 30 sec at 95°C, 30 sec at 61°C and 15 sec at 72°C. Threshold cycle (Ct) values were 
determined by application of the corresponding Bio‐Rad CFX Manager software version 1.1 
using the Ct determination mode “Regression”. The IP efficiency (not PCR efficiency) and 
fold enrichment of any given region over control regions, such as an open reading frame 
(ORF)‐free heterochromatic region on chromosome V, was determined as described in (83). 
 
 
 
2.2 Chromatin immunoprecipitation with tiling array hybridization (ChIP-chip) 
 
2.2.1 ChIP for ChIP-chip 
For ChIP-chip experiments the standard ChIP protocol as described in sections II 2.1.1-2.1.2 
had to be adapted as follows. Firstly, yeast cultures were grown in 600 ml YPD medium at 
30°C to mid-log phase (OD600 ~ 0.8). Secondly, cell lysis via bead beating was performed for 
2 h, with cooling of the sample after 30, 60 and 90 min. Thirdly, the chromatin pellet was 
washed two times with FA lysis Buffer before sonication. To be more precise, the cell lysate 
was centrifuged at 13,200 rpm for 15 min (4°C), the supernatant was discarded and the 
chromatin pellet was resuspened with 1 ml FA lysis Buffer. This step was repeated one time. 
Fourthly, the elution from the IgG Sepharose beads was performed at 65°C for 60 min. 
Fifthly, after purification of DNA with the QIAquick PCR Purification Kit (Qiagen), DNA 
was eluted with 100 µl H2O and 5 µl RNase A (10 mg/ml) was added, and incubated at 37°C 
for 20 min. DNA was purified with the QIAquick PCR Purification Kit, eluted with 50 µl 
H2O, concentrated via vacuum centrifugation, and amplified as described in the following 
section.      
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2.2.2 Whole genome amplification 
DNA samples were amplified and re‐amplified with GenomePlex© Complete Whole Genome 
Amplification 2 (WGA2) Kit using the Farnham Lab WGA Protocol for ChIP‐chip (226) 
(http://www.genomecenter.ucdavis.edu/farnham/protocol.html). Briefly, 10 µl of concentrated 
ChIP DNA was used to generate the PCR-amplifiable OmniPlex© Library, consisting of ChIP 
DNA molecules flanked by universal priming sites. Library preparation was performed 
essentially as described in the technical bulletin of the WGA2 Kit (Sigma). The OmniPlex© 
Library was then amplified by PCR within a limited number of cycles. This first whole 
genome amplification step was also conducted according to the manufacturer’s instructions. 
The amplified DNA was purified with the QIAquick PCR Purification Kit (Qiagen). DNA 
was eluted with 50 µl H2O and the DNA quantity and quality control was performed with a 
ND‐1000 Spectrophotometer (NanoDrop Technologies), and was usually larger than 1 μg. In 
addition, DNA quality was monitored by agarose gelelectrophoresis. 15 ng of purified DNA 
was re-amplified as described in the technical bulletin of the WGA2 Kit, but with the 
following modification. Re-amplification was carried out in the presence of 0.4 mM dUTP. 
Incorporation of dUTP was a prerequisite for the enzymatic fragmentation of DNA (described 
in the following section). After amplification DNA was purified with the QIAquick PCR 
Purification Kit. DNA was eluted with 50 µl H2O and the DNA quantity and quality control 
was again assessed with a ND‐1000 Spectrophotometer, and agarose gelelectrophoresis.  
 
 
 
2.2.3 DNA labeling, fragmentation and tiling array handling 
The enzymatic fragmentation, labeling, hybridization and array scanning were done according 
to the manufacturer’s instructions (Affymetrix Chromatin Immunoprecipitation Assay 
Protocol P/N 702238). Enzymatic fragmentation and terminal labeling were performed by 
application of the GeneChip WT Double‐Stranded DNA Terminal Labeling Kit (P/N 900812, 
Affymetrix). Briefly, re‐amplified DNA was fragmented in the presence of 1.5 μl 
Uracil‐DNA‐glycosylase (10 U/μl) and 2.25 μl APE1 (100 U/μl) at 30°C for 1 h 15 min. The 
average fragment size was in the range of 50‐70 bases as determined by automated gel 
electrophoresis on an Experion system (Bio‐Rad Laboratories) that allowed the analysis of 
small amounts of DNA. The fragmented DNA was then labeled at the 3′‐end by adding 2 μl 
and 1 μl of Terminal nucleotidyl transferase (TdT, 30 U/μl) and GeneChip DNA Labeling 
Reagent (5 mM), respectively. 5.5 μg of fragmented and labeled DNA were hybridized to a 
high‐density custom‐made Affymetrix tiling array (64) (PN 520055) at 45°C for 16 h with 
constant rotational mixing at 60 rpm in a GeneChip Hybridization Oven 640 (Affymetrix, 
SantaClara, CA). Washing and staining of the tiling arrays were performed using the 
FS450_0001 script of the Affymetrix GeneChip Fluidics Station 450. The arrays were 
scanned using an Affymetrix GeneChip Scanner 3000 7G. The resulting raw data image files 
(.DAT) were inspected for any impairment. The CEL intensity files were used for 
bioinformatics analysis. 
At least two independent biological replicates were analyzed for each factor. 
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2.2.4 Bioinformatics analysis 
2.2.4.1 ChIP-chip data normalization 
All data normalization procedures were performed using R (259) and Bioconductor (94). For 
data import of the Affymetrix CEL files and the conversion into the basic Bioconductor object 
class for microarray data ExpressionSet, we used the R package Starr (338). Data 
normalization consisted of three steps. Firstly, we performed quantile normalization between 
replicate measurements (not between non‐replicate measurements). Secondly, for each 
condition (including the reference measurements) we averaged the signal for each probe by 
calculating the geometric average over the replicate intensities. Thirdly, data from all factors 
were normalized using a combined mock IP (referring to ChIP-chip experiments with non-
tagged wild-type strain) plus input reference normalization. Additional aspects of data 
normalization were described in (199).  
Normalized signal was converted to occupancy values between 0-100% by setting the 
genome-wide 99.8% quantile to 100% occupancy and the 10% quantile to 0% occupancy. For 
the Pol II phospho-isoforms, ChIP enrichments were obtained by dividing ChIP intensities by 
the genomic input intensities.  
 
2.2.4.2 Transcript-wise occupancy profiles 
In order to calculate occupancy profiles over genes or other genomic features the normalized 
occupancy signal at each nucleotide of the region was calculated as the median signal of all 
probes overlapping this position (6.5 probes on average). Individual probe intensities were 
further smoothed using the sliding window smoothing procedure (window half size of 75 bp) 
implemented in the R package Ringo (303). 
 
2.2.4.3 Gene-averaged occupancy profiles 
Before the occupancy of a particular factor was averaged over different genes, the genes were 
selected as follows. We started with all nuclear Saccharomyces cerevisiae S288C 
protein‐coding genes classified as 'verified' or 'uncharacterized' by the Saccharomyces 
Genome Database (5769 genes; http://www.yeastgenome.org/). To align gene profiles across 
entire transcripts, only genes with available TSS and pA assignments from RNA‐seq 
experiments (219) were taken into account (4366 genes). Genes with TSS (pA) measurements 
downstream (upstream) of the annotated ATG (Stop) codon were excluded. To remove 
possible wrongly annotated TSSs and pAs, we only included genes with TSS (pA) 
annotations showing a distance less than 200 bp to the corresponding downstream (upstream) 
ATG (Stop) codon (3448 genes). As a result of the limited ChIP‐chip resolution and the 
compactness of the yeast genome with its short intergenic regions (median inter‐ORF length: 
368 bp, median inter‐transcript length: 259 bp), a gene's factor occupancy profile can have 
spurious contributions from flanking genes. To minimize these “spill‐over” effects, we 
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focused on genes exhibiting a minimal ORF and transcript distance to flanking genes of 250 
bp and 200 bp, respectively (1786 genes). Furthermore, we restricted our analysis to the 50% 
highest expressed nuclear protein‐coding genes according to measurements by Dengl et al. 
(70) (1140 genes, ALL set). We grouped genes into four ORF length classes: Xtremely Short 
(XS) ranging from 256 to 511 bp, Short (S) 512 to 937 bp, Medium (M) 938 to 1537 bp, and 
Long (L) 1538 to 2895 bp, comprising 93, 266, 339, and 299 genes, respectively. Profiles 
within these groups were scaled to median gene length. We calculated gene‐averaged profiles 
by taking the median over gene factor profiles. 
 
 
2.2.4.4 Pairwise profile correlations and correlation network 
Analyses were done using 4366 genes with available TSS and pA annotations (219). Pairwise 
Pearson correlations over factor occupancy profiles were calculated between concatenated 
gene profiles ranging each from TSS minus 250 bp to pA plus 250 bp. The correlation‐based 
network was calculated using the GraphViz's Neato algorithm (90). 
Singular value decomposition (SVD) analysis was performed as described in (199).  
 
 
 
2.3 Molecular cloning and preparation of DNA 
A standard Polymerase Chain Reaction (PCR) such as for the validation of TAP-tagged 
yeast strains was performed as follows. PCR reactions contained 3 μl (150  ng) genomic DNA 
template, 1.25 μl of 10 μM forward and reverse primer (usually 18 to 24 nt long), 5 µl 10x 
Taq Buffer, 6 µl of 10 mM MgCl2, 2.5 µl of 2 mM dNTP-Mix, 30 µl H2O and 1 µl Taq DNA 
Polymerase. PCR was performed on a T3000 Thermocycler (Biometra) using a 2 min 
denaturing step at 94°C, followed by 35 cycles of 30 sec at 94°C, 30 sec at 50°C and 1 min at 
72°C. Finally, the PCR reaction was incubated at 72°C for 10 min and stored at 4°C. 
In cases where a new yeast strain was generated, such as an N-terminally TAP-tagged TFIIS 
strain, the PCR was typically performed as follows. PCR reactions contained 1 μl (100 ng) 
DNA template, 2 μl of 10 μM forward and reverse primer (usually 18 to 24 nt long), 10 µl 5x 
HF Buffer, 5 µl of 2 mM dNTP-Mix, 29 µl H2O and 1 µl Phusion© DNA Polymerase. PCR 
was performed on a T3000 Thermocycler (Biometra) using a 30 sec denaturing step at 98°C, 
followed by 35 cycles of 7 sec at 98°C, 20 sec at 55°C and 1 min at 72°C. Finally, the PCR 
reaction was incubated at 72°C for 10 min and stored at 4°C. 
In cases where no PCR product was obtained, the standard protocols were adjusted by 
changing particular parameters. Most critical parameters turned out to be the primers itself, 
the type of DNA polymerase and the elongation time. 
For enzymatic restriction cleavage DNA was digested using restriction endonucleases (New 
England Biolabs, Fermentas) according to the manufacturer’s instructions. Cleaved PCR 
products and cleaved plasmids were purified with the QIAquick PCR Purification Kit 
(Qiagen) and with the QIAquick gel extraction Kit (Qiagen), respectively. 
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Ligation of digested DNA into vectors was done with T4 DNA ligase (Fermentas) and its 
corresponding buffer in a volume of 20 µl for 1 h at room temperature or over-night at 16°C. 
In a typical ligation experiment a 5- to 10-fold excess of insert, relative to linearized vector 
was used. Ligation products were transformed into E. coli and yeast cells. 
For transformation of E. coli cells chemically competent XL-1 Blue cells (see II 2.4 and 
Table 3) were used. Approximately 2 µg of DNA (usually 3 µl ligation product) were added 
to 50 µl of competent cells and incubated for 5 min on ice. Next, cells were heated for 30 sec 
at 42°C in a water bath and then put back on ice for 2 min. Transformed E. coli cells were 
recovered by incubation at 37°C for 1 h in 700 µl of LB medium. Recovered cells were 
centrifuged at 13,000 rpm for 30 sec (at room temperature) and 650 µl of the supernatant was 
removed. Cells were resuspended in the remaining volume and plated onto solid LB medium 
plates containing the respective antibiotic (see Table 11). Plates were incubated at 37°C over-
night. 
For preparation of plasmid DNA, 5 ml LB medium (containing the respective antibiotic) 
were inoculated with a single colony/clone and incubated at 37°C over-night (160 rpm). Cells 
were harvested by centrifugation at 4,500 rpm (Rotana 46R) for 10 min (4°C). Next, plasmid 
DNA was prepared with the QIAquick Miniprep Kit (Qiagen) according to the manufacturer’s 
instructions. 
For transformation of chemically competent S. cerevisiae cells (see section II 2.4) 10 µl 
PCR product (≥ 1 µg of linear DNA) and 360 µl LitPEG was added to 50 µl of competent 
cells. After incubation at room temperature for 30 min, 47 µl DMSO was added and in case 
that the yeast strain was not temperature-sensitive heated at 42°C for 15 min. Alternatively, if 
the yeast strain was temperature-sensitive cells were incubated at 30°C for 10 min and at 
37°C for 5 min. After recovery (30°C, 1 h, 150 rpm), cells were collected by centrifugation at 
2,000 rpm for 3 min (room temperature) and the supernatant was removed. Transformed yeast 
cells were resuspended in 50 µl sterile ddH2O, plated on selective media plates and incubated 
at 30°C. 
For preparation of genomic DNA 5 ml yeast were grown at 30°C (150 rpm) over-night. 
Cells were harvested by centrifugation at 2,500 rpm for 5 min (4°C), washed with 1 ml sterile 
ddH2O and resuspended in 500 µl Lyticase Buffer. Next, 20 µl Lyticase (10 U/µl) were 
added. After incubation at 37°C for 45 min, yeast spheroblasts were collected by 
centrifugation at 5,000 rpm for 5 min (4°C). The supernatant was removed and spheroblasts 
were gently resuspended in 1 ml Spheroblast wash Buffer. Spheroblasts were centrifuged 
again and resuspended in 500 µl Spheroblast wash Buffer. Spheroblasts were collected again 
and resupended in 500 µl of TE 50/100 Buffer. 50 µl 10% SDS were added and incubated at 
70°C for 30 min. Then, 250 µl 5 M Potassium acetate were added and incubated on ice for 15 
min. The precipitated genomic DNA was collected by centrifugation at 13,000 rpm for 20 min 
(4°C), the supernatant was removed and 700 µl Isopropanol was added. Precipitated genomic 
DNA was collected by centrifugation at 13,000 rpm for 10 min (4°C). Precipitated DNA was 
washed with 70% Ethanol and resuspended in 500 µl TE 50/100 Buffer via heating at 42°C 
for 30 min. DNA quantity and quality control was performed with a ND‐1000 
Spectrophotometer (NanoDrop Technologies). Genomic DNA was stored at -20°C. 
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2.4 Preparation of competent cells 
Chemically competent E. coli cells were prepared as follows. 200 ml LB medium (containing 
the respective antibiotic) were inoculated with 5 ml of an over-night culture of the desired E. 
coli strain. Cells were grown at 37°C (160 rpm) to an OD600 of 0.4 to 0.5 and incubated on ice 
for 10 min. The following steps were performed at 4°C with pre-cooled buffers. Cells were 
harvested by centrifugation and washed with 50 ml TFB-1 Buffer. After a second 
centrifugation step, cells were resuspended in 4 ml TFB-2 Buffer. Aliquots of competent E. 
coli cells were frozen in liquid nitrogen and stored at -80°C (see Table 12). 
Chemically competent S. cerevisiae cells were prepared as follows. 50 ml YPD medium was 
inoculated (start OD600 of 0.2) with yeast that was grown to stationary phase over-night. Next, 
yeast cells were grown at 30°C (150 rpm) to an OD600 of 0.5 to 0.7 and harvested by 
centrifugation at 4,000 rpm for 10 min (room temperature). Yeast cells were washed with 25 
ml sterile ddH2O and finally resuspended in 360 µl LitSorb. 40 µl of heated (10 min at 100°C) 
salmon sperm DNA was added. Aliquots of competent yeast cells were stored at -80°C (see 
Table 12).      
 
 
 
2.5 Protein expression in E. coli 
Proteins were recombinantly expressed in BL21-CodonPlus (DE3)RIL E. coli cells (see Table 
3). The plasmids that contained the genes coding for the desired protein variants were 
transformed into E. coli cells as described in section II 2.3. 10 ml LB medium containing 
chloramphenicol and other antibiotics (depending on the plasmid used) were inoculated with a 
single E. coli colony and grown (37°C, 160 rpm) to stationary phase over-night. The 10 ml 
culture was used to inoculate 1 L LB medium containing the respective antibiotics. Cells were 
grown (37°C, 160 rpm) to OD600 of 0.6 to 0.9 and cooled on ice for 30 min. Protein 
expression was induced by the addition of 0.5 mM IPTG and was performed at 18°C and 160 
rpm over-night. Cells were harvested by centrifugation at 4,000 rpm (SLC6000 rotor, Sorvall) 
for 20 min. The cell pellet was resuspended in 30 ml of the corresponding lysis buffer, frozen 
in liquid nitrogen and stored at -80°C.       
 
 
 
 
2.6 Protein purification 
For cell lysis frozen cell suspensions (30 ml; see previous section) were thawed rapidly. All 
following steps were performed at 4°C with pre-cooled buffers. 20 ml of the respective lysis 
buffer and 0.5 ml of protease inhibitors (PIs) were added. Cells were disrupted by sonication 
(3x 10 min; duty cycle of 30%; output control of 40). Afterwards, the lysate was cleared by 
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centrifugation at 15,000 rpm (SS34 rotor, Sorvall) for 20 min. The supernatant was 
centrifuged a second time. The resulting cleared supernatant was used for further purification. 
Nickel-NTA-Agarose in a column was used to purify hexahistidine-tagged protein variants of 
interest. The Nickel-NTA-Agarose was washed with 10 ml ddH2O and equilibrated with 10 
ml of the respective lysis buffer (without PI). The cleared cell lysate was applied to the 
equilibrated Nickel-NTA-Agarose column (bed volume: 2 ml). The flow-through was applied 
to the Nickel-NTA column for a second time. After binding of the protein variant, the column 
was washed with 10 ml of the respective washing buffers and the protein was eluted with 10 
ml of the corresponding elution buffer. All purification steps were performed at 4°C and with 
pre-cooled buffers.  
Usually, proteins were further purified by ion exchange and gel filtration chromatography. 
Protein precipitation was performed with trichloroacetic acid (TCA). An equal volume of 
20% TCA was added to the protein sample and incubated on ice for 30 min. Next, the sample 
was centrifuged at 13,000 rpm for 15 min (4°C), the supernatant was removed and the pellet 
was washed with 300 µl pre-cooled Acetone. The sample was centrifuged at 13,000 rpm for 5 
min (4°C), the supernatant was removed and the pellet was dried. Precipitated protein was 
resuspended in 1x SDS-PAGE loading Buffer and heated at 65°C for 3 min. If necessary, the 
protein sample was neutralized with ammonia vapor. 
Protein concentration was determined with a ND‐1000 Spectrophotometer (NanoDrop 
Technologies). Thereby, the protein concentration was calculated from the absorption rate at a 
wavelength of 280 nm (OD280). Individual extinction coefficients for the protein variant of 
interest were calculated with the ProtParam tool (http://web.expasy.org/protparam/) that is 
part of the ExPASy Bioinformatics Resource Portal. 
 
 
 
2.7 Western Blot analysis 
For Western blotting the protein sample was separated by SDS-PAGE as described in section 
II 2.8. Separated proteins were then transferred to a PVDF membrane (Schleicher & Schuell; 
pre-equilibrated with 100% Ethanol) in the presence of the WB transfer Buffer (see Table 12). 
Thereby, the wet blotting system from Bio-Rad was used according to the manufacturer’s 
instructions. Transfer was performed at 100 V for 2 h on ice or at 20 V over-night (4°C). For 
quantitative Western blots, transfer was always performed over-night (see also section V 2.6). 
After transfer, the membrane was air-dried for 30 min. Next, the dried membrane was blocked 
for at least 1 h with WB blocking Buffer. The blot was then incubated at room temperature for 
at least 1.5 h with the primary antibody in WB blocking Buffer. The blot was washed four 
times with WB blocking Buffer at room temperature for 10 min and then incubated with the 
secondary antibody in WB blocking Buffer at room temperature for at least 1 h. Afterwards, 
the blot was washed four times with 1x PBS at room temperature for 10 min. Secondary 
antibodies were usually coupled to horseradish peroxidase. Final signals were detected with 
the Chemiluminescence Kit (Pierce) followed by exposure of the blot to high-sensitivity films 
(Invitrogen). Films were developed with the X-omat M35 developing machine (Kodak). 
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Alternatively, the chemiluminescent signals were measured with the Mini-LAS300 System 
(Fujifilm Life Sciences) and quantified with the ImageQuant software suite (GE Healthcare).        
The standard protocol was adjusted if needed. An overview of the different antibodies that 
were used in this work is given in Table 8 and 9. 
 
 
2.8 Electrophoretic separation of DNA and proteins 
Electrophoretic separation of DNA was performed in horizontal 1x TBE agarose gels that 
contained either Ethidium bromide (0.7 µg/ml) or SYBR Safe® (0.01 µg/ml; Invitrogen). 
Depending on the size of DNA molecules that were separated, the agarose concentration 
varied between 0.8% and 2% (w/v). Agarose gelelectrophoresis was carried out in 
PerfectBlue Gelsystem electrophoresis devices from Peqlab (110 V, 35 min). DNA samples 
were mixed with 6x loading dye (Fermentas). The sizes of the separated DNA molecules were 
assessed with the help of the GeneRulerTM 1kb DNA ladder or the GeneRulerTM 100bp DNA 
ladder (Fermentas). 
The electrophoretic separation of protein samples was performed by SDS-PAGE with 15% 
to 17% acrylamide gels (acrylamide:bisacrylamide ratio = 37.5:1) (174) in Bio-Rad gel 
systems. Before loading onto the gel, protein samples were mixed with SDS-PAGE loading 
Buffer and boiled at 95°C for 2 min. Samples that required separation at a high spatial 
resolution, such as purified protein complexes via TAP (see section III 2.3), were separated by 
ready-to-use NuPAGE Novex Bis-Tris minigels (Invitrogen). MES and MOPS running 
buffers (Invitrogen) were used. SDS-PAGE with ready-to-use gels was carried out according 
to the manufacturer’s instructions. 
Gels were stained with Gel staining solution at room temperature for at least 20 min and 
destained at room temperature over-night in Gel destaining solution. Corresponding buffers 
and solutions are listed in Table 12. 
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III. Uniform transitions of the general RNA polymerase II 
transcription complex 
 
 
1. Introduction 
Gene transcription begins with the assembly of Pol II and its initiation factors on promoter 
DNA (309). Pol II then starts mRNA synthesis and exchanges initiation factors for elongation 
factors during initiation-elongation transition (2, 155, 243). Elongation factors are required for 
chromatin passage and RNA processing (137). During the elongation-termination transition 
that usually occurs at the 3’ end of genes, elongation factors are exchanged by termination 
factors that are required for transcription termination (see also section IV 1.3; (155)).  
 
 
1.1 Pol II transcription elongation 
Pol II transcription elongation represents a distinct stage within the Pol II transcription cycle 
(274). During transcription elongation a nascent RNA molecule is synthesized by a stable 
elongation complex in a processive manner (198). In the course of the last years data has 
accumulated showing that transcription elongation is extremely complex and highly regulated 
(196, 274). 
 
 
1.1.1 Transcript elongation occurs discontinuously and is highly regulated   
Studies in higher eukaryotes have shown for selected genes (26, 103) and genome-wide (217, 
221, 339) that Pol II pauses 25-50 nt downstream of the TSS at a subset of genes. In 
Drosophila cells, promoter proximal pausing was observed at one third of all genes, mainly at 
developmentally regulated and stimulus-responsive genes (221). ChIP-chip analyses in yeast 
grown to stationary phase detected Pol II occupancy at the promoter region of many inactive 
genes but not downstream of that region (255). Although this observation was interpreted as 
Pol II pausing, it is not known whether promoter proximal pausing exists in proliferating 
yeast. Promoter proximal pausing is currently considered as an important regulatory step after 
the recruitment of Pol II to the gene promoter (196). Particular elongation factors, certain 
DNA  sequences (may be also RNA sequences) and nucleosome occupancy play a role in 
specifying promoter proximal pausing (220). It is currently under debate whether promoter 
proximal pausing is a true pausing event of Pol II during transcription elongation or whether 
the observed occupancy peak of Pol II downstream of the TSS rather represents an 
intermediate of early termination (David Bentley, University of Colorado, and Stephen 
Buratowski, Harvard Medical School, personal communication; (288)).   
Apart from promoter proximal pausing that usually occurs shortly after the TSS, pausing 
events can occur throughout the body of genes. ChIP, ChIP-chip and NET-seq studies in yeast 
could show that Pol II pauses at arrest sites (171), upstream of nucleosomes (49) and at the 3’ 
end of introns (5, 39). Single cell experiments revealed that the transcript elongation rate 
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along a gene can vary considerably (62). This is in accord with the observation that 
transcription occurs in bursts with pulses of high polymerase density (48). All these 
observations led to the view that transcription elongation is a discontinuous process, 
interrupted by periods of regulated pauses and arrests. Given the reasonable assumption that 
several Pol II elongation complexes can transcribe the same gene at a time, pausing would 
lead to rear-end collisions between the leading elongation complex and the subsequent 
complexes (267). 
 
 
1.1.2 Transcription elongation through chromatin 
Gene transcription in living cells occurs in a chromatin context (170). Chromatin consists of 
repeating subunits, the nucleosomes (see also section I 2.2; (191)). Linear nucleosomal arrays 
represent an extremely strong barrier to Pol II passage (230). One possibility of how Pol II 
elongation can proceed is nucleosome disassembly in front of Pol II. This mechanism was 
observed at highly transcribed genes with a high density of Pol II molecules (165, 273). 
Additionally, a genome-wide analysis of nucleosome occupancy in yeast revealed that the 
transcription rate is inversely proportional to the histone density in the coding region of genes 
(178). Although, transcriptionally very active yeast genes were depleted of histones in the 
coding region, histones immediately re-associated with the DNA at a very high rate when 
genes were turned off (273). Taken together, during gene transcription the chromatin structure 
is reversibly altered.  
To achieve transcription in a chromatin environment, cells have evolved different classes of 
factors that together with Pol II are able to modify chromatin structure. Among those factors 
are chromatin remodelers, histone chaperones, histone modifying enzymes and other 
transcription factors (13). Whereas chromatin remodelers use the energy of ATP hydrolysis to 
move, destabilize, eject or restructure nucleosomes (50), histone chaperones assemble or 
disassemble nucleosomes without using the energy of ATP (13). For example Spt16/Pob3 
(also called FACT complex in higher eukaryotes) and Spt6 (see following section) are histone 
chaperones in yeast that facilitate Pol II transcription elongation in vivo by destabilizing 
nucleosome structure and by reassembling nucleosomes after Pol II passage (24).  
Histone modifying enzymes predominantly modify the flexible histone tails, but also the 
nucleosomal core (88). Although the best characterized modifications at the moment are 
histone methylation and acetylation, many other post-translational modifications were known 
including phosphorylation, ubiquitylation and crotonylation (300). According to the histone 
code model (292) the post-translational histone modifications are rather used for binding of 
chromatin-related proteins than directly affecting chromatin compaction by its 
physicochemical properties. The biological function of the various histone modifications as 
well as the crosstalk between the different marks is currently far from being understood.     
Apart from these distinct subsets of factors that alter the chromatin structure other proteins 
associate with Pol II during transcription elongation to achieve its passage through the 
nucleosomal DNA template. Among these transcription factors are the Paf1 complex, Spt4/5 
(see also section V 1.1), TFIIS, Elf1 and Spn1 (167). Whereas several studies have shed some 
light on the biological role of the Paf1 complex (142), Spt4/5 (184), and TFIIS (45, 151), 
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almost nothing is known about Elf1 and Spn1. Elf1 is a non-essential nuclear protein that 
genetically interacts with Paf1, Spt4/5, Spt6 and Spt16, and localizes to actively transcribed 
regions (246). Spn1 represents an essential nuclear protein that directly interacts with Spt6 
(167). Spn1 may regulates the binding of Spt6 to nucleosomes (200).         
Spt6 is a highly conserved nuclear protein and is essential for viability in yeast. Spt6 is 
required for Pol II transcription elongation and normal chromatin structure. Consistent with its 
role in transcription elongation, Spt6 co-localizes to chromosomal regions in S. cerevisiae and 
Drosophila melanogaster actively transcribed by Pol II. Spt6 stimulates the elongation rate of 
Pol II in vivo and interacts with several other transcription elongation factors, including 
Spt4/5, Elf1 and Spn1. In addition, Spt6 contains a C-terminal tandem SH2 domain that binds 
phosphorylated Pol II CTD (73, 185, 294) (Figure 5). Deletion of that domain in yeast cells 
leads to a slow-growth phenotype and is lethal in the presence of 6-azauracil (6-AU), 
indicating a role in transcription elongation (294). Spt6 may also bind nascent RNA via its S1 
domain (Figure 5). 
 
 
 
 
Figure 5: Domain architecture of yeast Spt6. HtH, helix-turn-helix domain, binds double-stranded DNA; YqgFc, predicted 
to be resolvase or ribonuclease, but in Spt6 catalytic residues are exchanged, thus probably not active; HhH, triple-helix-
domain, binding of double stranded DNA; S1, RNA binding domain; SH2-N, SH2-C, tandem SH2 domain; numbers for 
amino acid residues are indicated; Spt6 is a modular protein with different interaction faces: nucleosome/DNA, RNA and Pol 
II interaction faces (70). (modified from (294)) 
 
 
Consistent with its role in influencing the chromatin structure, Spt6 directly interacts with 
histone H3 and can assemble nucleosomes in vitro (32). In agreement with this study, spt6 
mutations lead to transcription from cryptic promoters within the coding region of genes, 
suggesting that Spt6 is required to re-establish correct chromatin structure after Pol II passage 
(145), especially at highly transcribed genes (133). Spt6 seems also to be involved in the 
positioning of the +1 nucleosome (133). Recently, it could be shown that Spt6 is required in 
heterochromatic silencing in Schizosaccaromyces pombe (152).  
 
 
 
1.2 Modification of the Pol II CTD during gene transcription 
In the course of the Pol II transcription cycle the CTD is dynamically phosphorylated and 
dephosphorylated by site-specific CTD kinases and CTD phosphatases (161). During 
transcription initiation Ser5 residues of the CTD consensus repeats are phosphorylated (S5P) 
by Kin28 and CDK7, subunits of the yeast and mammalian TFIIH complex, respectively (4, 
162, 272). Srb10/CDK8 that is part of the Mediator complex can also phosphorylate Ser5 
residues of the Pol II CTD (34, 121). But in contrast to Kin28, Srb10 phosphorylates the CTD 
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prior to the formation of the initiation complex what interferes with the recruitment of Pol II 
to the gene promoter and results in inhibition of transcription (121). This modification 
facilitates the association of the mRNA capping enzyme (98), the termination factor Nrd1 
(308) and of the histone methyltransferase Set1 (222).  
During transcription initiation Kin28 also phosphorylates the Pol II CTD at Ser7 residues in 
yeast (157). Its function, if any, is currently not known. However, in mammalian cells CTD 
Ser7-phosphorylation (S7P) by CDK7 occurs further downstream of the TSS, during 
transcription elongation (41). S7P recruits the Integrator complex and thus is important for 3’ 
end processing of snRNAs (80, 81). Shortly downstream of the TSS, S5P and S7P marks were 
removed in yeast (157, 162, 272). S5P levels can be modulated by the CTD phosphatase 
Ssu72 (328). It is currently under debate whether Rtr1 is a bona fide phosphatase that may 
also contribute to reduce S5P levels (213). The S7P CTD phosphatase is not known. 
In the course of transcription elongation CTD Ser2-phosphorylation (S2P) levels increase 
(162). The CTD Ser2-kinases in yeast are Bur1 and Ctk1 (253). Bur1 is recruited by CTD 
Ser5-phosphorylation (253). However, the mechanism of Ctk1 recruitment remains to be 
determined. In higher eukaryotes P-TEFb/CDK9 phosphorylates CTD on Ser2 residues (239). 
CTD Ser2-phosphorylation facilitates the association of elongation factor Spt6 (294) and 
recruits termination factors Pcf11 and Rtt103 to transcribing Pol II (193, 201). Levels of Ser2-
phosphorylation are modulated by the CTD phosphatase Fcp1 (46). 
Apart from phosphorylation of serine residues, the CTD in mammals can also be 
phosphorylated at tyrosine-1 residues (Y1P) (see section IV 1.2; (19)). The biological 
function of this modification and the corresponding CTD Y1P phosphatase is not known. It is 
also an open question whether Tyr1-phosphorylation exists in lower eukaryotes such as yeast.  
As this work was in preparation, a study appeared showing that Pol II CTD is also 
phosphorylated on residue Thr4 by the Ser2 kinase P-TEFb/CDK9  (128). The study revealed 
that in chicken cells Thr4 phosphorylation seems to be specifically required for 3’ end 
processing of histone mRNAs (128). Although Thr4 phosphorylation was also detected in 
yeast and human it remains to be determined whether it plays a similar role, as observed in 
chicken cells, or not. The CTD posphatase that targets phosphorylated Thr4 residues as well 
as factors that may bind to this mark is currently not known. 
Apart from phosphorylation, the Pol II CTD can also be modified by acetylation (Melanie Ott, 
University of California, San Francisco, personal communication), glycosylation (147) and 
methylation (279). Whereas the biological function of CTD acetylation and glycosylation is 
currently not known, methylation of the arginine residue R1810 of the CTD in mammals by 
the coactivator-associated arginine methyltransferase 1 (CARM1) facilitates the expression of 
snRNA and snoRNA genes (279). Similar to the Ser7-phosphorylation in mammals, CTD 
methylation seems to have a gene-class specific role. Although R1810 is conserved in 
mammals, Drosophila melanogaster and Caenorhabditis elegans, the arginine residue is 
absent in yeast. It is not known whether CTD methylation occurs in yeast.    
Additionally, the peptidylprolyl-cis/trans isomerase Ess1 catalyzes the cis-trans isomerization 
of peptide bonds N-terminal of proline residues (Pro-3 and Pro-6 of CTD), resulting in a 
conformational change of the Pol II CTD (275). Ess1 and its mammalian homologue, called 
Pin1, was shown to directly bind to phosphorylated CTD and to CTD that is doubly 
phosphorylated at Ser2 and Ser5 residues, respectively (212, 312). Inhibition of Pin1 by a 
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specific inhibitor blocked Pol II transcription (40). Recently, it was shown that Ess1 plays a 
role in snRNA transcription termination (280).    
 
 
 
1.3  Aims and scope of this work 
Until recently, most models of Pol II transcription were based on experiments performed for a 
very limited number of genes. Additionally, these case studies were often conducted in vitro 
in the absence of regulatory constraints that prevail in the living cell. Therefore for a long 
time the picture of Pol II gene transcription was gene biased and rather incomplete. However, 
during the last couple of years new methods were developed that allowed the analysis of Pol 
II transcription on a systems-wide level in vivo (see section I 3). Microarray and sequencing 
based techniques have shown that more than 75% of the genome in proliferating yeast is 
expressed (64, 219). Complementary to these studies, ChIP-chip analyses have shown that 
large parts of the genome in proliferating yeast is occupied by Pol II (287, 309).  
Recently, it could be shown that initiation factors such as TFIIB are present at all active gene 
promoters in yeast. However, it was unknown whether all Pol II elongation factors are 
recruited to all active genes or only to subsets of genes. Similarly, it was also not known 
whether 5’- and 3’-RNA processing factors are recruited to all active genes. Therefore the 
main goal of this work was to investigate whether a general Pol II transcription complex 
exists that is required for the transcription of all active genes in yeast. To achieve this aim, 
key components of the Pol II transcription machinery should be subjected to systematic ChIP-
chip analysis to reveal whether these factors co-localize at active genes. Statistical analyses of 
the data should provide additional evidence for the existence of a general Pol II transcription 
complex. This genome-wide localization analysis should be combined with classical 
biochemical approaches such as tandem affinity purifications (TAPs) to look whether factors 
that co-localize on chromatin also interact in vivo. 
Our genome-wide study also bears the potential to answer another interesting question, 
namely whether the composition of the Pol II transcription complex changes during 
transcription. Case studies already indicated that parts of the initiation factors are exchanged 
by elongation factors, and that in turn some elongation factors are exchanged by termination 
factors at the 5’- and 3’-region of genes, respectively (155, 243). However, it is not known 
whether these 5’- and 3’-tranistions occur at all active genes in a uniform manner. 
Furthermore, the exact locations of the transitions within the transcribed region are also 
unknown. 
More than a decade ago the laboratories of Stephen Buratowski (Harvard Medical School) 
and David Bentley (University of Colorado) could show for selected genes that the Pol II 
CTD is dynamically phosphorylated and dephosphorylated during transcription in yeast (162, 
272). It is unknown whether this CTD phosphorylation cycle occurs on a genome-wide level. 
This question should be tackled by ChIP-chip analyses of Pol II and its various CTD 
phosphoisoforms. In addition, all the occupancy profiles should be used to investigate how 
factor recruitment correlates with distinct Pol II CTD phosphorylation patterns. 
In higher eukaryotes, Pol II often pauses during early transcription elongation near the TSS 
(217, 339). Although Pol II is stalled at the promoter region of inactive genes in yeast grown 
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to stationary phase (255), it is unknown whether similar type of pausing occurs in 
proliferating yeast. ChIP-chip analyses of Pol II and its different CTD phosphorylated forms 
may provide evidence for pausing during transcription elongation.           
 This work was performed in cooperation with Michael Lidschreiber and Matthias Siebert. 
    
 
 
2. Specific procedures 
 
 
Table 17: Proteins analyzed by ChIP-chip (other proteins that were investigated by ChIP-chip are listed in 
Table 19 and 22) 
Protein Process involved ChIP protocol 
Rpb3 (Pol II) Gene transcription For TAP-tagged proteins 
S5P (Pol II) Pol II transcription early elongation/ 5’-RNA 
processing 
For Pol II phospho-
isoforms 
S7P (Pol II) Currently not known in yeast For Pol II phospho-
isoforms 
S2P (Pol II) Pol II transcription elongation/3’-RNA 
processing 
For Pol II phospho-
isoforms 
TFIIB Pol II transcription initiation For TAP-tagged proteins 
Kin28 (TFIIH) Pol II transcription initiation For TAP-tagged proteins 
Tfg1 (TFIIF) Pol II transcription initiation For TAP-tagged proteins 
Cet1 (mRNA capping enzyme) 5’-RNA processing (mRNA Capping) For TAP-tagged proteins 
TFIIS Pol II transcription initiation/elongation For TAP-tagged proteins 
Bur1 Pol II transcription elongation For TAP-tagged proteins 
Ctk1 (CTDK-I complex) Pol II transcription elongation For TAP-tagged proteins 
Elf1 Currently not known For TAP-tagged proteins 
Paf1 (Paf1 complex) Pol II transcription elongation For TAP-tagged proteins 
Pcf11 (CFIA complex) Pol II transcription termination/ 3’-RNA 
processing 
For TAP-tagged proteins 
Spn1 (also called Iws1) Pol II transcription elongation For TAP-tagged proteins 
Spt4 Pol II transcription elongation For TAP-tagged proteins 
Spt5 Pol II transcription elongation For TAP-tagged proteins 
Spt6 Pol II transcription elongation For TAP-tagged proteins 
Spt6∆C (C-terminal truncation) For TAP-tagged proteins 
Spt16 (FACT complex) Pol II transcription elongation For TAP-tagged proteins 
 
 
 
2.1 Molecular cloning and phenotyping of epitope-tagged yeast strains 
The TAP-tag has a molecular weight of 25 kDa and thus leads to a markedly extension of the 
epitope-tagged protein of interest. It has been shown that the TAP-tag can interfere with the 
biological function of the tagged protein (31, 143). Although, this seems to be true for only a 
small subset of proteins, a C-terminal TAP-tag on TFIIS led to a slow-growth phenotype in 
the presence of 6-azauracil. This indicated that a C-terminal TAP-tag could interfere with the 
biological function of TFIIS. To test whether an N-terminally TAP-tagged version of TFIIS is 
compatible with yeast cell growth and thus with the biological function of TFIIS, an N-
terminally TAP-tagged TFIIS strain was generated essentially as described in (31). Briefly, 
the URA3 gene (of Kluyveromyces lactis) was originally amplified from the plasmid CIp10 
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(215) (primers: DST1_URA_Fw; DST1_URA_Rev; Table 6) and transformed into BY4741 
wild-type yeast cells. The amplified DNA was inserted after the start codon of DST1, the gene 
coding for TFIIS. Positive transformants were identified on SC -ura plates. In a second step 
the URA3 gene was replaced by the TAP-tag, originally amplified from the plasmid pBS1539 
(251) (primers: DST1_TAP_Fw; DST1_TAP_Rev; Table 6). Transformants were plated on 5-
FOA to select for loss of the inserted URA3 gene (counter selection). Finally, the strain 
expressing an N-terminally TAP-tagged version of TFIIS was validated by control PCR 
(primers: DST1_cont_Fw; DST1_cont_Rev; Table 6), DNA sequencing and Western Blotting 
(see section II 2.1.1 and II 2.7). This strain was further characterized by phenotyping 
experiments (described in following section). By the application of this cloning strategy the 
tagged gene was still under the control of the endogenous DST1 promoter and no additional 
sequences other than the TAP-tag encoding nucleotides were inserted into the genome. 
To test whether Elf1 and Spn1 could interact in vivo, a yeast strain was generated that 
expresses a C-terminally 3HA-tagged version of the Pol II transcription elongation factor Elf1 
and a C-terminally TAP-tagged version of Spn1.   
The plasmid pFA6a-3HA-kanMX6 (190) was used as a PCR template to amplify the DNA 
coding for the 3HA-Tag and the kanMX6 marker cassette (primers: 66_Elf1-3HA_Fw, 
68_Elf1-3HA_Rev; Table 6). The PCR product was transformed into the Spn1-TAP strain 
(BY4741 background) and replaced the original stop codon of ELF1 (new stop codon at the 
3’-end of the DNA region that codes for the 3HA-tag).  Positive transformants were identified 
on G418 selective media plates. The Spn1-TAP Elf1-3HA yeast strain was validated by 
control PCR (primers: 68_Elf1-3HA_control_Fw, 66_Elf1-3HA_control_Rev; Table 6), DNA 
sequencing, Western blotting and phenotyping as described in section II 2.1.1 and II 2.7.   
To test whether a TAP-tag fused either C-terminally or N-terminally to the Pol II transcription 
elongation factor TFIIS may interferes with yeast cell growth, serial dilutions of the C-
terminally and N-terminally TAP-tagged TFIIS strains were grown at different temperatures 
or in the presence of the nucleotide depleting drug 6-azauracil (6-AU). Yeast cells were 
grown at 30°C to stationary phase over-night. Yeast cell cultures were diluted to an OD600 ~5 
and spotted in 1:10 serial dilutions on YPD plates or on selective media plates containing 25, 
50 or 100 µg/ml 6-AU. YPD plates were incubated at 30°C (= standard condition), 37°C or at 
14°C for several days and inspected daily. 6-AU selective media plates were incubated at 
30°C for several days and inspected daily. Wild-type yeast (no TAP-tag) and TAP-tagged 
TFIIS strains were grown on the same solid media plate. Biological duplicate measurements 
were performed. 
 
 
 
2.2 ChIP-chip analysis of the Pol II transcription machinery 
An overview of all factors that were investigated by ChIP-chip in this study is given in Table 
17. ChIP-chip analysis of the Pol II transcription machinery in proliferating yeast was 
performed as described in section II 2.1, II 2.2 and according to (9, 83). However, the 
standard protocol had to be optimized for the genome-wide localization analyses of the 
Spt6∆C mutant, the Pol II transcription elongation factor TFIIS and for the different Pol II 
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phospho-isoforms. For all factors at least two independent biological replicate measurements 
were conducted. Before ChIP-chip analyses of the various factors, the corresponding yeast 
strains were validated as described in section II 2.1.1. 
 
 
2.2.1 Genome-wide occupancy profiling of Spt6∆C and TFIIS 
For ChIP-chip analysis the Spt6∆C-TAP yeast strain (70) (Table 4) was used. This strain 
expressed a C-terminally TAP-tagged version of a C-terminally truncated form of the Pol II 
elongation factor Spt6 (lacking the 202 C-terminal residues). Since the lysis efficiency of 
Spt6∆C-TAP cells was two-fold lower than for all the other yeast strains used for ChIP-chip 
analysis, the cell number was doubled. Therefore, 1.2 L (instead of 600 ml) of yeast was 
grown to mid-log phase (OD600 ~ 0.8). All the other steps were performed as described in 
section II 2.2. 
For the genome-wide localization analysis of the Pol II transcription elongation factor TFIIS, 
the TFIIS N-TAP strain was used. This yeast strain expressed an N-terminally TAP-tagged 
form of TFIIS (see also III 2.1). This strain was used, since a C-terminal TAP-tag interfered 
with yeast cell growth and thus with the biological function of TFIIS. The initial ChIP-signal 
of TFIIS obtained with the standard protocol was low. The fold enrichment over an 
unoccupied genomic region was in the range of 3- to 4-fold. By doubling the amount of cells, 
the ChIP-signal of TFIIS could be improved. Therefore, 1.2 L (instead of 600 ml) of yeast 
was grown to mid-log phase (OD600 ~ 0.8). All the other steps were performed as described in 
section II 2.2.  
    
 
2.2.2 ChIP-chip analysis of Pol II and its different phosphorylated forms 
ChIP-chip analysis off Pol II was performed with a yeast strain expressing a C-terminally 
TAP-tagged version of the core subunit Rpb3. This allowed the genome-wide localization 
analysis of Pol II independent of the CTD phosphorylation state. ChIP-chip experiments were 
performed essentially as described in II 2.1.1 and II 2.2.  
For ChIP-chip analyses of the Pol II phospho-isoforms a set of monoclonal antibodies with 
strong specificity and affinity for phosphorylated serine residues S5P (3E8), S2P (3E10) and 
S7P (4E12) were used (41). Since the monoclonal antibodies were generated in rats, it 
remained to be determined whether these antibodies work in ChIP experiments performed in 
yeast. Furthermore, it was reported that the amount of antibody used influences the occupancy 
profiles obtained for Pol II phospho-isoforms (157). Therefore, we carried out ChIP-qPCR 
experiments with different amounts of antibodies before ChIP-chip analyses as described in 
(199). Based on these experiments the amount of antibody for chromatin immunoprecipitation 
could be optimized (see Table 8). ChIP-chip analyses of the different Pol II phospho-isoforms 
were performed essentially as described in section II 2.1.2 and II 2.2.  
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2.3 Tandem affinity purification of Elf1 and Spn1 
Tandem affinity purification (TAP) of Elf1 and Spn1 was performed essentially as described 
(251). Briefly, for Elf1 TAP an Elf1-TAP yeast strain was used. Spn1 TAP was performed with a 
yeast strain that expressed a C-terminally TAP-tagged version of Spn1 as well as a C-terminally 
3HA-tagged version of Elf1 (Spn1-TAP Elf1-3HA; see section III 2.1). 4 L of yeast were grown 
from OD600 of 0.1 to ~3 at 30°C. Cells corresponding to a 1 L yeast culture were harvested, 
washed with 500 ml of sterile H2O (4°C), resuspended in 25 ml TAP lysis Buffer, flash-frozen in 
liquid nitrogen and stored at -80°C. Two pellets were pooled (corresponding to a 2 L yeast 
culture), the same volume of glass beads were added and lysed by bead beating for 12 min at 500 
rpm and 4°C (Pulverisette). The cell lysate was ultra-centrifuged for 1.5 h at 27,000 rpm (SW28 
rotor, Beckman Coulter) and 4°C. 0.5 ml (slurry) of IgG beads pre-equilibrated in TAP lysis 
Buffer were added to the lysate and incubated for 1.5 h at 4°C. Beads were transferred into a 
column (Bio-Rad) and washed with 10 ml TAP wash Buffer (4°C). Beads were resuspended in 
150 µl TAP wash Buffer and incubated with 2 µl (8 µg) TEV protease for 1.5 h at 20°C. After 
incubation 150 µl of TAP wash Buffer was added. The resuspension was diluted with an equal 
volume of Calmodulin Buffer 1 and 0.5 ml (slurry) Calmodulin beads, pre-equilibrated in 
Calmodulin Buffer 2, was added and incubated for 1 h at 4°C. Beads were washed with 5 ml 
Calmodulin Buffer 2. Next, 600 µl of TAP elution Buffer was added and proteins were eluted 
during a 20 min incubation step at 37°C. Proteins in the final eluate were precipitated with 
Trichloroacetic acid (TCA) as described in section II 2.6. All buffers are listed in Table 14.    
Proteins associated with the purified TAP‐tagged proteins were identified either by mass 
spectrometry (Zentrallabor für Proteinanalytik, Ludwig‐Maximilians‐Universität München) or by 
Western blot analysis using monoclonal antibodies directed against an epitope tag of the protein 
of interest (α-3HA-tag, 3F10; α-TAP-tag, PAP;) or, if available, against the protein of interest 
itself (α-Rpb1, 8WG16; α-Rpb3, 1Y26). For further details of the antibodies please see Table 9. 
Western blot analysis was performed as described in section II 2.7. 
 
 
 
3. Results 
3.1 Genome-wide profiling reveals Pol II on a majority of genes  
We determined genome-wide occupancy profiles by ChIP in exponentially growing 
Saccharomyces cerevisiae strains expressing tandem affinity purification (TAP)-tagged 
proteins (see Table 4 and 17). Chromatin immunoprecipitation was performed as described in 
section II 2.1, II 2.2 and III 2.2. Enriched DNA fragments of an average size of 250 nt were 
analyzed with tiling microarrays that cover the yeast genome at 4 nt resolution (64). For data 
normalization, we developed a procedure that corrects for non-specific antibody binding by 
using both mock immunoprecipitation and input measurements (see section II 2.2.4.1). Data 
from two or three highly reproducible replicates were averaged. The profile for the Pol II 
subunit Rpb3 (Figure 6) matched our previous profiles, which were obtained with different 
strains, experimental protocols, and array platforms (136), but showed more details. Pol II 
was observed at protein-coding, snRNA, and snoRNA genes, and at regions producing cryptic 
unstable and unannotated transcripts (330), but was lacking at genes transcribed by Pol I and 
Pol III.  
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Out of 4366 yeast genes with annotated TSS and pA sites (219), 2465 (56%) showed Pol II 
peak occupancies above 20%, consistent with transcription of most of the genome (64). To 
average Pol II profiles over genes, genes with the 50% highest mRNA levels (70) and a 
minimum distance to neighbouring genes were sorted into four major length classes, scaled to 
adjust length differences, and aligned with their TSS and pA sites (see section II 2.2.4). The 
pA site marks the point of RNA 3′-cleavage and polyadenylation, but transcription continues 
beyond this site until termination. Consistent with this, the gene-averaged Rpb3 profile 
revealed Pol II occupancy through the transcribed region into the region flanking the pA site 
on the 3′-side (Figure 6 b,c). Although this observation already indicates that the gene-
averaged occupancy profile of Pol II is biologically meaningful, we also looked whether one 
can find this occupancy pattern also at single genes. As shown in Figure 6 a, the gene-
averaged profile of Pol II is also true on a single-gene level.   
Taken together, ChIP-chip analysis in yeast revealed a uniform Pol II occupancy pattern on 
most protein coding genes, as well as Pol II binding at snRNA genes, snoRNA genes and at 
regions coding for CUTs and SUTs.    
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Figure 6: Genome-wide occupancy 
profiling of the Pol II machinery. (a) Factor 
occupancy on selected genes. Colored profiles 
represent normalized factor occupancies 
smoothed by a 150 nt window running 
median. Black boxes indicate transcripts (64) 
on the Watson (top) and Crick strands 
(bottom). (b) DNA frame with promoter, 5′ 
untranslated region (UTR), open reading 
frame (ORF) and 3′ UTR. Dashed black lines 
indicate the TSS and pA site. Dashed gray 
lines mark the positions 150 nt downstream of 
the TSS and 100 nt downstream of the pA 
site. (c) Gene-averaged profiles for the 
median gene length class (1,238 ± 300 nt, 339 
genes) of Pol II and its phosphorylated forms. 
Profiles of other length classes are generally 
similar (exemplarily shown for Pol II 
initiation and 5’ capping factors Figure 7). 
Occupancies and signal intensities are given 
for Rpb3 and phosphorylated Pol II on the left 
and right y axes, respectively. (d) Gene-
averaged profiles as in (c) for initiation 
(TFIIB, TFIIF, TFIIH), 5′ capping (Cet1) and 
termination (Pcf11) factors. (e,f) Gene-
averaged profiles as in (c) for elongation 
factors of groups 1 (Spt4, Spt5, Spt6), 2 (Elf1, 
Spn1) and 3 (Spt16, Paf1, Ctk1, Bur1). (g) 
Cartoon representation of Pol II (black dots) 
and its CTD (black lines) transcribing along 
DNA (horizontal gray line) from left to right, 
to produce mRNA (gray lines). IFs, initiation 
factors; EFs 123, elongation factors of groups 
1, 2 and 3; S2/5/7P, phosphorylation of 
serines 2, 5 and 7. 
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3.2 Initiation/termination factors flank the transcribed region 
Gene-averaged profiles for the initiation factors TFIIB, -F, and -H show a single strong peak 
50-30 nucleotides upstream of the TSS (Figure 6 b,d and Figure 7) and was independent of 
the gene length (Figure 7). This indicates the presence of initiation complexes at promoters 
and is consistent with a scanning mechanism for TSS location in yeast (163, 168). TFIIF was 
only observed at promoters and not within transcribed regions, indicating that its reported 
elongation-stimulatory activity in vitro (261) is restricted in vivo to early RNA elongation and 
to downstream sites of transient association. Weaker peaks for initiation factors were 
observed in the 3′-region and this may indicate gene looping at selected genes. Occupancy of 
the capping enzyme subunit Cet1 peaked just downstream of the TSS, consistent with capping 
when the nascent RNA appears on the Pol II surface. The symmetric peaks of averaged 
occupancy of initiation factor and capping enzyme indicated that these factors are restricted to 
defined locations just upstream and downstream, respectively, of the TSS. Occupancy for the 
3′-processing and termination factor Pcf11 peaked downstream of the pA site, consistent with 
transcription and completion of mRNA 3′-end formation downstream of the pA site. The 
location of Pcf11 peak occupancy levels were independent of the gene length (Figure 6 and 
6/7). Thus, representative initiation and termination factors show peak occupancies outside 
the transcribed region, and are apparently not present during mRNA chain elongation. 
 
Figure 7: Gene-averaged median profiles of Pol II initiation and termination factors for (a) “Short” and (b) “Long” 
genes. The “Short” gene length class includes genes with a length ranging from 512 to 937 bp (in total 266 genes, see 
methods). The “Long” gene length class contains genes with a length ranging from 1538 to 2895 bp (in total 299 genes, see 
methods). The gene-averaged median profiles of Pol II initiation factors for “Medium” sized genes are shown in Figure 6. 
 
 
3.3 Elongation factors enter during a single 5′-transition 
Elongation factor profiles did not correlate with profiles of initiation or termination factors 
(Figure 8). Elongation factors were absent at the promoter, but their occupancies sharply 
increased downstream of the TSS within a narrow window of ~50 nt, indicating coordinated 
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elongation complex assembly during a single 5′-transition (Figure 6, e-f). Spt16/FACT was an 
exception, as it entered already ~30 nucleotides further upstream. Elongation factors showed 
characteristic distributions over the transcribed region. Three distinct profile shapes were 
observed and used to group the factors (Figure 8 b). Group 1 includes Spt4, Spt5, and Spt6, 
group 2 includes Spn1/Iws1 and Elf1, and group 3 includes Spt16/FACT, Paf1, and the CTD 
kinases Bur1 and Ctk1. 
 
 
 
Figure 8: Statistical analysis indicates a general elongation complex. (a) Correlation analysis of genome-wide occupancy 
profiles. Initiation factors TFIIB, Tfg1 (TFIIF), Kin28 (TFIIH) and the capping enzyme Cet1 have similar profiles that are 
distinct from those of the nine elongation factors and the termination factor Pcf11. Elongation factors of groups 1, 2 and 3 
(dark red, light green and blue) cluster in two dimensions when Pearson correlation coefficients between occupancy profiles 
are provided as similarity metric. Lines represent direct and functional interactions previously known (gray) or described here 
(black). Factors represented by ovals are not essential in yeast. (b) Pol II factors can be grouped by their gene-averaged 
profiles. See Results for details. (c) SVD analysis. The contributions of the first five singular vectors to the variance (red) are 
shown in comparison to a control with randomly permuted matrix elements (gray). SVD reveals that 92% of the variance of 
peak occupancies of elongation factors at each gene can be explained by strictly covarying factor occupancies as a 
contribution from the first singular vector (left). When all factors are included, 83.1% of the variance is explained by 
covariation (right). (d) Residual correlations described by all but the first singular vector reveal a modular substructure 
among factors and phosphorylated Pol II forms, suggesting physical and functional interactions. 
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3.4 Spn1 and Elf1 interact within a Pol II complex 
The close resemblance of the gene-averaged profiles of the poorly characterized factors Spn1 
and Elf1 suggested that these factors may interact in vivo (Figure 6 e and Figure 9 a). To test 
this, we generated a yeast strain that expressed a C-terminally TAP-tagged version of Spn1 as 
well as a C-terminally HA-tagged version of Elf1 (see III 2.1). We performed tandem affinity 
purification (TAP) of Spn1 (see III 2.3). Spn1 TAP led to the co-purification of Elf1, Pol II 
(Rpb3) and Spt6 (Figure 9 b,c), consistent with an interaction between Spn1 and Elf1. We 
also performed an Elf1 TAP, which led to co-purification of the two Pol II subunits Rpb1 and 
Rpb3 (Figure 9 c). Since there were no specific antibodies available that recognize yeast 
Spn1, we could not test for co-purification of Spn1. These results suggested that Spn1 and 
Elf1 interact within a Pol II complex, and the profiling data suggests that their function and 
requirement during the transcription cycle is distinct from that of other elongation factors. 
 
 
 
 
Figure 9: Elf1 co-purifies with Spn1 and Pol II. (a) Gene-averaged occupancy profiles of Elf1 (green) and Spn1 (orange). 
Western blotting analysis was performed to validate the TAP strains (inset). The results for the Spn1- and Elf1-TAP strains 
are indicated on lane 1 and 2, respectively. The molecular weight marker is given on lane M. (b) Spn1 TAP: the purified 
protein sample was analyzed by SDS-PAGE and Coomassie staining. Spt6 could be identified by mass spectrometry. The 
molecular weight marker (kDA) is given on the right. Spn1 copurifies with Spt6. (c) Elf1 and Spn1 TAPs: the protein 
samples were analyzed by SDS-PAGE and Western blotting. The TAP-strains as well as the control strain (with no TAP tag) 
are given above the panels. The proteins identified by Western blotting are indicated on the left. Elf1 co-purifies with two Pol 
II subunits Rpb1 and Rpb3. Spn1 copurifies with Rpb3 and Elf1 bearing a C-terminally 3HA tag. For the latter experiment, a 
yeast strain was generated that expressed both, a C-terminally 3HA-tagged version of Elf1 as well as a C-terminally TAP-
tagged version of Spn1. 
 
 
 
3.5 Elongation factors exit during a two-step 3′-transition 
Around the pA site, two steps of a 3′-transition could be distinguished. The two-step transition 
was most easily seen at genes with high factor occupancies, such as ribosomal protein genes 
(Figure 10). Whereas group 3 factor occupancies sharply decreased upstream of the pA site, 
group 1+2 factors apparently exited further downstream, suggesting they are present during 
RNA 3′-end formation and/or transcription termination. Spn1 and Elf1 peaked just upstream 
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of the pA site and dropped only to around 80% of their peak occupancies at 100 nt 
downstream of the pA site (Figure 6 e and Figure 9 a). 
 
 
 
 
 
 
3.6 A general Pol II elongation complex for chromatin transcription 
High correlations between elongation factor profiles (Figure 8 and 11) suggested that all 
elongation factors co-occupy active genes. 
 
 
 
Figure 10: Two-step 3‘ transition observed at 
ribosomal protein (RP) genes. Shown are 
averaged elongation factor profiles on selected 
ribosomal protein genes. Dashed lines indicate 
the TSS and pA sites. The regions of the two-
step 3′ transition are indicated. In contrast to the 
averaged profiles in Figure 6 and 7, the very 
high occupancies did not allow us to align 
profiles with their promoter minima along the y 
axis. 
 
Figure 11: Pol II elongation factors 
co-localize genome-wide. Elongation 
factor occupancies are shown for a 
representative region of yeast 
chromosome 12. The exact genomic 
position is given above factor 
occupancies. The location of 
transcripts (64) are indicated as black 
boxes and are indicated below. The 
transcripts are shown for the Watson 
(upper line) and Crick strand (lower 
line). Each bar in the occupancy 
profile represents the normalized 
signal from a 150 bp sliding window. 
Note the high degree of covariation 
among the 9 occupancy profiles.  
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To investigate this, we measured co-variation in the data sets by singular value decomposition 
(SVD). We calculated peak occupancies for nine elongation factors within 4366 genes. After 
subtracting the row mean of the 9×4366 matrix from each element, the resulting matrix was 
subjected to SVD. The first singular value, which describes strict co-variation, explained 92% 
of the total variance (Figure 8 c, left panel). Thus elongation factor occupancies co-varied 
over all genes, consistent with a general composition of the elongation complex. 
The apparent elongation complex composition and coordinated assembly during a 5′-
transition were independent of gene length, expression, function, transcript type, size of the 
nucleosome-depleted promoter region and the presence of introns (Figure 12 and not shown). 
Although differences in the composition of elongation complexes in individual cells can not 
be ruled out, these results strongly indicate a general initiation-elongation transition and a 
general elongation complex composition on Pol II genes. 
 
 
 
 
 
 
 
Figure 12: Transcription complex 
composition and transitions are 
independent of gene length, expression, 
and NFR size. (a, c, e) Medians of the peak 
factor occupancies covary between different 
length classes (a), expression level classes (c), 
nucleosome-free promoter region (NFR) size 
classes (e) (123, 335), gene function (gene 
functions include 213 G1 cell cycle genes, 
206 amino acid (aa) synthesis genes, and 421 
protein synthesis genes, obtained as 
transcription modules from Ihmels et al. 
(130)) (b, d, f) Gene-averaged profiles of the 
representative elongation factor Elf1 have 
shapes and transition points that are 
independent of gene length (b), expression 
level (d) and NFR size (f). The same holds 
for all other profiled factors and also for 
genes grouped by transcript type and 
functional class (data not shown).  
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3.7 CTD phosphorylation profiles depend on TSS location 
To investigate how the observed profiles and transitions correlate with CTD phosphorylation, 
we determined occupancy profiles for Pol II phosphorylated at CTD residues Ser7, Ser5, and 
Ser2, using site-specific antibodies (41) (see Table 8). The averaged profiles reveal broad 
peaks of Ser7 and Ser5 phosphorylation at around 20 and 120 nt downstream of the TSS 
(Figure 6 a,b,c). Levels of Ser7/Ser5 phosphorylation decrease over the transcribed region, 
whereas Ser2 phosphorylation increases, saturates at 600-1000 nt downstream of the TSS, and 
sharply decrease 100-200 nt downstream of the pA site on all genes (Figure 6 b,c). The point 
where full Ser2, Ser5 and Ser7 phosphorylation was reached did not depend on pA site 
location, but rather on TSS location (Figure 13). The point where Ser2 phosphorylation 
decreased depended on the pA site location (Figure 13, right panel). We note however that 
changes in ChIP efficiency that are due to the accessibility of the phosphorylated CTD to 
antibodies may not be ruled out.  Taken together, CTD phosphorylation patterns that were 
observed on individual genes (162, 272) occur globally and depend on TSS location. 
 
 
 
Figure 13: Occupancy levels of Pol II phospho-isoforms depend on the TSS location (exemplified for S2P). Gene-
averaged median profiles of the Ser2 phosphorylated form of Pol II are shown for three gene length classes (see section II 
2.2.4.3) aligned at TSS (left) and pA sites (right), respectively. 
 
  
 
3.8 Recruitment of CTD kinases explains CTD phosphorylations 
The Ser7/Ser5 peaks just downstream of the TSS are consistent with the presence of the 
Ser7/Ser5 kinase Kin28 (4) just upstream of the TSS (Figure 14 a). The early peak of Ser7 
phosphorylation is further consistent with dependence of Ser7 phosphorylation on Mediator 
(30), which binds at promoters. The subsequent increase in Ser2 phosphorylation is consistent 
with entry of the Ser2 kinases Bur1 and Ctk1 (187, 216) during the 5′-transition, and with 
their continued presence in transcribed regions (Figure 14 a). Thus specific CTD 
phosphorylations can be explained by the recruitment of corresponding specific CTD kinases 
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at defined distances from the TSS. Unfortunately we could not obtain satisfactory profiles for 
CTD phosphatases to study their recruitment with respect to the observed decreases in CTD 
phosphorylations. 
 
 
Figure 14: Pol II phosphorylation and factor occupancy. (a) Gene-averaged profiles (for gene length class long (L) only) 
of CTD phosphorylations, CTD Ser5 kinase Kin28 and Ser2 kinases Bur1 and Ctk1. (b) Profiles for Ser2-phosphorylated Pol 
II and Pcf11 aligned at the TSS and pA site, respectively, and averaged for length classes short (S), medium (M) and long 
(L). Occupancy and signal intensity for Pcf11 and S2P are plotted on the left and right y axes, respectively. (c) Gene-
averaged profiles of Spt6 and the C-terminal deletion variant Spt6∆C (lacking the 202 C-terminal residues) (70). As 100% 
occupancy levels are not expected for Spt6∆C, the y axis shows ChIP enrichments obtained by normalization with input 
measurements as well as mock IPs without scaling to 100% occupancy.  
 
 
3.9 CTD phosphorylation and factor recruitment 
To unravel relations between CTD phosphorylations and factor occupancies, we subjected all 
profiles to SVD and correlated residual profiles lacking contributions of the first SVD term 
that described 85.6% of the covariation of factor occupancies. Ser7 and Ser5 phosphorylation 
correlated with capping enzyme occupancy (Figure 8 d), as expected from binding of capping 
enzyme to Ser5-phosphorylated CTD in vitro (264). Since Ser5 phosphorylation levels peaked 
over 100 nt downstream from the Cet1 peak, the capping enzyme may bind already when the 
first Ser5 residues are phosphorylated. Cet1 occupancy drops very sharply further 
downstream, whereas Ser5 phosphorylation levels remain high, suggesting an active 
mechanism to release the capping enzyme from the CTD. Ser2 phosphorylation correlated 
strongly with Spn1 and Elf1 occupancy (Figure 8 d), suggesting these factors are stabilized 
within the elongation complex by Ser2 phosphorylation. 
 
3.10 Possible Pol II CTD masking and CTD-independent recruitment 
CTD Ser2 phosphorylation did not correlate with occupancy of Pcf11 and Spt6, although 
these factors bind to the Ser2-phosphorylated CTD in vitro (15). Pcf11 was recruited mainly 
at the pA site (Figure 14 b), consistent with the known role of Pcf11 in RNA 3′-processing. 
This may be explained if the Ser2-phosphorylated CTD only becomes accessible to Pcf11 
after pA site passage and 3′-RNA cleavage. Alternatively, Pcf11 crosslinking may be 
increased by cooperative interactions of factors and RNA around the pA site and/or 
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conformational changes in the elongation complex. Spt6 entered early, during the 5′-
transition, suggesting a CTD Ser2 phosphorylation-independent recruitment mechanism. To 
investigate this, we determined the occupancy profile of Spt6 lacking its CTD-binding C-
terminal domain (Spt6∆C) with the use of a yeast strain that expresses only a truncated Spt6 
variant lacking the last 202 residues (70). Deletion of the Spt6 CTD-binding domain strongly 
decreased Spt6 recruitment, but did not abolish its entry during the 5′-transition (Figure 14 c 
and Figure 15). Thus Spt6 is apparently recruited in a CTD-independent manner during the 5′-
transition, but full recruitment requires the CTD-binding domain. The CTD-binding domain is 
required for retaining Spt6 until the pA site (Figure 14 c), consistent with its preference for 
binding the Ser2-phosphorylated CTD.  
 
 
 
These results indicate that binding of a factor to the phosphorylated CTD in vitro cannot 
predict factor recruitment in vivo. This suggests that the CTD may be transiently masked and 
its accessibility may be regulated, and that CTD-independent and CTD phosphorylation type-
independent recruitment contributes to factor recruitment. 
 
3.11 No evidence for promoter-proximally stalled Pol II 
In higher eukaryotes, Pol II is often stalled early during elongation near the promoter (56, 
221, 339), and can be released by activators (257). Our data do not provide evidence for the 
presence of such promoter-proximally stalled Pol II in growing yeast. Genes with stalled Pol 
II would show Ser5- but not Ser2-phosphorylation, or at least more Ser5- than Ser2-
phosphorylation. However, we do not observe genes that show a peak for Ser5 
phosphorylation and at the same time lack a peak for Ser2 phosphorylation (not shown). SVD 
analysis of initiation and elongation factor profiles revealed a high covariance of 83.1% 
(Figure 8 c), suggesting that initiation complexes are generally efficiently converted to 
elongation complexes. Although Rpb3 occupancy peaks around 150 nt downstream of the 
TSS (Figure 6 c), this does not indicate polymerase stalling, since stalling generally occurs 
closer to the TSS. Instead, this Pol II peak may be explained by the 5′-transition that is may be 
Figure 15: Deletion of the Spt6 C-terminal 
Pol II CTD-binding domain results in a 
reduction of fold enrichment at the gene 
encoding ADH1. A TAP-tagged Spt6 wild-
type strain and a Spt6 variant strain lacking 
the 202 C-terminal residues (Spt6∆C) as well 
as a BY4741 strain (without tag) were 
analyzed by ChIP of the ADH1 gene. 
Precipitated DNA was used for quantitative 
PCR amplification with primers directed 
against the promoter, central and 3′ regions of 
the ORF, and against the pA site. The fold 
enrichments for the different positions of the 
ADH1 gene over an ORF-free region on 
chromosome V are given on the y-axis. Error 
bars show standard deviations for three 
independent experiments. 
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slow due to capping, phosphorylation, and assembly events, leading to an apparent 
accumulation of Pol II. Alternatively or additionally, the peak may reflect transient pausing of 
Pol II between the +1 and +2 nucleosomes, which are positioned around 40 and 210 nt 
downstream of the TSS, respectively (139). Our data obtained in exponentially growing yeast 
also do not show evidence for polymerase peaks upstream of the TSS as observed in yeast 
during stationary growth (255). 
 
3.12 General elongation complexes are productive 
To investigate whether the general elongation complexes are active on most genes, we 
correlated averaged Rpb3 and elongation factor occupancies with mRNA levels (70). The 
mRNA level should be proportional to the mRNA synthesis rate of a single elongation 
complex times its occupancy, divided by the mRNA decay rate (Figure 16 caption). For 
constant mRNA synthesis and decay rates we therefore expect a linear dependence between 
occupancy and mRNA level, corresponding to a slope of 1 in a log-log plot. Indeed we find a 
robust correlation of 0.65 between the log occupancy and the log mRNA levels (Figure 16 a). 
However, the slope is only ~0.5. A correlation of 0.71 is obtained when we use the distance-
filtered gene set. This shows that increased mRNA levels are not only due to increased 
elongation complex occupancy, but also due to an increased ratio of mRNA synthesis over 
decay rates. The same dependence leads to a high correlation of 0.79 between the observed 
average occupancy and the expected occupancy calculated from the mRNA level (Figure 16 
b). These correlations indicate that most general elongation complexes are active in producing 
mRNA and that gene occupancy with the general elongation complex is a good predictor for 
gene expression level. 
 
Figure 16: Elongation complex occupancy predicts mRNA expression. (a) The logarithm of the average elongation factor 
and Rpb3 transcript occupancy is highly correlated with the logarithm of mRNA levels. For constant mRNA synthesis rates 
(elongation complex speeds) v and decay rates r, we expect a linear relationship between elongation factor occupancy o and 
mRNA levels c, because at equilibrium the rates of mRNA synthesis and decay are equal, and thus ov = cr. This would result 
in a linear dependence between log o and log c with slope 1: log o = log c + log (r/v). The actual slope of 0.49 (green) implies 
that the ratio of Pol II speed to decay rate increases slightly with increasing mRNA level (v/r ן c0.51). For ribosomal protein 
genes, v/r is about three-fold higher than average. (b) The averaged transcript occupancy of Rpb3 and the nine elongation 
factors is highly correlated with the occupancy expected on the basis of the relationship between occupancies and observed 
mRNA levels in (a). 
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3.13 Unpublished result: Genome-wide occupancy profiling of TFIIS   
Several studies have shown that TFIIS plays a role during initiation and elongation of Pol II 
transcription (86, 111, 151, 153, 247, 325). However, until now it is not known whether TFIIS 
is recruited at the promoter of genes and is retained during transcription elongation or whether 
TFIIS is recruited transiently to elongating Pol II. To address this question in vivo, we 
determined the genome-wide occupancy pattern of TFIIS by ChIP-chip analysis. Since it was 
shown that the C-terminal region of TFIIS interacts with the Pol II active site and thus is 
important for triggering the nascent RNA-cleavage activity of Pol II, a 25 kDa C-terminal 
TAP-tag would interfere with the biological function of TFIIS (151). Therefore, we generated 
a new yeast strain that expressed an N-terminally TAP-tagged version of TFIIS (see section 
III 2.1). Phenotyping experiments in the presence of the nucleotide-depleting drug 6-azauracil 
(6-AU) were conducted for wild-type (wt) yeast (no TAP-tag) and for strains expressing 
either an N-terminally (N-TAP) or C-terminally TAP-tagged (C-TAP) version of TFIIS. 
These experiments revealed a slow-growth phenotype for C-TAP but not for the wt and N-
TAP TFIIS strain. This indicated that a C-terminal TAP-tag, but not an N-terminal TAP-tag, 
indeed interferes with the biological function of TFIIS in vivo. However, no differences in 
yeast growth were observed at different temperatures.  
To determine the occupancy pattern of TFIIS on a genome-wide level, we performed ChIP-
chip analysis for the N-terminally TAP-tagged version of TFIIS. This analysis revealed TFIIS 
occupancy at the promoter and at the transcribed region of most protein coding genes in yeast 
(Figure 17 a,b). This suggests that TFIIS, in contrast to the other Pol II elongation factors 
investigated in this work, is present during transcription initiation and elongation. 
Furthermore, we also observed TFIIS occupancy at genes that are transcribed by RNA 
polymerase (Pol) III, such as tRNA genes (Figure 17 c). The latter observation is in accord 
with a recent study showing that TFIIS is also part of the Pol III transcription machinery (96). 
Taken together, ChIP-chip experiments revealed that TFIIS localizes to the promoter and to 
the transcribed region of protein coding genes, what agrees with the view that TFIIS is 
recruited at the promoter region and stays associated with Pol II during transcription 
elongation.  
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Figure 17: ChIP-chip occupancy of TFIIS at protein coding and tRNA genes. (a) Gene-averaged profile for the median 
gene length class (1,238 ± 300 nt, 339 genes) of TFIIS. Profiles of other length classes are generally similar (data not shown). 
(b) TFIIS occupancy on selected protein coding genes. The profiles represent normalized TFIIS occupancies smoothed by a 
150-nt window running median. Violet boxes indicate transcripts (64) on the Watson (top) and Crick strands (bottom). The 
direction of transcription is indicated by black arrows. (c) TFIIS occupancy on selected tRNA genes that are transcribed by 
Pol III. Please note the strong TFIIS ChIP-signal at the beginning and at the end of tRNA genes. The profiles are shown as 
described in (b).  
    
 
 
 
4. Discussion 
4.1  The initiation-elongation transition of the Pol II transcription cycle 
Published biochemical and genetic data suggest that the 5’ transition corresponds to a 
coordinated conversion of a general initiation complex to a general elongation complex. The 
conversion includes initiation factor dissociation, which liberates the Pol II clamp domain 
(43) for binding Spt5 (124). Spt5 could coordinate entry of group 1 factors because it binds 
Spt4 in vitro (112) and associates with Spt6 in vivo (184). Group 1 factors could recruit group 
2 factors, since Spt6 binds Spn1 (167, 184). Consistently group 1 factors interact genetically 
with Elf1 (246), and, as shown here, Spn1 and Elf1 interact within a Pol II complex. 
Recruitment of group 3 factors may commence with CTD Ser5 phosphorylation, which 
recruits Bur1 (253), which in turn phosphorylates Spt5, thereby recruiting Paf1 (176, 187, 
343). Spt16/FACT enters already around 30 nt upstream from other elongation factors 
(Figure 6 f), perhaps due to binding the +1 nucleosome (293), and consistent with its role as a 
histone chaperone (23). Initiation factors are not present when the 5’ transition is completed 
around 150 nt downstream of TSS, consistent with a role of Ctk1 in promoting dissociation of 
initiation factors (2). 
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4.2  A two-step elongation-termination transition at the 3’-end of Pol II genes 
The general two-step 3’ transition we observed is consistent with ChIP data obtained at 
individual genes. The early exit of group 3 factors Paf1, Ctk1, and Bur1 and the continued 
presence of Spt4/5 and Spt6 have previously been observed (148, 155). Our results, however, 
show that the reported Spt16 occupancy downstream of the pA site (155) does not occur 
globally. Also, our observation of peak levels of the bona fide 3’-processing factor Pcf11 
downstream of the pA challenges the idea of an early loading of 3’-processing factors in the 
5’-region of genes (105). We observed continued presence of group 1 and group 2 factors 
downstream of the pA site, consistent with their reported roles in mRNA 3’-processing (144), 
mRNA export (333), and in re-establishing chromatin structure after Pol II passage (145).  
 
 
 
4.3  The role of Pol II CTD phosphorylation during 5’ and 3’ transitions 
Our results also provide insights into the role of CTD phosphorylation during transcription 
complex transitions and in the coordination of transcription-coupled events. Firstly, peak 
levels of Ser7 and Ser5 phosphorylation were generally observed in the 5’ regions of genes, 
and peak Ser2 phosphorylation in the 3’ regions of genes. Secondly, the 5’ transition occurs 
before any substantial Ser2 phosphorylation, suggesting that the assembly of the general 
elongation complex is independent of Ser2 phosphorylation, consistent with the observation 
that the Ser2 kinase Ctk1 is not required for association of elongation factors with transcribing 
Pol II (3). Thirdly, peak levels of Ser2 phosphoryation are always reached 600-1,000 nt 
downstream of the TSS, regardless of the position of the pA site. This argues against a role of 
Ser2 phosphorylation in triggering the 3’ transition, although Ser2 phosphorylation is required 
for co-transcriptional 3’ RNA processing (3). Forthly, the recruitment of Pcf11 and Spt6, 
which both bind the Ser2-phosphorylated CTD in vitro, cannot be explained solely by factor 
binding to the Ser2-phosphorylated CTD in vivo. Instead, late Pcf11 entry suggests CTD 
masking within the transcribed region and an increase in CTD accessibility upon RNA 
cleavage at the pA site, allowing for Pcf11 binding. This issue is addressed in section IV 
(“Topic II”) of this work. Furthermore, Spt6 enters during the 5’ transition even when it lacks 
its CTD-binding domain, indicating that a CTD-independent recruitment mechanism exists. 
The CTD-binding domain seems to be more important for retaining Spt6 until the pA site is 
reached than recruiting it during the 5’ transition. 
 
 
 
4.4  TFIIS co-lovalizes with Pol II at promoter and coding regions of genes 
Several studies have shown that TFIIS plays an important role during Pol II transcription 
initiation and elongation (86, 111, 153, 247, 325). ChIP analysis in yeast revealed that after 
heat shock, TFIIS localizes to the promoter and coding regions of two heat shock responsive 
genes HSP82 and SSA4 (243). Another ChIP study showed TFIIS binding to the upstream 
activating sequence (UAS), promoter and coding regions of GAL1 after galactose induction 
(247). Since the spatial resolution of factor binding of classical ChIP experiments is very 
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limited it is still not known (i) whether TFIIS is transiently recruited to Pol II arrest sites 
during transcription elongation or (ii) whether it is stably associated with the Pol II elongation 
complex after its initial recruitment. ChIP-chip analysis with our optimized protocol revealed 
that TFIIS crosslinks to the promoter and transcribed region of genes, what provides strong 
evidence for the second model of TFIIS recruitment. According to this view, TFIIS is 
recruited during transcription initiation at the promoter of genes via a direct interaction with 
the Pol II core (151, 252). This is also in accord with in vitro studies showing that TFIIS is 
part of the Pol II initiation machinery (111, 153, 247). TFIIS stays associated during the 
initiation-elongation transition and during elongation but dissociates from the Pol II 
elongation complex upstream of the pA site of genes. Our ChIP-chip data support the idea 
that TFIIS has not to be recruited from a distant location to arrested Pol II but is rather closely 
associated with Pol II. Nevertheless, structural changes of the transcription complex have to 
occur that allow TFFIIS to insert its C-terminal domain III into the active site of Pol II to 
induce RNA cleavage activity and reactivation of arrested Pol II (45, 151).   
 
 
 
5. Conclusions and Outlook 
In this work we have established an improved ChIP-chip protocol that allowed us to 
determine the genome-wide binding behaviors of central components of the Pol II 
transcription machinery in yeast at a high resolution. Our data support the following view of a 
productive chromatin transcription cycle. The initiation complex forms ~30–50 nt upstream of 
the TSS and contains unphosphorylated Pol II and initiation factors such as TFIIB, TFIIF and 
TFIIH. The complex then scans for the TSS downstream, begins RNA synthesis and triggers 
RNA 5′ capping, where maximal CTD Ser7 phosphorylation levels occur. Next, the complex 
is converted into a general elongation complex by exchanging initiation factors for elongation 
factors. This initiation-elongation transition is completed around 150 nt downstream of the 
TSS, where CTD Ser5 phosphorylation levels peak. During subsequent elongation, CTD Ser2 
phosphorylation increases until it reaches peak levels 600–1,000 nt downstream of the TSS. 
During a two-step 3′ transition, a group of elongation factors exits upstream of the pA site, 
whereas another group persists downstream, where it is joined by factors such as Pcf11, 
resulting in mRNA 3′ processing and transcription termination. 
This genome-wide study of Pol II transcription in yeast gave rise to several new questions. As 
detailed below, two of the main questions were already addressed in follow-up projects and 
helped to elucidate new aspects of Pol II gene transcription (see section IV “Topic II” and 
section V “Topic III” of this work). Other questions that have arisen from that study are 
currently under investigation or will be investigated in future.   
One interesting finding of our study was that the Pol II CTD modifications S2P, S5P and S7P 
occur at all active genes in proliferating yeast, indicating the importance of CTD 
phosphorylation cycle. However, as this project was completed it was not known whether the 
CTD in yeast could also be phosphorylated at highly conserved Tyr1 and Thr4 residues, and 
thus whether a more complicated “CTD code” exists. Based on these considerations a follow-
up project was launched to investigate whether Tyr1-phosphorylation exists in yeast and if so, 
what the biological function of this modification is (section IV “Topic II” of this work). 
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Furthermore, it is currently not known whether the CTD can be glycosylated in yeast and if 
so, what the biological function of this new type of CTD modification is. This is currently 
under investigation.   
This study also provided evidence for a mechanism that prevents the premature recruitment of 
transcription termination factors, such as Pcf11, to elongating Pol II. The mechanism of how 
the accessibility of the CTD is regulated was not known. This question has already been 
addressed by a follow-up study (section IV “Topic II” of this work).  
Our study revealed that the transcription elongation factor Spt5 co-localizes with Pol II 
throughout the transcribed region and past the pA-site of genes. This already illustrated that 
Spt5 is in an excellent position to recruit other factors during transcription. As our study was 
in progress, it was additionally shown by two other groups that the C-terminal repetitive 
region (CTR) of Spt5 recruits the Paf1 complex to elongating Pol II in yeast (187, 343). All 
these observations prompted us to ask whether the Spt5 CTR may act as a general platform to 
recruit other transcription factors, in a way similar to the Pol II CTD. This question has 
already been addressed (section V “Topic III” of this work). 
The transcription elongation factor Spt6 contains a C-terminal tandem SH2 domain that was 
shown to bind to Ser2-phosphorylated CTD peptides in vitro (294). This observation led to 
the suggestion that Spt6 is recruited to Pol II via a direct interaction of its tandem SH2 domain 
with the Ser2 phosphorylated CTD. However, our ChIP-chip analyses have shown that in the 
absence of the tandem SH2 domain, Spt6 is still recruited to active genes. What are the 
alternative recruitment mechanisms of Spt6 that obviously act in vivo? 
Our study revealed an interaction between the transcription elongation factors Elf1 and Spn1. 
Consistently, the genome-wide occupancy profiles of both factors are almost identical and 
show maximum levels upstream of the pA site of genes. What is the biological function of 
both proteins?   
We have also profiled the occupancy of CTD kinases. An important result was that the 
recruitment of CTD kinases could explain the appearance of CTD phosporylations. However, 
CTD phosphorylation by CTD kinases represents only one part of the CTD phosphorylation 
cycle. Another integral part is the dephosphorylation of the CTD by CTD phosphatases. 
Currently, no genome-wide occupancies of CTD phosphatases are available. Therefore, it is 
an open question whether the recruitment of CTD phosphatases can explain the decrease in 
CTD phosphorylation levels. Another interesting question in this context is which 
phosphatase targets Ser7-phosphorylated CTD?  
Our study provides strong evidence for the existence of general Pol II elongation complex that 
is required for the expression of all genes in proliferating yeast. Although the elongation 
factors investigated here co-localize to active genes in vivo, it is currently not known whether 
the elongation complex is established in a step-wise manner or whether a preformed complex 
of factors is recruited at the 5’ region of genes. For most of these factors it is also not known 
whether they interact with the tail-like CTD or the core of Pol II, or with both parts. 
In the present ChIP-chip study we not only averaged over thousands of yeast cells but also 
over different cell cycle stages. Although single-cell ChIP-chip experiments are currently not 
available and will be extremely difficult to realize, the second issue can be tackled easily. 
Yeast cells can be arrested at a certain stage of the cell cycle from which the whole culture 
can be released simultaneously. ChIP-chip using synchronized yeast cells may provide new 
insights in cell-cycle dependent mechanisms of transcription regulation. 
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 In our genome-wide study presented here, we used ChIP-chip to investigate the DNA binding 
of components of the Pol II transcription machinery. However, a very fascinating question is 
whether and if so, how the Pol II transcription machinery interacts with nascent RNA during 
the transcription cycle. This dynamic binding interface is at the moment almost 
uncharacterized. New innovative techniques such as NET-seq and PAR-CLIP now open up 
new ways to tackle this issue.  
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IV. CTD tyrosine phosphorylation impairs termination factor 
recruitment to transcribing RNA polymerase II 
 
 
1. Introduction 
1.1 Read-out of the Pol II CTD code 
During the transcription cycle the C-terminal repeat domain (CTD) of the largest subunit of 
Pol II gets phosphorylated and dephosphorylated by CTD kinases and phosphatases (37). This 
leads to different phosphorylation patterns that predominate at each stage of the transcription. 
These different phosphorylation states of the CTD were suggested to form a code (36) (for 
details see section I 2.3.2 and III 1.2). However, a biological meaning of that CTD code only 
arises when there are at the same time proteins that can “read” the code. Proteins read that 
code via special domains that recognize a specific CTD phosphorylation pattern (202). CTD 
binding domains usually make contacts with CTD residues that are part of two consecutive 
heptapeptide repeats (202). Additionally, it was shown for yeast that insertion of alanine 
residues between diheptads had little phenotypic effect, while inserting alanines between 
consecutive heptades turned out to be lethal for yeast cells (289). This led to the suggestion 
that the functional unit of the Pol II CTD is contained within pairs of heptapeptides (289). 
CTD-binding proteins mainly comprise factors that are involved in mRNA processing and 
histone-modification (37). The list of factors that associate with the CTD is currently growing 
and therefore it seems likely that proteins involved in other processes may also contact the 
CTD (240).  
 
 
1.1.1 CTD recognition by Nrd1, Pcf11 and Rtt103 
Proteins that were shown to directly bind to particular CTD phosphoisoforms are the Pol II 
transcription termination factors Nrd1, Pcf11 and Rtt103 (193, 201, 308). All three factors 
contact the CTD via a conserved CTD interacting domain (CID) (193, 201, 266, 308). The 
structures of these CIDs are very similar and consist of eight α-helices in a right-handed 
superhelical arrangement (193). The Nrd1-CID was shown to preferentially bind to Ser5 
phosphorylated CTD peptides in vitro (308). In case of Pcf11 the CID is essential for cell 
viability in yeast (266). Pcf11-CID binds to Ser2 phosphorylated CTD mimicking peptides in 
vitro and a co-structure of the Pcf11-CID bound to a S2P CTD peptide reveals the details of 
its binding interface (201). The S2P CTD adopts a β-turn conformation, when bound to 
Pcf11-CID. Interestingly, the phosphate group of the CTD residue Ser2 points away from the 
CID surface and no direct CID contacts were observed (201). Similarly to the Pcf11 and 
contrary to Nrd1, the Rtt103-CID preferentially associates with S2P CTD peptides in vitro 
(193). The co-structure of the Rtt103-CID bound to a S2P CTD peptide helps to explain the 
higher affinity of Rtt103-CID for S2P CTD as compared to the Pcf11-CID. In contrast to 
Pcf11, several residues of the Rtt103-CID directly contact the Ser2 phosphate group of the 
CTD peptide. Interestingly, the S2P CTD peptide is also in a β-turn conformation, when 
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bound to the Rtt103-CID (193). Recently, another interesting aspect of CTD binding via CIDs 
could be revealed. According to this study, CIDs achieve high affinity and specificity for the 
Pol II CTD by cooperatively binding to neighboring CTD repeats (193). This was shown to be 
true for the CIDs of Pcf11 and Rtt103 (193).   
 
 
1.1.2 CTD recognition by Spt6 
In yeast there are three proteins that bear a canonical CID (Nrd1, Pcf11, Rtt103) and one 
protein is predicted to contain a CID (Ctk3; Saccharomyces Genome Database (SGD), 
http://www.yeastgenome.org/). However, more than 100 proteins were known to interact with 
the Pol II CTD in yeast (240). This implies that other domains must exist that allow proteins 
to bind the CTD. Structural studies begin to show that CTD binding proteins use a variety of 
different domains that allow them to read the different phosphorylated states of the CTD 
(202). One example is the CTD binding of Spt6. Spt6 represents an essential nuclear protein 
in yeast (296) that is involved in Pol II transcription elongation in a chromatin environment 
and possesses histone chaperone activity (295). The C-terminal region of mammalian Spt6 
that contains a SH2 domain binds to Ser2 phosphorylated CTD in vitro (333). Recently, 
sequence and structural analyses have shown that the C-terminal region of yeast Spt6 
possesses a “tandem SH2 domain” that consists of two SH2 domains forming an extended 
interface (52, 73, 185, 294). The tandem SH2 domain binds preferentially to Ser2 
phosphorylated CTD in vitro (52, 294). Since no co-structure of the Spt6 tandem SH2-CTD is 
currently available, the molecular details of this interaction remain to be determined.   
 
 
 
1.2 Tyrosine-phosphorylation of the mammalian Pol II CTD 
The CTD is modified by phosphorylation at Ser2, Ser5 and Ser7 residues in yeast and 
mammals (for details see section I 2.3.2 and III 1.3), (37, 41, 157)). In mammals the Pol II 
CTD can also be phosphorylated and dephosphorylated at at tyrosine residues (19). Kinases 
that can target tyrosine residues of the mammalian Pol II CTD are c-Abl (19) and Arg (18), 
but not the c-Src tyrosine kinase (19). The Pol II CTD specificity of c-Abl is conferred by its 
N-terminal SH2 domain (77) as well as by a C-terminally located CTD binding domain (17). 
Furthermore, c-Abl can interact with the Pol II CTD in vitro and with Pol II in vivo (17). 
Tyrosine phosphorylation of the Pol II CTD can enhance transcription of certain genes (17). 
Additionally, genotoxic stress such as treatment of mouse cells with the DNA damaging 
reagent methyl methanesulphonate (MMS) or via an exposure of cells to ionizing radiation 
leads to an increase of tyrosine phosphorylation of the Pol II CTD by the c-Abl kinase, which 
in turn is activated via phosphorylation by the ATM kinase  (21, 188). Although, the 
mammalian Pol II CTD represents a substrate for the c-Abl tyrosine kinase, Drosophila and 
yeast CTD are not efficiently phosphorylated by c-Abl in vitro (20). The biological role of 
CTD tyrosine phosphorylation is not known. It is also not known whether CTD tyrosine 
phosphorylation is restricted to mammals or also exists in lower eukaryotes such as yeast.  
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1.3 Pol II transcription termination 
Accurate termination is important since stopping transcription too late or too early would 
disrupt proper gene expression. Pol II does not terminate transcription at a specific DNA 
sequence at the 3’ end of genes. Transcription termination sites are rather located in a region 
up to 1 kb downstream of the poly(A) site (218). Different models of how Pol II may 
terminate transcription were proposed. 
 
1.3.1 Antitermination versus torpedo model 
Based on the mechanism of how Pol II transcription termination may occur at protein coding 
genes, two major models have been proposed. According to the “anti-terminator” model (also 
called “allosteric” model) transcription through the poly(A) signal changes the properties of 
the elongating Pol II complex. This may occurs by dissociation of positive elongation factors 
or by the recruitment of termination factors (189). The model is supported by chromatin 
immunoprecipitation (ChIP) experiments showing that some elongation factors are exchanged 
for termination factors during an elongation-termination transition at the 3’ end of genes (155, 
199). However, the “torpedo” model proposes that endonucleolytic cleavage of the nascent 
RNA transcript at the poly(A) site transmits a signal to Pol II that leads to the destabilization 
of the elongation complex and thus to transcription termination (54). This model is supported 
by experiments showing that the 5’ to 3’ exoribonuclease Rat1/Xrn2 degrades RNA from the 
5’ end that is created by transcript cleavage at the poly(A) site (156, 322). Therefore, Rat1 
may act as a torpedo that removes Pol II from DNA. It was also shown that apart from Rat1 
other proteins are involved in this termination pathway including Rai1, Rtt103 and yet 
uncharacterized factors (69, 156). Since both models have experimental support, it seems 
likely that Pol II transcription termination can occur by more than one mechanism.        
 
1.3.2 Early versus late transcription termination pathway 
Apart from the mechanism of transcription termination there is accumulating evidence for 
gene class specific Pol II termination pathways. In yeast, at least two termination pathways 
can be distinguished: the “early” and the “late” termination pathway (37, 158, 265). The early 
termination pathway functions at snRNA, snoRNA genes and at regions coding for cryptic 
unstable transcripts (CUTs) (37, 287). Termination of these non-coding RNAs requires the 
Sen1/Nrd1/Nab3 termination complex (287, 308) and occurs within the first few hundred 
nucleotides of elongation at a region with high levels of Ser5 phosphorylated Pol II CTD (37). 
The late termination pathway functions at most protein-coding genes. Messenger RNA 
transcripts terminate downstream of the coding regions in a process that is coupled to RNA 
cleavage and polyadenylation (63). An obvious question is how Pol II discriminates between 
both termination pathways? There is no simple answer to that question, but sequences in the 
nascent RNA seem to play a role. Nrd1 and Nab3 were shown to bind to specific RNA 
sequences. Those binding sites for Nrd1 and Nab3 may predominantly occur at genes coding 
for snRNAs, snoRNAs and CUTs. However, it is very likely that other processes also help Pol 
II to distinguish between both termination pathways, including histone modifications (301).  
  IV. Pol II CTD tyrosine phosphorylation 
 
   58 
 
 
 
1.4  Aims and scope of this work 
More than ten years ago the laboratories of Steve Buratowski (Harvard Medical School) and 
David Bentley (University of Colorado) could show that the CTD is mainly phosphorylated at 
Ser5 and Ser2 residues and that the CTD phosphorylation pattern changes during gene 
transcription (162, 272). In both studies ChIP experiments with monoclonal antibodies that 
recognize S5P or S2P CTD were conducted to reveal S5P and S2P peak occupancies at the 5’ 
and 3’ regions of genes, respectively (162, 272). Similar observations were made in other 
organisms including mammals. In the following years plenty of studies have elucidated the 
binding of particular factors to certain phosphorylated forms of the Pol II CTD and thus have 
assigned distinct functions to the different phospo-modifications. Structural studies 
additionally revealed the details of some of these binding interfaces at atomic resolution 
(202).  
In 2007 and 2009, with the availability of a new monoclonal antibody that was generated and 
validated in the laboratories of Elisabeth Kremmer and Dirk Eick (Helmholtz Zentrum 
Munich), it could be shown by ChIP experiments that the CTD is also phosphorylated at Ser7 
residues in mammals and yeast (41, 157). Similar to S5P, S7P was predominantly detected at 
the 5’ region of genes (157). Recently, we and others have shown that S2P, S5P and S7P 
occur globally in yeast ((154, 199, 302); section III “Topic I” of this work).  
Although it is widely accepted that phosphorylation at the different serine residues of the Pol 
II CTD plays an important role in eukaryotic gene transcription, it is currently not known 
whether this is also true for CTD tyrosine phosphorylation. Almost two decades ago, one 
laboratory described CTD tyrosine phosphorylation in mammals, but its function remained 
unknown (19). Tyr1 represents the most conserved residue within the CTD consensus repeat 
and exchanging Tyr1 by Phe residues is lethal for yeast cells (321). This already illustrates 
how important Tyr1 is and to be more precise, how important its hydroxyl-group is. With this 
published data in hand we asked whether CTD tyrosine phosphorylation exists in yeast and if 
so, what the biological role of this type of CTD modification is. We addressed these questions 
in cooperation with Dirk Eick, Martin Heidemann and Elisabeth Kremmer (Helmholtz 
Zentrum Munich).  
Recently, we observed that CTD Ser2 phosphorylation did not correlate with the occupancy 
of the Pol II termination factor Pcf11 (199), although this factor binds to Ser2 phosphorylated 
CTD in vitro (15). The maximum occupancy levels of S2P Pol II were reached long before 
Pcf11 recruitment occurred (see section III 3.10). This observation led us to suggest that 
accessibility of the CTD is may be transiently masked and its accessibility regulated (section 
III “Topic I” of this work, (199)). Therefore, we were also interested in the influence of 
tyrosine phosphorylation on the regulation of the CTD accessibility and CTD masking. 
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2. Specific procedures 
 
Table 18: List of plasmids used in this study 
Plasmid Insert Type Tag Restriction 
sites 
Source 
AM001 S. cerevisiae Nrd1-CID (6-
151) 
pET28b(+) Ct His NcoI, NotI This work 
AM002 S. cerevisiae Rtt103-CID (1-
131) 
pET28b(+) Ct His NcoI, NotI This work 
213 (Cramer 
laboratory) 
S. cerevisiae Pcf11-CID (1-
140) 
pET28b(+) Ct His NcoI, NotI Anton Meinhart, 
(201)  
MS001 C. glabrata Spt6 tandem 
SH2 domain (1250-1444) 
pET28b(+) Nt His NdeI, NotI Mai Sun, (294) 
134 (Cramer 
laboratory) 
Human Ssu72 (full length) pET28b(+) Ct His NcoI, NotI Anton Meinhart, 
(203) 
KS001 D. melanogaster Ssu72 
(C13D/D144N; full length) 
pET15b Nt His NdeI, BamHI Kathrin 
Schwinghammer 
 
 
 
Table 19: Proteins analyzed by ChIP-chip in this study 
Protein Process involved ChIP protocol 
Y1P (Pol II) Under investigation For Pol II phospho-isoforms 
Nrd1 Pol II transcription termination For TAP-tagged proteins 
Rtt103 Pol II transcription termination For TAP-tagged proteins 
 
 
 
2.1 Generation and characterization of the monoclonal antibody 3D12  
The rat monoclonal antibody 3D12 (subclass IgG1) was generated as previously described 
(41). For immunization we used the CTD-specific phosphopeptide 
YSPTSPKme2YPSPTSPSC (Peptide Specialty Laboratories GmbH, Heidelberg, Germany) 
coupled to ovalbumin. 
For characterization of specificity, antibodies were analyzed in ELISA experiments using 
CTD-like peptides with different modification patterns (Peptide Specialty Laboratories 
GmbH, Heidelberg, Germany) coupled to 96-well maleimide plates (Thermo Fisher Scientific 
Inc., Rockford, IL USA) as antigen. Peptides were incubated with the monoclonal antibody 
and biotinylated, subclass-specific antibodies respectively. After incubation with horseradish 
peroxidase (HRP)-coupled avidin, H2O2 and TMB (3,3’,5,5’-tetramentylbenzidine) was 
added. Absorbance of each well was measured at 650 nm after color change and quantitated 
with an ELISA reader. 
Immunoprecipitation for antibody validation was carried out as follows. HeLa cells were 
washed twice with cold 1x PBS and lysed in 100 µl Ab lysis Buffer per 3x106 cells for 30 min 
on ice. All samples were sonicated on ice using a BRANSON Sonifier 250 (15 sec on, 15 sec 
off, 50% duty) and centrifuged at 16,400 rpm (FA-45-24-11 rotor) for 20 min at 4°C. The 
supernatant was incubated with antibody-coupled protein G-Sepharose beads (2.5 µg of 
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antibodies for 4 h at 4 °C, followed by 3 washes with 1 ml Ab lysis Buffer) rotating over-
night. Beads were washed five times with 1 ml Ab lysis Buffer before continuative 
experiments. 
For IPs from yeast, logarithmically grown cells (OD600 = 0.8) were pelleted, washed and lysed 
in 1 ml Ab lysis Buffer 2. After centrifugation (13,000 rpm, FA-45-24-11 rotor for 30 min at 
4°C) the supernatant was added to the antibody-precoupled beads respectively. After 
incubation over-night, the beads were washed 5 times with Ab lysis Buffer 2 and proteins 
were boiled off Sepharose beads in Laemmli Buffer for SDS-PAGE. 
For the in vitro kinase assay, immuno-purified Pol II from whole cell extracts with an 
antibody recognizing only unphosphorylated CTD (1C7) was used as substrate. 10 µl of the 
substrate coupled Sepharose G beads were incubated with 40 µl Tyrosine kinase Buffer or 
Serine kinase Buffer, 200 µM ATP, 1 µg BSA and 200 ng of the recombinant kinase 
(ProQinase GmbH, Freiburg, Germany) at 30°C for 30 minutes. 10 µl of 6x Laemmli Buffer 
was added and samples were boiled for 7 minutes at 95°C followed by SDS-PAGE and 
western analysis. 
Corresponding buffers are listed in Table 12. 
 
 
2.2 ChIP-chip of the Tyr1 Pol II phospho-isoform 
ChIP analysis of the Tyr1 Pol II phospho-isoform was conducted as decribed in section II 
2.1.2, but with the following modifications. Chromatin immunoprecipitation was performed 
with 3D12, a monoclonal antibody with strong specificity and affinity for Tyr1-
phosphorylated form of the Pol II CTD. Since it was reported that the amount of antibody 
used influences the occupancy profiles obtained for Pol II phospho-isoforms (157), we carried 
out ChIP experiments with different amounts of 3D12 antibody before ChIP-chip analyses. 
The antibody titration ChIP experiments revealed a similar occupancy pattern of the Tyr1 Pol 
II phospho-isoform at different amounts of antibody tested. These experiments also revealed 
that 50 µl of 3D12 antibody resulted in high fold enrichments (over control region) by an only 
minimal dilution of chromatin during immunoprecipitation. This optimized amount of 3D12 
was used in all consequent ChIP and ChIP-chip experiments. All the other steps were 
performed essentially as described in section II 2.1.2 and II 2.2. A list of all factors that were 
analyzed by ChIP-chip in this study is shown in Table 19. 
 
 
 
2.3 Ssu72 depletion in yeast cells 
2.3.1 Molecular cloning and validation of a Ssu72-degron yeast strain 
Since Ssu72 is essential for viability in yeast, a deletion of SSU72 gene is not possible. 
Therefore, Ssu72 had to be inactivated conditionally. We applied the head-inducible degron 
system to deplete Ssu72 in living yeast cells (268). This strategy was already shown to work 
successfully for Ssu72 in yeast (119). According to this system a degron cassette is inserted at 
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the beginning of the open reading frame of interest. This leads to a protein, with the degron 
tag fused to the N-terminus. The heat-inducible degron tag targets the protein of interest for 
degradation when the temperature is raised from 24°C to 38°C (268). Therefore, we amplified 
the degron cassette, consisting of the kanMX marker gene, the CUP1 promoter and the degron 
tag from the pKL187 plasmid (primers: 109_Degron_Fw; 103_Degron_Rev; Table 6) and 
used the PCR product to transform wild-type yeast (Pcf11-TAP; BY4741 background). 
Positive clones were selected on YPDCu+G418 plates (see Table 10). 
Yeast strain was validated by PCR to control whether the degron cassette has inserted at the 
corrected genomic position (primers: 110_ControlA_Fw; 104_ControlB_Rev; 
111_ControlC_Fw; 105_ControlD_Rev; Table 6). Furthermore, serial dilutions of wild-type 
and Ssu72-degron strain were grown on YPDCu+G418 plates at 24°C and 38°C, respectively. 
Whereas growth of wild-type yeast was observed at 38°C, no growth was detected for the 
Ssu72-degron strain, consistent with the observation that Ssu72 is essential for yeast cell 
viability.      
 
 
2.3.2 ChIP of Pcf11 and the Tyr1 Pol II phospho-isoform under Ssu72 depletion  
ChIP experiments were performed as described in section II 2.1, but with the following 
modifications. Wild-type (Pcf11-TAP strain) and Ssu72-degron yeast cells were grown in 40 
ml of YPDCu medium at 24°C from an OD600 of 0.1 to 0.2. The cultures were then transferred 
to 38°C and were grown to an OD600 of 0.7. This took 2.5 h and 3.5 h for wild-type and Ssu72 
depleted cells, respectively. Cells were harvested by centrifugation and treated essentially as 
described in section II 2.1.      
 
 
 
2.4 Protein sample preparations 
The DNA sequence coding for the S. cerevisiae Nrd1-CID (amino acid residues 6-151; 
(308)) was synthesized by Mr Gene GmbH (Regensburg) and cloned into a pET28b(+) vector 
(AM001; Table 18), resulting in an N-terminally hexahistidine tagged protein version. 
Proteins were expressed in E. coli BL21 (DE3) RIL cells in 1 L LB medium for 16 h at 18°C. 
Cells were harvested, washed with 1x PBS buffer, and lysed by sonication in the presence of 
Buffer A. The lysate was centrifuged two times at 15,000 rpm (SS34 rotor, Sorvall) for 20 
min at 4°C. The supernatant was loaded on a Ni-NTA column (Qiagen). The Ni-NTA column 
was equilibrated with Buffer B. The column was washed with Buffer B containing 10-50 mM 
Imidazole, and protein was eluted with Buffer B containing 100-300 mM Imidazole. The 
eluate fractions were pooled and applied to a cation exchange chromatography (Mono S, GE 
Healthcare). The column was equilibrated with Buffer C, and Nrd1 CID was eluted with a 
linear gradient of 20 column volumes from 50 mM to 1 M NaCl. After concentration, the 
sample was applied to a Superose 12 size exclusion column (GE Healthcare) equilibrated with 
Buffer D. Peak fractions were pooled and concentrated to 4-5 mg/ml as determined by ND-
1000 Spectrophotometer (NanoDrop Technologies).   
  IV. Pol II CTD tyrosine phosphorylation 
 
   62 
The plasmid 213 (Patrick Cramer laboratory; pET28b(+) based; originally generated by 
Anton Meinhart; Table 18), coding for N-terminally hexahistidine tagged Pcf11-CID (amino 
acid residues 1-140 (201); S. cerevisiae), was used for recombinant expression. Proteins were 
expressed in E. coli BL21 (DE3) RIL cells in 1 L LB medium for 16 h at 18°C. Cells were 
harvested, washed with 1x PBS buffer, and lysed by sonication in the presence of Buffer A. 
The lysate was centrifuged two times at 15,000 rpm (SS34 rotor, Sorvall) for 20 min at 4°C. 
The supernatant was loaded on a Ni-NTA column (Qiagen). The Ni-NTA column was 
equilibrated with Buffer E. The column was washed with Buffer E containing 10-30 mM 
Imidazole, and protein was eluted with buffer E containing 50-100 mM Imidazole. The eluate 
was dialysed against 2 L of Buffer F at 4°C over night. Pcf11 CID was purified by anion 
exchange chromatography (Mono Q, GE Healthcare). The column was equilibrated with 
Buffer G and Pcf11 CID was eluted with a linear gradient of 20 column volumes from 30 mM 
to 600 mM NaCl. After concentration, the sample was applied to a Superose 12 size exclusion 
column (GE Healthcare) equilibrated with buffer D. Pooled peak fractions were concentrated 
to 5 mg/ml as determined by ND-1000 Spectrophotometer (NanoDrop Technologies). 
The DNA sequence coding for the S. cerevisiae Rtt103-CID (amino acid residues 1-131; 
(193)) was synthesized by Mr Gene GmbH (Regensburg) and cloned into a pET28b(+) vector 
(AM002; Table 18), resulting in an N-terminally hexahistidine tagged protein version. The 
expression and protein purification was performed as described for Nrd1-CID, but with the 
following modifications. The eluate of the Ni-NTA affinity chromatography was concentrated 
and applied to a Superdex 75 size exclusion column (GE Healthcare) equilibrated with Buffer 
D. Pooled peak fractions were concentrated to 5 mg/ml as determined by ND-1000 
Spectrophotometer (NanoDrop Technologies). 
The plasmid MS001 (Patrick Cramer laboratory; pET28b(+) based; generated by Mai Sun, 
(294); Table 18), coding for N-terminally hexahistidine tagged Spt6 tandem SH2 domain 
(amino acid residues 1250-1444 (294); Candida glabrata), was used for recombinant 
expression as described for Nrd1-CID. The recombinantly expressed Spt6 tandem SH2 
domain was purified essentially as described in (294). The purified protein was concentrated 
to 10 mg/ml as determined by ND-1000 Spectrophotometer (NanoDrop Technologies) and 
stored in Buffer H. 
The plasmid 134 (Patrick Cramer laboratory; pET28b(+) based; generated by Anton 
Meinhart; (203); Table 18) coding for N-terminally hexahistidine tagged human Ssu72 was 
expressed in E. coli BL21 (DE3) RIL cells in 1 L LB medium for 16 h at 18°C. The 
recombinantly expressed Ssu72 was purified as described in (203). Briefly, cells were 
harvested, washed with 1x PBS buffer, and lysed by sonication in the presence of Buffer H. 
The lysate was centrifuged two times at 15,000 rpm (SA600 rotor, Sorvall) for 20 min at 4°C. 
The supernatant was loaded on a Ni-NTA column (Qiagen), pre-equilibrated with Buffer A 
(without PI). The column was washed with Buffer A (without PI) containing 10-30 mM 
Imidazole, and protein was eluted with Buffer A (without PI) containing 50-100 mM 
Imidazole. The eluates were diluted with 8 volumes Buffer J and loaded onto a Mono Q anion 
exchange column (GE Healthcare). The column was equilibrated with Buffer J and protein 
was eluted with a linear gradient of 25 column volumes from 50 mM to 1 M NaCl. After 
protein concentration, the sample was applied to a Superose 12 size exclusion column (GE 
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Healthcare) equilibrated with Buffer K. Pooled peak fractions were concentrated to 5 mg/ml 
as determined by ND-1000 Spectrophotometer (NanoDrop Technologies). Ssu72 phosphatase 
activity was measured essentially as described in (203). 
The DNA sequence coding for a mutated version of D. melanogaster Ssu72 (C13D/D144N, 
according to (319)) was synthesized by Mr Gene GmbH (Regensburg) and cloned into a 
pET15b vector using the restriction sites NdeI and BamHI (Table 18). This resulted in an N-
terminally hexahistidine tagged protein version. Proteins were expressed in E. coli BL21 
(DE3) RIL cells in 1 L LB medium for 18 h at 20°C, harvested by centrifugation, resuspended 
in Buffer L and lysed by sonification. The lysate was cleared by centrifugation at 15,000 rpm 
(SS34 rotor, Sorvall). The supernatant was loaded onto a Ni-NTA column equilibrated with 
Buffer M and washed with buffer M containing 20 mM imidazole. Protein was eluted with 
Buffer M containing 250 mM imidazole. The N-terminal hexahistidine tag was cleaved by 
dialysis in Buffer N in the presence of Thrombin (1 U per mg protein). Uncleaved protein was 
removed by a second Ni-NTA affinity chromatography. The eluate was loaded onto a 
Superose 12 10/300 column (GE Healthcare) equilibrated with Buffer O. Pooled peak 
fractions were concentrated to 10 mg/mL, flash frozen in liquid nitrogen and stored at -80°C. 
All buffers used for protein purification are listed in Table 12 and 13. 
 
 
 
2.5 Pol II CTD phosphopeptide interaction assay 
For fluorescence anisotropy measurements, we used a HORIBA Jobin-Yvon Fluoromax 3 
spectrofluorometer. The Pol II CTD mimicking phospho-peptides were synthesized by 
Peptide Specialty Laboratories (PSL) GmbH (Heidelberg) and PANATecs GmbH (Tübingen). 
An overview of all CTD-peptides used in this work is given in Table 20. The CTD-peptides 
were N-terminally labeled with fluorescein aminocaproic acid. 500 nM of the CTD-peptide 
was dissolved in FluA Buffer (150 mM NaCl) and was titrated at 20°C with pure yeast Nrd1-
CID, Pcf11-CID, Rtt103-CID or Ssu72 (C13D/D144N), respectively. For Pcf11-CID 
measurements were also performed in FluB Buffer (10 mM NaCl). For the Spt6 tandem SH2 
domain measurements were performed in FluB Buffer only. However, analyses were 
generally conducted at 150 mM NaCl to avoid protein precipitation and to reduce the risk of 
artificial protein interactions. The fluorescence anisotropy was measured after 2 min when 
equilibrium was reached. Data were fit to 1:1 binding models using non-linear least squares 
algorithm (Hill fit) as implemented in the software package OriginPro 8G (OriginLab 
Corporation, Northampton). Corresponding buffers are listed in Table 14. 
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 Table 20: Synthetic CTD peptides used in this study 
Name Amino acid sequence Company  
No-P P6 S7 Y1 S2 P3 T4 S5 P6 S7 Y1 S2 P3 T4 S5 P6 S7 PANATecs  
1,1* P6 S7 Y1 S2 P3 T4 S5 P6 S7 Y1 S2 P3 T4 S5 P6 S7 PSL  
2,2 P6 S7 Y1 S2 P3 T4 S5 P6 S7 Y1 S2 P3 T4 S5 P6 S7 PANATecs  
5,5* P6 S7 Y1 S2 P3 T4 S5 P6 S7 Y1 S2 P3 T4 S5 P6 S7 PSL  
1,2,1,2* P6 S7 Y1 S2 P3 T4 S5 P6 S7 Y1 S2 P3 T4 S5 P6 S7 PSL  
1,5,1,5 P6 S7 Y1 S2 P3 T4 S5 P6 S7 Y1 S2 P3 T4 S5 P6 S7 PSL  
1*  P3 T4 S5 P6 S7 Y1 S2 P3 T4 S5 PSL  
1,2*  P3 T4 S5 P6 S7 Y1 S2 P3 T4 S5 PSL  
7* Y1 S2 P3 T4 S5 P6 S7 Y1 S2 P3 T4 S5 P6 S7 C PSL  
S2  = Phosphorylated residue 
* = Peptides used in the Pol II CTD phosphatase assay 
 
 
 
2.6 Pol II CTD phosphatase assay 
Ssu72 phosphatase activity was quantified with the Malachite Green Phosphate Assay Kit 
(BioAssay Systems) that measures the formation of a green complex formed between 
Malachite Green, molybdate and free orthophosphate. The assay applicability was approved 
by the cleavage of the 5’ phosphate group of a random oligonucleotide by the antarctic 
phosphatase (New England Biolabs) (data not shown). The assay was performed according to 
the instructions of the manufacturer. Briefly, 80 µl of each sample were incubated at 37°C and 
contained 50 nM human Ssu72 and 20 µM CTD peptide or orthophosphorylated aminoacids 
(o-phospho-L-serine; o-phospho-L-threonine; o-phospho-L-tyrosine; SIGMA-ALDRICH 
GmbH, Schnelldorf, Germany) in Mal Buffer (Table 14). Except of the tyrosine 
phosphorylated CTD peptide (“1,1”, Table 20), the CTD peptides did not possess a 
fluorescein label. Substrate compounds used in this assay were dissolved in water. Reactions 
were stopped by the addition of 20 µL kit solution in a 96 well plate (286). Complex 
formation was measured via the absorption at 620 nm using an Infinite®M1000 (Tecan). As a 
control for each reaction one sample was prepared without enzyme and treated as the long-
term sample. 
 
 
 
3. Results and discussion 
3.1  A monoclonal antibody that recognizes tyrosine phosphorylated Pol II CTD in 
yeast and mammals 
Chromatin immunoprecipitation (ChIP) with antibodies that recognize different 
phosphorylated forms of the Pol II CTD have revealed that the CTD is phosphorylated at Ser2 
(S2P), Ser5 (S5P), Ser7 (S7P) and Thr4  in vivo (128, 154, 157, 162, 199, 272, 302). Although 
it is now accepted that the Pol II CTD is phosphorylated at serine and threonine residues in 
vivo, it is currently not known whether the CTD is also phosphorylated at tyrosine residues in 
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yeast. To address this question we generated a monoclonal antibody (3D12) that recognizes 
CTD heptads that are phosphorylated at Tyr1 (Y1P).  
Previous results have shown, that the functional unit of the Pol II CTD lies in between a pair 
of heptapeptides (186, 314). Therefore, a panel of di-heptapeptides bearing various 
modification patterns was used (Figure 1a) to characterize the binding epitope and specificity 
of our antibody. The analysis revealed that some modifications on neighboring residues 
prevent Y1P recognition. For example, the binding of α-Tyr1-P antibody 3D12 interferes with 
upstream S7P, but is not affected by downstream S2P (Figure 18 a). To show that tyrosine 
phosphorylation of Pol II CTD occurs in vivo, Saccharomyces cerevisiae (S. cerevisiae) 
whole cell extracts were analyzed in immunoprecipitation and immunoblotting experiments 
(Figure 18 b). The data reveals phosphorylation of Tyr1 in vivo and immunoprecipitation of 
RNA Pol II by the monoclonal antibody 3D12. To further confirm the Y1P specificity of 
monoclonal antibody 3D12, unphosphorylated Pol IIA form was purified from HeLa whole 
cell extracts as substrate for the mammalian CTD-tyrosine-kinase c-Abl (20). Phosphorylation 
of Pol IIA by c-Abl leads to a strong signal for monoclonal antibody 3D12 while addition of 
reaction buffer and ATP alone was not sufficient (Figure 18 c). The dramatic increase of Y1P 
additionally results in a shift of Pol IIA into the hyperphosphorylated Pol II0 form. Taken 
together, these experiments show that the antibody 3D12 specifically recognizes the Tyr1-
phosphorylated CTD and that Tyr1 phosphorylation occurs in yeast.  
This work was performed in cooperation with Dirk Eick, Martin Heidemann and Elisabeth 
Kremmer (Helmholtz Zentrum Munich). 
 
 
 
 
      
 
 
 
Figure 18: The Pol II CTD is phosphorylated on 
Tyr1-residues in proliferating yeast. (a) 
Specificity of the 3D12 antibody. Phosphate groups 
on black shaded residues interfere with the binding 
of the 3D12 antibody. (b) Western blot analysis 
with yeast whole cell extract reveals CTD Tyr1 
phosphorylation. Whole cell extract prepared from 
proliferating yeast was either directly probed by 
8WG16 or 3D12 antibodies (Input) or used for 
immunoprecipitations of Pol II and then analyzed 
by Western blotting (“IP Pol II”). The 
corresponding isotype controls are displayed 
(“control”). (c) Western blot analysis with HeLa 
whole cell extract also detects CTD Tyr1 
phosphorylation (Input). 1C7 antibody 
immunoprecipitates Pol II that is unphosphorylated 
at its CTD. Consistently, no signal was detected 
with 3D12 antibody (lane “IP 1C7”). However, 
incubation of immunoprecipitated (1C7) Pol II with 
cAbl tyrosine kinase led to a very strong signal in 
case of 3D12 antibody (lane “IP+cAbl”). The 
corresponding heights for the hyperphosphorylated 
form (II0) and the hypophosphorylated form (IIA) 
of Pol II are indicated on the right. 
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3.2  The CTD of genome-associated Pol II is phosphorylated on Tyr1 (Y1P) residues    
To investigate whether genome-associated Pol II can be phosphorylated at CTD Tyr1 
residues, we carried out occupancy profiling by ChIP experiments coupled to high-resolution 
microarray analysis in proliferating yeast as described (199). Data from two biological 
replicates (R = 0.94) were averaged and showed strong signals over protein-coding gene 
regions. We next averaged occupancy profiles of genes of similar lengths (199). The resulting 
gene-averaged profiles revealed that Tyr1-phosphorylated Pol II occupies the coding region of 
protein-coding genes (Figure 19 a,b). Whereas at promoter regions Y1P occupancy levels 
were lowest, the signal increased downstream of the TSS towards the 3’-end of the coding 
region, with the highest levels in a region 200-600 nt upstream of the pA site (Figure 19 a,b). 
The profile resembled that of Ser2-phosphorylated Pol II (154, 199, 302), with two striking 
differences. Firstly, maximal Y1P occupancy levels were reached earlier than those of S2P. 
Secondly, Y1P levels started to decrease ~180 nucleotides upstream of the pA site, whereas 
S2P occupancy levels decreased ~200 nucleotides downstream of that site (Figure 19 a,b). 
 
 
 
 
 
 
Figure 19: Genome-wide occupancy 
profiling of Pol II phospho-isoforms and 
CTD binding termination factors. (a) DNA 
frame with promoter, 5’ untranslated region 
(UTR), open reading frame (ORF) and 3’ 
UTR. Dashed black lines indicate the TSS 
and pA site. Dashed gray lines mark the 
positions 300 nt downstream of the TSS and 
180 nt upstream of the pA site. (b) Gene-
averaged profiles for the “medium” gene-
length class (1,238 ± 300 nt, 339 genes) of the 
Ser5- (“Topic I” of this work, (199)), Ser2- 
(“Topic I” of this work, (199)) and Tyr1-
phosphorylated form of Pol II. Profiles of 
other length classes are similar (data not 
shown). (c) Gene-averaged profiles as in (b) 
for Pol II termination factors Nrd1, Pcf11 
(“Topic I” of this work, (199)) and Rtt103. 
All three termination factors contain a CTD-
interacting domain (CID) that were shown to 
directly contact particular phosphorylated 
forms of the Pol II CTD (193, 201, 308) 
ChIP-chip occupancy of Nrd1 and Rtt103 is 
on the left y-axis, the occupancy of Pcf11 is 
on the right y-axis.  
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The point of Y1P level increase was dependent on the TSS, whereas the point of decrease was 
dependent on the pA site (Figure 20), and not on gene length or expression level (Figure 20 
Figure 22 b), arguing that the Tyr1 phosphorylation mark is set and removed within a general 
Pol II transcription cycle. 
 
 
 
Figure 20: CTD Tyr1 phosphorylation occurs within a general Pol II transcription cycle. (a) Gene-averaged profiles of 
the Tyr1 Pol II phospho-isoform of three gene length classes (“small”: 725 ± 213 nt, 266 genes; ”medium”: 1,238 ± 300 nt, 
339 genes; “long”: 2,217 ± 679 nt, 299 genes;) aligned at TSS. The point where Tyr1 phosphorylation levels start to increase 
depends on the distance to the TSS. (b) Gene-averaged profiles of the Tyr1 Pol II phospho-isoform as in (a), but aligned at 
the pA site. The location where Tyr1 phosphorylation starts to decrease depends on the distance to the pA site. 
 
 
 
3.3  Y1P is a mark for all active genes in proliferating yeast 
Recently, we and others have shown that S2P and S5P represent general types of CTD 
modifications that were detected at all actively transcribed Pol II genes in proliferating yeast 
(154, 199, 302). To test whether Pol II phosphorylation at Tyr1 occurs also on all transcribed 
genes, we measured co-variation in the occupancy data for Tyr1-phosphorylated Pol II and 
the other phosphorylated forms of Pol II (199) by singular value decomposition (SVD) as 
described (199). The first singular value describes strict co-variation and explained 83.8% of 
the total variance (Figure 21). Thus, Pol II phospho-isoform occupancies co-varied over all 
genes, indicating that Tyr1 phosphorylation is not a gene-specific or rare modification, but 
rather comparable in occurrence to Ser2 and Ser5 phosphorylation, which have clearly 
defined functional roles.  
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Consistent with this observation, there is a robust correlation of 0.65 between the occupancy 
of Tyr1-phosphorylated Pol II and mRNA expression levels (70) (Figure 22 a). Interestingly, 
the correlation was as high as detected between components of the general Pol II elongation 
complex and mRNA levels (199), also indicating that Y1P is a mark of active genes. Next, we 
grouped yeast genes based on their mRNA levels (70) in three different gene expression 
classes (“high”, “medium” and “low”) and determined the corresponding Y1P occupancies. 
As illustrated in Figure 22 b, this analysis revealed that the higher the expression level of a 
gene, the stronger was the corresponding Y1P occupancy signal.  
Thus, Tyr1 phosphorylation similar to S2P and S5P represents a general CTD modification 
that is associated with active genes in proliferating yeast. 
 
 
 
Figure 22: Tyr1 phosphorylation of the CTD is a mark of actively transcribed genes in proliferating yeast. (a) 
Correlation analysis between the logarithm of the average Y1P occupancy and the logarithm of mRNA levels. (b) Gene-
averaged profiles for genes in three different mRNA expression level classes. The genes were partitioned into three groups: 
low (25-50% quantile), medium (50-75% quantile) and high (>75% quantile) expression according to data from (70). From 
this set of genes, those with ORF lengths between 938 and 1538 were selected.  
 
 
 
Figure 21: Tyr1 phosphorylation is a 
general type of CTD modification. SVD 
analysis of S2P, S5P and Y1P occupancies. 
The contributions of the first three singular 
vectors to the variance (red) are shown in 
comparison to a control with randomly 
permuted matrix elements (gray). SVD 
reveals that 83.8% of the variance is 
explained by covariation.  
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3.4  Termination factors localize to gene regions with low Y1P levels  
To investigate whether and how Tyr1 phosphorylation could influence the recruitment of 
factors that bind the phosphorylated CTD, we determined genome-wide occupancy profiles of 
the three yeast proteins that contain CTD-interacting domains (CIDs), Nrd1, Pcf11, and 
Rtt103, which are all factors involved in transcription termination. The genome-wide 
occupancy profile of Rtt103 showed peak occupancy in the region downstream of the pA site, 
resembling the previously determined profile for Pcf11 (199), whereas Nrd1 showed peak 
occupancy at the beginning of the transcribed region, with peak levels ~150 nt downstream of 
the TSS in protein-coding genes (Figure 19 c). Comparison with the occupancies of the 
different phosphorylated forms of Pol II revealed an Nrd1 peak at a region with maximal 
levels of S5P and very low levels of Y1P and S2P. Consistently, correlation analysis could 
detect a correlation between Nrd1 and S5P occupancy levels (R = 0.6) but not for S2P (R = 
0.1) and only a weak correlation for Y1P (R = 0.4). This agrees with the previous observation 
that Nrd1 can bind to Ser5-phosphorylated CTD in vitro (308). Strong Pcf11 and Rtt103 
occupancy peaks were detected at the region immediately downstream of the pA site where 
the maximum difference between Y1P and S2P signals occurs (Figure 19 c). Consistently, the 
occupancies of Pcf11 and Rtt103 correlate only weakly with Ser2 phosphorylation (R = 0.4, 
for both), although they are both known to bind the Ser2-phosphorylated CTD in vitro (193, 
201). This observation suggested that the Ser2-phosphorylated CTD may be masked by an 
unknown mechanism within coding regions and we now hypothesized that this masking is 
achieved by Tyr1 phosphorylation. This would offer an explanation for why Pcf11 and Rtt103 
are primarily recruited downstream of the pA site, although maximal S2P levels were reached 
long before the pA site.  
 
 
 
3.5  Y1P impairs CID-CTD interactions in vitro 
To investigate whether Tyr1 phosphorylation would prevent the direct interaction of the CID-
containing termination factors with the CTD, we determined the affinity of the three CID 
domains for various CTD diheptad phosphopeptides (Figure 23). We purified recombinant 
CIDs of yeast Nrd1 (residues 6-151), Pcf11 (residues 1-140), and Rtt103 (residues 1-131), 
and determined their binding affinity to CTD peptides (Table 20) by fluorescence anisotropy. 
None of the CID domains bound to unphosphorylated CTD (Figure 23, black curves). This is 
in contrast to a previous report showing that Pcf11-CID can also bind to unphosphorylated 
CTD (15). Consistent with previous results (193, 308), the Pcf11-CID and the Rtt103-CID 
bind to the Ser2-phosphorylated CTD peptide with dissociation constants of 54±6 µM and 
12±2 µM, respectively, whereas the Nrd1-CID binds to both Ser2- and Ser5-phosphorylated 
CTD peptides, with slightly higher affinity for Ser5-phosphorylated form (KD = 85±25 µM, 
compared to 131±15 µM for the Ser2-phosphorylated peptide) (Figure 23). However, Nrd1-
CID, Pcf11-CID and Rtt103-CID cannot bind CTD peptides that are phosphorylated on Tyr1. 
Furthermore, Nrd1-CID cannot bind to Ser2- and Ser5-phosphorylated CTD peptides if they 
are additionally phosphorylated at Tyr1 (Figure 23 c). Similarly, Pcf11- and Rtt103-CID can 
also not bind to Ser2-phosphorylated CTD if additionally phosphorylated at Tyr1 residues. 
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Thus, Tyr1 phosphorylation prevents CTD binding of all CIDs in yeast, consistent with the 
idea that Tyr1 phosphorylation masks the Ser2- and Ser5-phosphorylated CTD.  
Although Pcf11 is highly conserved from yeast to human, Nrd1 and Rtt103 have no clear 
homologues in humans. Nevertheless, the human genome encodes a protein, SCAF8, that 
shares sequence homology to yeast Nrd1 in the CID and the RRM domains and has a similar 
domain arrangement (337). Similarly to Nrd1, SCAF8 associates with Pol II during 
transcription elongation and also plays a role in pre-mRNA processing (234). SCAF8-CID 
was shown to preferentially interact with Ser2-phosphorylated CTD in vitro (22). 
Interestingly, a previous report has demonstrated that CTD tyrosine-phosphorylation prevents 
the binding of SCAF8-CID (337). Therefore, the finding that Tyr1 phosphorylation prevents 
CID-CTD interactions in yeast seems also to be true in humans. 
 
 
 
 
 
      
   
 
Figure 23: CTD Tyr1 phosphorylation prevents the 
binding of CID-containing termination factors in 
vitro. (a) Analysis of the binding affinity and specificity 
of the Pcf11-CID for different CTD-mimicking 
synthetic peptides by fluorescence anisotropy titration 
experiments. The Pcf11-CID from S. cerevisiae was 
recombinantly expressed in E. coli cells and purified to 
homogeneity. Purified Pcf11-CID was titrated to 
fluorescently labeled CTD peptides and the 
fluorescence anisotropy was detected in the presence of 
10 mM NaCl (for details see section IV 2.5).  A non-
linear binding curve could be fitted in case of S2P, 
allowing the determination the corresponding binding 
affinity (Hill fit, Origin). Standard deviations refer to 
two replicate measurements. (b-c) Analysis of the 
binding affinities of Rtt103-CID (S. cerevisiae) and 
Nrd1-CID (S. cerevisiae) for different CTD peptides, 
respectively. Experiments were performed as in (a) but 
in the presence of 150 mM NaCl. For details about the 
CTD peptides used in this study, please see Table 20. 
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3.6  Molecular basis for the impairment of CID-CTD interaction by Y1P 
High-resolution X-ray structures of Nrd1-CID (308), Pcf11-CID (201) and Rtt103-CID (193) 
are available. Co-crystal structures of CID-CTD complexes are available for Pcf11-CID and 
Rtt103-CID, both bound to CTD-S2P peptides (193, 201). In the Pcf11-CTD structure, the 
Tyr1 hydroxyl group forms a hydrogen bond with the Asp68 side chain of the CID, that is 
conserved from yeast to human (201). Thus binding of a Tyr1-phosphorylated peptide would 
be impaired due to electrostatic repulsion of the Tyr1 phosphate and the Asp68 side chain. 
Modeling a Tyr1 phosphate group onto the CTD peptide results in a steric clash (Figure 24 
a,b). The same situation is expected for Nrd1 CID, which contains a highly conserved CTD-
binding site, including the asparate residue (308). In the Rtt103-CTD structure, the Tyr1 
hydroxyl group forms a hydrogen bond with the side chain carboxyl of Asn65 (193), which 
corresponds to Asp68 in Pcf11. This hydrogen bond would not be possible after Tyr1 
phosphorylation, which again leads to a steric clash when modeled onto the structure (Figure 
24 c,d).  
Additionally, the co-structures reveal that both the Pcf11-CID and the Rtt103-CID bind to 
Ser2-phosphorylated CTD that is in a β-turn conformation (193, 201). The β-turn is formed by 
S2P-P3-T4-S5 motif within the same CTD repeat and is stabilized by an intramolecular 
hydrogen bond between the S2P phosphate and the side-chain hydroxyl group of Thr4 (193, 
201). A phosphate group on Tyr1 instead of Ser2 interferes with the formation of that 
hydrogen bond and thus destabilizes the β-turn formation what in turn interferes with the 
CID-CTD interactions. The high conservation of CID residues that directly contact the CTD 
and the observation that all CIDs in yeast can bind to Ser2-phosphorylated CTD peptides 
illustrates the importance of the β-turn stabilization. The results described for the Pcf11- and 
Rtt103-CIDs are also true for human SCAF8 bound to several Ser2-phosphorylated CTD 
peptides (22).  
Taken together, structural data indicate that a phosphate group on Tyr1 would impair 
formation of all CID-CTD complexes, due to charge repulsion, steric hindrance and 
destabilizazion of the β-turn conformation of the CTD. 
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Figure 24: Tyr1 phosphorylation blocks CID-CTD interactions. (a) Surface representation of Pcf11-CID bound to Ser2-
phosphorylated CTD peptide (stick model) (201). Blue, white and red colored surfaces correspond to positively charged, 
electrically neutral and negatively charged regions, respectively. The phosphate group (orange) on the Ser2 residue points 
away from the CID surface and does not contact the CID directly. (b) Structural model of Pcf11-CID (201) bound to Tyr1-
phosphorylated CTD peptide. The Pcf11-CID is shown in the same orientation and the CTD peptide is bound in the same 
register as in (a). The modeled phosphate group on Tyr1 resulted in a steric clash (yellow arrow) with Pcf11-CID. The 
surface area of Pcf11-CID where the steric clash occured is positively charged, resulting also in an electrostatic repulsion. (c) 
Surface representation of the Rtt103-CID bound to Ser2-phosphorylated CTD peptide (stick model) (193). The phosphate 
group on Ser2 directly contacts the Rtt103-CID. (d) Structural model of Rtt103-CID (193) bound to Tyr1-phosphorylated 
CTD peptide. Rtt103-CID is shown in the same orientation as in (c). The Tyr1-phosphorylated CTD peptide is bound in the 
same register as in (c).  Modeling a phosphate group on Tyr1 resulted in a steric clash with Rtt103-CID (yellow arrow) and in 
electrostatic repulsion. Structural modeling and generation of Figures was performed with PyMol version 1.4.1. The surface 
charges were calculated with APBS.        
 
  
 
3.7  The Pol II elongation factor Spt6 associates with Y1P 
These results described in the previous sections converge on a model that Tyr1 
phosphorylation prevents binding of termination factors, which use a CID domain, to 
associate with elongating Pol II, but also raise the questions whether Tyr1 phosphorylation 
would interfere with CTD interactions of factors that use other CTD-binding domains. To 
address this, we investigated the CTD binding to the tandem SH2 domain of Spt6 (residues 
1250-1444), which binds the Ser2-phosphorylated but not the unphosphorylated CTD (52, 73, 
185, 294) and contributes strongly to Spt6 occupancy on transcribed genes (199). Since Spt6 
occupies genes throughout the coding region and downstream of the pA site (155, 199), we 
predicted that Tyr1 phosphorylation must not interfere with CTD binding of the tandem SH2 
domain. Indeed, the purified recombinant tandem SH2 domain of Spt6 bound very well to 
CTD peptides phosphorylated at Tyr1 (KD = 3.6±0.15), Tyr1 and Ser2 (KD = 1.9±0.04) as 
well as Tyr1 and Ser5 (KD = 1.3±0.06) (Figure 25). Interestingly, the interaction of the 
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tandem SH2 domain with Tyr1-phosphorylated CTD was even slightly stronger as compared 
to the Ser2-phosphorylated CTD (KD = 8.4±0.19), representing the known interaction partner, 
and the Ser5-phosphorylated CTD (KD = 5.2±0.09) (Figure 25). This observation agrees with 
previous reports showing that the tandem SH2 domain has a stronger affinity for CTD 
peptides phosphorylated on Tyr1 than on Ser2 or Ser5 residues (52, 185). This demonstrates 
that Tyr1 phosphorylation does not impair CTD binding of a well-studied elongation factor, 
but that it selectively prevents binding of CID-containing termination factors. 
 
 
 
 
 
 
 
3.8  Y1P restricts the recruitment of termination factors to narrow regions at the 5’ 
and 3’ end of genes 
To illustrate the mechanism for exclusion of termination factors from a central transcribed 
region by Tyr1 phosphorylation, we summed up the genome-wide occupancies for Ser2- and 
Ser5-phosphorylated Pol II and subtracted from this sum the occupancy with Tyr1-
phosphorylated Pol II. Although calculation of such a difference profile is problematic due to 
unknown normalization factors between data sets, we obtained a curve that contains peaks 
just downstream of the TSS and the pA site, and an extended depression in between (Figure 
26). Whereas the peaks correspond to regions where termination factors are usually recruited 
(5’ recruiting region, Nrd1; 3’ recruiting region, Pcf11 and Rtt103), the depression indicates a 
central region in which the Ser2-phosphorylated CTD is masked and Pol II is shielded from 
termination factors. We note that additional factors can contribute to the recruitment of 
termination factors to elongating Pol II. For instance, Nrd1 functions in a complex with Nab3 
and Sen1 (308). Nrd1 and Nab3 interact specifically with nascent RNA (60) what contribute 
to Nrd1 recruitment or its persistency near Pol II even when Tyr1 phosphorylation levels rise. 
As detailed later, this seems to be especially true at snoRNA genes. In addition, our model 
assumes uniform CTD phosphorylation on all repeats, which does not necessarily occur, but 
there is currently no data that address this issue. 
 
 
Figure 25: Spt6 binds to Tyr1-phosphorylated 
CTD peptides in vitro. The C-terminal tandem 
SH2 domain of Spt6 (S. cerevisiae) was 
recombinantly expressed in E. coli cells and 
purified to homogeneity as described (294). The 
binding affinity of the yeast Spt6 tandem SH2 
domain for different CTD peptides (Table 20) was 
analyzed by fluorescence anisotropy titration 
experiments. The tandem SH2 domain bound to all 
CTD peptides tested, but with a slightly higher 
affinity to Tyr1-phosphorylated peptides. Fitting of 
non-linear binding-curves was performed with 
Origin (Hill fit). The color code is the same as in 
Figure 23. 
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3.9  An extended model of the Pol II CTD code 
Our results extend the previously proposed CTD code (36, 55, 79) and lead to a model for the 
phosphorylation-regulated recruitment of CTD-binding factors to Pol II during the 
transcription cycle (Figure 27). During transcription initiation the CTD is phosphorylated on 
Ser5 residues, which facilitates recruitment of Nrd1 at the beginning of genes. About 150 nt 
downstream of the TSS, peak occupancy levels for Nrd1 and Pol II (199) are reached. This 
observation is consistent with the idea of an early decision point, where Pol II either 
terminates early or continues RNA synthesis after transient pausing (37). In case Pol II 
continues RNA synthesis, Tyr1 and Ser2 phosphorylation levels rise, facilitating the binding 
of elongation factors such as Spt6. However, at the same time Tyr1 phosphorylation releases 
Nrd1 and impairs recruitment of termination factors Rtt103 and Pcf11. Before the pA site, 
Tyr1 phosphorylation levels drop, whereas Ser2 phosphorylation levels remain high, enabling 
recruitment of Rtt103 and Pcf11, and leading to mRNA 3’-end processing and transcription 
termination. Termination factors can bind cooperatively to neighboring CTD repeats (193) 
and can also interact with nascent RNA (60). This cooperative binding may lead to the 
observed sharp occupancy peaks. The key functional role of Tyr1 phosphorylation during 
active transcription explains why mutation of Tyr1 residues to phenylalanine, which removes 
the oxygen atom required for phosphorylation, is lethal (321). 
 
 
 
 
 
 
 
 
 
 
Figure 26: Tyr1 phosphorylation of the CTD restricts the 
recruitment of Pol II transcription termination factors to 
the 5’ and 3‘ end of genes. Subtracting the genome-wide 
Y1P occupancy from the occupancy formed by S5P+S2P, 
results in a difference curve with peaks downstream of the 
TSS and the pA site, and an extended depression between 
both peaks. This observation may indicate that Tyr1 
phosphorylation of the CTD establishes three distinct regions 
along transcribed protein-coding genes: 5’ and 3’ recruiting 
regions (5’RR and 3’RR) that are separated by an extended 
central masked region (CMR; violet). Whereas at the narrow 
5’RR and 3’RR Pol II termination factors can associate with 
transcribing Pol II (5’RR: Nrd1; 3’RR: Pcf11 and Rtt103), 
the interaction is blocked during the CMR by Tyr1 
phosphorylation of the CTD. This analysis was performed 
for the “medium” gene-length class, but the results of other 
length classes were similar (data not shown).      
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3.10  The CTD phosphatase Ssu72 targets S5P but not Y1P 
Based on the presence of a protein tyrosine phosphatase (PTPase) signature motif, structural 
similarities to PTPases and its ability to cleave the phosphotyrosine analogue p-
nitrophenylphosphate in vitro, Ssu72 was proposed to by a tyrosine phosphatase (203). Ssu72 
was also shown to act as a CTD phosphatase with specificity against S5P (164, 319, 328). 
Therefore, we asked whether Ssu72 also targets Y1P. However, several lines of evidence 
indicate that this is most likely not the case.  
Firstly, we performed a binding assay to determine the substrate specificity of Ssu72. We 
expressed and purified a catalytically inactive form of Ssu72 (C13D/D144N) from Drosophila 
melanogaster (319) and measured its affinity against various synthetic diheptad CTD peptides 
that represent potential substrates by fluorescence anisotropy measurements (Table 20). The 
data shows that Ssu72 binds to S5P (KD = 32±8 µM) but neither to Y1P, Y1PS2P, S2P nor to 
the unphosphorylated CTD indicating that Ssu72 can discriminate between different Pol II 
phosphoisoforms (Figure 28 a).  
Secondly, we measured the phosphatase activity of Ssu72 for different substrates by a 
malachite green assay that allows the detection of liberated orthophosphate (see section IV 
2.6). We expressed and purified human Ssu72 (203) since we were not able to clone the yeast 
SSU72 gene. This assay revealed a weak activity of Ssu72 for S5P but not for the other 
substrates tested, including Y1P and Y1PS2P (Figure 28 b). 
Thirdly, we conducted ChIP experiments of Pol II (Rpb3) and of its tyrosine phosphorylated 
form under wild-type condition and under Ssu72 depletion. We generated an Ssu72 degron 
strain (see section IV 2.3.1, (8)) and used this yeast strain for ChIP experiments. Since SSU72 
is an essential gene, Ssu72 depletion was not viable for yeast cells what served as a quality 
control. ChIP data for the ADH1 gene illustrates that the decrease of Y1P occupancy under 
Ssu72 depleting condition was substantially stronger than for Pol II (Rpb3) (Figure 28 c). 
This was true over the whole length of the transcribed region and indicates that Ssu72 rather 
plays a role in inhibiting than in promoting Y1P dephosphorylation under wildtype 
Figure 27: Extension of the Pol II CTD 
code. During the mRNA transcription 
cycle (internal black circle, different stages 
as well as the TSS and the pA site are 
indicated) the phosphorylation pattern of 
the CTD changes, as illustrated by red 
(S5P), blue (S2P) and violet (Y1P) 
semicircles. The color saturation 
corresponds to the occupancy level (the 
stronger the color saturation, the stronger 
the occupancy). The color code is the same 
as in Figure 2. Factors that associate with 
particular CTD phosphorylation patterns 
are indicated. 
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conditions. Taken together, our in vitro and in vivo data indicate that Ssu72 targets S5P but 
most likely not Y1P. 
 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
Figure 28: Ssu72 is most likely not the Y1P 
CTD phosphatase. (a) Analysis of the binding 
affinity of Ssu72 for different CTD peptides by 
fluorescence anisotropy titration experiments. A 
catalytically inactive form of Ssu72 (Ssu72 
C13D/D144N, D. melanogaster) was 
recombinantly expressed in E. coli cells and 
purified to homogeneity. A binding of Ssu72 
could only be detected for the S5P CTD peptide. 
Fitting of non-linear binding-curves was 
performed with Origin (Hill fit). The color code is 
the same as in Figure 23. (b) Analysis of the 
phosphatase activity of human Ssu72 for different 
CTD substrates by a malachite green assay. 
Consistent with the fluorescence anisotropy 
measurements, a weak phosphatase activity was 
only detected for the S5P CTD peptide. (c) ChIP 
experiments of Rpb3 (Pol II, independent of CTD 
phosphorylation status; upper panel) and the 
Tyr1-phosphorylated form of Pol II (lower panel) 
for wild-type (black bars) and for Ssu72 depleting 
conditions (gray bars; Ssu72 degron strain, see 
methods). Occupancies are shown for four distinct 
regions of the ADH1 gene. Standard deviations 
refer to two biological replicates.     
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4. Conclusions and Outlook 
In this study we used a monoclonal antibody that specifically recognizes tyrosine 
phosphorylated Pol II CTD to show that this type of CTD modification exists in yeast. High-
resolution genome-wide occupancy profiling revealed that Tyr1 phosphorylation occurs at all 
transcribed genes and that its level correlates with mRNA expression. Tyr1 phosphorylation 
was absent at the gene promoter, increased downstream of the TSS and decreased before the 
pA site. Our data also indicated that Tyr1 phosphorylation prevents the recruitment of 
transcription termination factors to Pol II. First, the Pol II termination factors Nrd1 and 
Pcf11/Rtt103 showed occupancy peaks upstream or downstream of the region containing high 
Tyr1 phosphorylation levels, in vivo. Second, Tyr1 phosphorylation blocked CTD binding to 
the conserved CTD-interacting domains (CIDs) of Pol II termination factors in vitro. Third, 
structural modeling implied that Tyr1 phosphorylation results in an electrostatic repulsion 
from an aspartate residue. However, Tyr1 phosphorylation did not impair CTD binding of the 
elongation factor Spt6, which is present in transcribed regions. The data consistently 
supported the view that Tyr1 phosphorylation of the CTD shields active Pol II from 
termination factors within transcribed regions.   
 
This study raises several questions that can be addressed in follow up projects. 
Firstly, it is currently not known which kinase(s) is responsible for the Tyr1 phosphorylation 
of the CTD in yeast. One way to tackle this question in vivo is to inhibit the kinase of interest, 
for instance by the use of analog-sensitive (as) yeast strains (29), and observe whether the 
Tyr1 phosphorylation level is altered by ChIP experiments. The identification of the Tyr1-
kinase(s) would enable plenty of follow up studies. For example, the Tyr1-phosphorylation 
could be inhibited by conditionally depleting the Tyr1-kinase. Under those conditions ChIP 
time-course experiments would reveal factors that are recruited viaTyr1-phosphorylation in 
vivo. 
Secondly, the phosphatase(s) which targets phosphorylated Tyr1 residues is also not known. 
One way to address this question in vivo is conditionally deplete the phosphatase of interest 
and observe the levels of Tyr1-phosphorylation via ChIP experiments. Also in vitro 
phosphatase assays with purified phosphatases and tyrosine phosphorylated CTD as substrates 
could contribute to the identification of the Tyr1-phosphatase.  
Thirdly, it is currently unknown whether apart from Spt6 other proteins interact with the 
tyrosine phosphorylated form of the CTD. One way to systematically identify potential 
interaction partners, including kinases and phosphatases, is by a combined approach of 
affinity purification (such as tandem affinity purification, TAP (251)) and mass-spectrometry 
(MS). Once new interaction partners were discovered, co-crystallization trials could be 
performed to reveal details of the respective binding interface at atomic resolution. These 
experiments would not only contribute to a better understanding of basic aspects of 
transcription regulation but also bear the potential to assign entirely new functions to the Pol 
II CTD.   
Fourthly, our current knowledge of CTD modifications are based on studies using specific 
monoclonal antibodies. Since, a particular antibody recognizes a certain epitope on the CTD 
our current view of how the CTD is modified is rather indirect and most likely incomplete. 
Additionally, antibodies always bear the risk of crossreactivity as was also shown to be an 
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issue for some antibodies directed against certain CTD phosphoisoforms  (157). Mass-
spectrometry analyses of the CTD would avoid some of the drawbacks described for 
antibodies and would provide a more direct view on the CTD modification status. MS could 
help to solve the long-standing questions what modifications occur in which parts of the CTD 
and in which combinations in cells. Interesting questions in this context are whether Tyr1 
residues are predominantly phosphorylated at the proximal or distal part of the CTD and 
whether phosphorylated Tyr1 co-occur with other CTD modifications.  
Fivthly, apart from the observation that Tyr1 phosphorylation of the CTD also occurs in 
mammals, nothing is known of its biological role in other organisms. The analyses of CTD 
tyrosine phosphorylation in different organisms would reveal similarities and differences that 
result in new insights into the evolution of gene regulation in the context of the Pol II CTD. 
A more longterm perspective would be to understand whether Tyr1 phosphorylation of the 
CTD plays a role in the regulation of the cell cycle, in certain diseased states and during 
development. Another key question is whether the different CTD phosphorylation marks 
influence each other.  
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V. The Spt5 C-terminal region recruits yeast 3’-RNA cleavage 
factor I 
 
 
1. Introduction 
1.1  The transcription factor Spt5 
1.1.1  Basic aspects 
The gene encoding the Spt5 protein was originally identified in a genetic screen in 
Saccharomyces cerevisiae (S. cerevisiae) as a suppressor of reporter gene insertions in 1984 
(326). Spt5 was later described as an essential nuclear protein (297). Spt5 forms a tight 
complex with the zinc-binding protein Spt4 (118). Spt5 physically associates with RNA 
polymerase II in vivo and mutations of SPT5 lead to a slow-growth phenotype in the presence 
of  the nucleotide-depleting drug 6-azauracil (6-AU), arguing for a role in Pol II transcription 
elongation in yeast (118). The human homolog of yeast Spt4/5, also called DSIF complex, 
affects transcription elongation by Pol II (315). Furthermore, Spt5 co-localizes with Spt6 and 
Pol II at transcriptionally active loci on Drosophila polytene chromosomes (7, 146). 
Chromatin immunoprecipitation (ChIP) analyses revealed that Spt5 co-localizes with Pol II 
throughout the transcribed region and past the pA site (243). Recently, it was shown that 
Spt4/5 is present on all transcribed yeast genes and that it is a general component of the Pol II 
elongation complex ((199, 311); see also section III. 3). 
Spt5 is the only known Pol II-associated transcription factor that is conserved in all three 
domains of life (320). The bacterial Spt5 homolog NusG and archaeal Spt5 consist of an N-
terminal (NGN) domain and a flexibly linked C-terminal Kyrpides-Ouzounis-Woese (KOW) 
domain (160, 211) (Figure 29). In contrast to bacteria, archaea also have a Spt4 homolog 
(Figure 29). Recently, the structures of archaeal Spt4/5 bound to the RNA polymerase clamp 
domain could be determined by X-ray crystallography and cryoelectron microscopy (159, 
198). These structures indicate that the NGN domain closes the active center cleft to lock 
nucleic acids and render the elongation complex stable and processive (124, 159, 198). 
Eukaryotic Spt5 possesses additional regions and domains. Yeast Spt5 consists of an acidic 
N-terminal region, followed by an NGN domain, five KOW domains, and a repetitive C-
terminal region (CTR) (245, 297, 343). 
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Spt5 has recently emerged as a platform that recruits factors to elongating Pol II. Spt5 co-
purifies with more than 90 yeast proteins that are involved in several distinct processes 
including transcription elongation, RNA processing, transcription termination and mRNA 
export (184). Spt4/5 interacts with the Pol II transcription factor and histone chaperone Spt6 
to modulate chromatin structure in yeast (118, 298). Spt5 directly interacts with the mRNA 
capping enzyme in fission yeast and humans (236, 318). Mammalian Spt5 recruits the 
activation-induced cytidine deaminase to DNA during antibody gene diversification (235). 
Recently, it was shown that yeast Spt5 recruits She2 to the nascent RNA, coupling mRNA 
localization with Pol II transcription (276). The recruitment of factors can be mediated by the 
CTR of Spt5. The yeast Spt5 CTR recruits the Paf1 complex and the histone deacetylase 
subunit Rco1 during Pol II transcription elongation (75, 187, 343).   
 
 
1.1.2  The repetitive C-terminal region (CTR) of Spt5 
The CTR forms a repeat structure similar to the Pol II CTD (297). In yeast, the CTR consists 
of 15 hexapeptide repeats of the consensus sequence S[T/A]WGG[A/Q] (343). However, the 
consensus sequence of the Spt5 CTR repeats can vary from one organism to another. For 
example, the CTR of human Spt5 consists of pentapeptide repeats with the consensus 
sequence GS[R/Q]TP (331), whereas the Spt5 CTR of fission yeast consists of nonapeptide 
repeats with the consensus sequence TPAWNSGSK (236). In contrast to the Pol II CTD, 
deletion of the Spt5 CTR is not lethal in yeast (74, 187, 343), but leads to 6-AU sensitivity 
and a slow-growth phenotype at 16°C (187, 343). The CTR deletion is synthetically lethal 
with the deletion of the gene for the Pol II CTD kinase Ctk1 (187). Deletion of the CTR in 
fission yeast leads to a slow-growth phenotype and abnormal cell morphology (271). The 
slow-growth phenotype is intensified if the Pol II CTD is truncated (271), suggesting that the 
CTR co-operates with the CTD. Deletion of the CTR impairs embryogenesis in zebrafish and 
leads to a de-repression of transcription of genes in zebrafish and human cells (44). Similar to 
the Pol II CTD, the CTR of Spt5 can be phosphorylated by the kinases Bur1 and P-TEFb in 
yeast and human, respectively (187, 331, 343). CTR phosphorylation promotes transcription 
elongation in yeast, and is important for the co-transcriptional recruitment of the Paf1 
complex and for histone modification (187, 343). In human cells, CTR phosphorylation by P-
Figure 29: Domain organization of Spt4/5 in 
three domains of life. The NGN domain, the 
KOW motifs and the repeats of the C-terminal 
region (CTR) are indicated as red, green/white 
and violet barrels, respectively. Please note 
that Spt4 homologs only exist in eukaryotes 
and archaeal cells. This Figure is taken from 
(124).   
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TEFb converts Spt5 from a negative to a positive elongation factor (331). The Spt5 CTR may 
also play a role in the suppression of transcription-coupled nucleotide excision repair in yeast 
(74). 
 
 
 
1.2 The cleavage factor (CF) I complex 
Processing of mRNA 3’-ends occurs in two steps, endonucleolytic cleavage and addition of a 
pA tail (25). In yeast, the multisubunit complexes that carry out cleavage and polyadenylation 
are the cleavage factor (CF) I and the cleavage/polyadenylation factor (CPF) (195). The CFI 
can be separated into CFIA and CFIB (108, 150). CFIA consists of Clp1, Rna14, Rna15 and 
Pcf11 (6, 208, 209), whereas CFIB consists of a single subunit called Hrp1 (108, 149, 207). 
This machinery is highly conserved, with most of the subunits having homologs in 
mammalian cells (195). Rna15 forms a heterodimer with Rna14 (224). Two Rna14/15 
heterodimers can in turn form tetramers in vitro, what led to the suggestion that CFI may 
functions at a dimer during 3’-RNA processing in vivo (14, 224). 3’-RNA processing occurs 
co-transcriptional (237). The CFIA subunit Pcf11 and Rna14 can bind to the phosphorylated 
form of the Pol II CTD (15, 266, 341). Pcf11 preferentially binds to the Ser2-phosphorylated 
form of the CTD ((182, 201); for details see section IV 1.1 and IV 3.5). In addition, the CFIA 
subunit Rna15 and the CFIB Hrp1 contain RNA recognition motifs (RRMs) that were shown 
to bind RNA in vitro (109, 181, 224, 233, 238). However, the role of nascent RNA in the 
recruitment of 3’-RNA processing factors in vivo remains to be determined. 
 
 
 
1.3  Aims and scope of this work 
Spt5 is the only Pol II-associated transcription factor that is conserved in all three domains of 
life, indicating its important role in gene transcription (320). Spt5 associates with Pol II 
during transcription elongation. Spt5 enhances the stability of the elongation complex and 
renders transcription elongation processive (159, 198).  In yeast, Spt5 is essential for viability 
and co-purifies with more than 90 proteins that are involved in many different nuclear 
processes (184). ChIP experiments have detected Spt5 at selected genes that are actively 
transcribed by Pol II (243). Recently, we have shown that Spt5 co-localizes with transcribing 
Pol II throughout the coding region and past the pA site of all active genes in proliferating 
yeast (see section III Figure 6; (199)). 
Interestingly, Spt5 contains a repetitive C-terminal region (CTR) that has been shown to 
recruit the Paf1 complex to Pol II (187, 343) and that is also involved in the recruitment of the 
histone deacetylase complex Rpd3 (75). All these observations have led us to assume that the 
Spt5 CTR, similar to the Pol II CTD, may act as a general platform that recruits factors during 
Pol II transcription.  
Since Spt5 co-localizes well with Pol II throughout the coding region of genes, one question 
was whether the CTR is involved in the recruitment of particular elongation factors. An 
interesting finding of our genome-wide analyses was that Spt5 also co-localizes with Pol II 
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and transcription termination factors past the pA site until the region where transcription 
terminates (see section III Figure 6 e). Therefore, another question to be addressed was 
whether the CTR of Spt5 is also involved in the recruitment of 3’-RNA processing and 
termination factors. These questions should be addressed by ChIP experiments in vivo and by 
interaction studies with recombinantly expressed CTR constructs in vitro. In cases where 
valid interactions could be detected, its biological roles should be elucidated. This study bore 
not only the potential to assign entirely new functions to the chromatin transcription factor 
Spt5 but also to reveal new regulatory mechanisms of Pol II transcription. This work was 
performed in cooperation with Amelie Schreieck.        
 
 
2. Specific procedures 
 
Table 21: List of plasmids used in this study 
Plasmid Insert Type Tag Restriction 
sites 
Source 
GST-CTR GST-CTR (S. cerevisiae 
Spt5 CTR; 931-1063) 
pET28b(+) Nt GST NcoI, HindIII This work 
pGEX-4T-1-
GST 
GST-tag pGEX-4T-1 GST  GE Healthcare 
 
 
Table 22: Proteins analyzed by ChIP-chip in this study 
Protein Process involved ChIP protocol 
Rpb3 (Pol II) in Spt5 ∆CTR cells Gene transcription For TAP-tagged proteins 
Rna14 (CFIA complex) 3’-RNA processing For TAP-tagged proteins 
Rna15 (CFIA complex) 3’-RNA processing For TAP-tagged proteins 
 
 
Table 23: Proteins analyzed by ChIP-qPCR in this study (all factors were analyzed wild-type and Spt5 ∆CTR 
yeast cells, except Spt5 (only analyzed in wild-type)) 
Protein Process involved ChIP protocol 
Rpb3 (Pol II) Gene transcription For TAP-tagged proteins 
Bur1 Pol II transcription elongation For TAP-tagged proteins 
Cet1 (mRNA capping enzyme) 5’-RNA processing (mRNA Capping) For TAP-tagged proteins 
Clp1 (CFIA complex) 3’-RNA processing For TAP-tagged proteins 
Ctk1 (CTDK-I complex) Pol II transcription elongation For TAP-tagged proteins 
Elf1 Currently not known For TAP-tagged proteins 
Hrp1 (also called CFIB) 3’-RNA processing For TAP-tagged proteins 
Paf1 (Paf1 complex) Pol II transcription elongation For TAP-tagged proteins 
Pap1 3’-RNA processing For TAP-tagged proteins 
Pcf11 (CFIA complex) Pol II transcription termination/ 3’-RNA 
processing 
For TAP-tagged proteins 
Rna14 (CFIA complex) 3’-RNA processing For TAP-tagged proteins 
Rna15 (CFIA complex) 3’-RNA processing For TAP-tagged proteins 
Spn1 Pol II transcription elongation For TAP-tagged proteins 
Spt4 Pol II transcription elongation For TAP-tagged proteins 
Spt5 Pol II transcription elongation For TAP-tagged proteins 
Spt6 Pol II transcription elongation For TAP-tagged proteins 
Spt16 (FACT complex) Pol II transcription elongation For TAP-tagged proteins 
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2.1 Molecular cloning and phenotyping of Spt5 ∆CTR yeast strains 
For the generation of the Spt5 ∆CTR (deleted residues: 931-1063) yeast strain, the kanMX6 
marker cassette was amplified from the plasmid pFA6a-3HA-kanMX6 (primers: 
Spt5∆CTR_Fw; Spt5∆CTR_Rev; Table 6). The PCR product was used for transformation of 
wild-type yeast (BY4741; no epitope-tag) and of various yeast TAP-strains listed in Table 4. 
Positive transformants were identified on G418 selective media plates. Yeast strains were 
validated by control PCR (primers: ∆CTR_cont1_Fw; ∆CTR_cont2_Fw; ∆CTR_cont3_Fw; 
∆CTR_cont1_Rev; ∆CTR_cont2_Rev; ∆CTR_cont3_Rev; Table 6) and DNA 
sequencing.Wild-type-pRS316 and Spt5 ∆CTR-pRS316 yeast strains were generated by 
transformation of the pRS316 plasmid into wild-type (BY4741; no epitope-tag) and Spt5 
∆CTR (no epitope-tag) cells, respectively. Positive transformants were identified on SC -ura 
plates. 
For growth curve measurements, overnight cultures of wild-type and Spt5 ΔCTR strains were 
diluted with fresh YPD medium to a starting OD600 of 0.1. Yeast cells were grown for 18 h 
and the OD600 was determined every 90 minutes. Biological triplicate measurements were 
performed and analyzed by Microsoft Excel 2007. Growth of wild-type and Spt5 ΔCTR 
strains was also tested on YPD plates at different temperatures. Cells were grown in YPD at 
30°C to stationary phase and diluted to OD600 ~ 1.0 with fresh medium. Equal amounts of 
cells were spotted on YPD plates in 20-fold serial dilutions. Plates were incubated at 16°C, 
30°C or 37°C, respectively, and inspected daily. To assess potential defects in transcription 
elongation, serial dilutions of the wild-type-pRS316 and the Spt5 ΔCTR-pRS316 strain were 
spotted on SC –ura plates containing 50 µg/mL 6-azauracil (6-AU) or 15 µg/mL 
mycophenolic acid (MPA) at 30°C.  
 
 
2.2  RNase-ChIP assay  
RNase-ChIP analysis was performed as described in section II 2.1 and according to (1), but 
with the following modifications. Firstly, the time of formaldehyde crosslinking was reduced 
from 20 min to 5 min. Secondly, the prepared chromatin was separated before the 
immunoprecipitation (IP) step. One chromatin sample was treated with 7.5 U of RNase A and 
300 U of RNase T1 (Ambion), the other sample was treated with the same volume of the 
RNase storage buffer. After incubating for 30 min at room temperature, the following steps 
were performed as described in section II 2.1. After qPCR the fold enrichment for different 
gene regions over an unoccupied genomic region was calculated as described in (83), but with 
the following modifications. The calculated fold enrichment values of the respective gene 
region were averaged between the different biological replicates. The fold enrichment values 
of chromatin samples that were not treated with the RNase-mix were averaged as well and set 
to 100%.  
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2.3 Rapid amplification of cDNA 3’-ends (3’-RACE) 
For RNA isolation, overnight yeast cultures were diluted in 50 mL fresh YPD medium to 
OD600 ~ 0.1 and grown at 30°C to mid-log phase (OD600 ~ 0.8). The RiboPure™-Yeast Kit 
(Applied Biosystems) was used to isolate yeast RNA according to the manufacturer’s 
instructions. 3’-RACE was performed for the ACT1 gene as described (89). This gene was 
shown to possess several alternative pA sites and was used in 3‘-end processing studies (3). 
The ACT1 cDNA was synthesized as described (3) using Superscript II reverse transcriptase 
(Invitrogen), 0.5 µM OligodT-anchor primer containing a XhoI restriction site and 2 µg RNA 
template. Next, RNA was digested using RNase H (New England BioLabs Inc.) for 20 
minutes at 37°C. The enzyme was inactivated by incubation at 65°C for 20 min. PCR 
reactions were conducted using 2 µL of the cDNA samples, 0.25 µM gene-specific Upstream 
primer 1 containing an EcoRI restriction site, the Anchor primer 2 and Taq DNA Polymerase 
(Fermentas, Thermo Fisher Scientific). The PCR product and the pET28b(+) vector were 
digested with EcoRI-HFTM as well as XhoI (New England BioLabs Inc.) and then ligated and 
transformed into competent E. coli XL1-blue cells. Plasmids from at least three different 
clones were sequenced (GATC Biotech) using pET28b(+) Sequencing primer 1 and 2. The 
sequences of the corresponding primers are listed in Table 6.  
 
 
2.4  Pol II readthrough assay  
The readthrough was performed for the PMA1 gene according to (3), using the gene-specific 
forward primer RTh1 and five reverse primers (RTh2 to RTh6; Table 6)) positioned at 
different regions downstream of the transcription termination site. RNA isolation, reverse 
transcription and PCR were conducted as described in 3’RACE and the PCR products for 
wild-type and Spt5 ΔCTR mutant were analyzed by standard agarose gelelectrophoresis. 
 
 
2.5  GST pull-down assay 
To prepare yeast cell lysates, cell lysis was performed as for ChIP experiments but with the 
following modifications: (i) cell cultures were grown in 200 mL YPD medium at 30°C but not 
crosslinked with formaldehyde; (ii) phosphatase inhibitors (PhoI) were added to the FA lysis 
buffer at all steps; (iii) cell debris was removed by centrifugation. A synthetic DNA construct 
of the GST tag based on the pGEX3T vector fused to the DNA sequence coding for Spt5 CTR 
residues 931-1063 (343) was synthesized (Mr Gene GmbH, Regensburg, Germany) and 
cloned into vector pET28b(+) (Table 21). Expression of the GST-Spt5CTR fusion construct 
(pET28b(+)) and the GST tag alone (pGEX-4T-1) in E. coli was induced with 0.5 mM IPTG 
at 18 °C over night in 1 L cultures. Cells were lysed by sonification in 50 mL GST lysis 
Buffer for 15 minutes (Branson Sonifier 250). The cell debris was removed by centrifugation. 
For pull-down experiments, E. coli cell lysates were incubated with 100 µL Glutathione 
Sepharose beads (GE Healthcare), pre-equilibrated in GST lysis Buffer for 1 h at 4°C. Beads 
were washed 8x with GST lysis Buffer and incubated for 1 h at room temperature with 300 
µL Rna14-TAP yeast cell lysate. Next, beads were washed 8x with GST lysis Buffer and 
proteins were eluted from the beads 8x with GST lysis Buffer containing 10 mM glutathione. 
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All elution fractions were pooled and the protein precipitated with 10% trichloroacetic acid 
(TCA). The protein pellet was washed with ice-cold acetone and resuspended in 2x SDS-
PAGE loading buffer. Wash and elution fractions were analyzed by SDS-PAGE and Western 
blotting with antibodies against the TAP-tag of Rna14 (PAP, Sigma-Aldrich) and the GST-tag 
(RPN1236, GE Healthcare). To test whether the interaction depends on phosphorylation, the 
GST pull-down assay was performed with the following modification: 5 mM fresh ATP was 
added to the Rna14-TAP yeast cell lysate before incubation with Glutathione Sepharose 
beads. The buffers are listed in Table 14. 
 
 
2.6  Quantitative Western blot analysis 
Western Blot analysis was performed as described in section II 2.7, but with the following 
modifications. For evaluation of the GST pull-down experiments the membrane was probed 
with the PAP antibody against the TAP-tag of Rna14 (PAP, P1291, Sigma-Aldrich) and the 
GST antibody (RPN1236, GE Healthcare, Chalfont St. Giles, UK). For quantitative Western 
Blot analysis, quantification of the Spt5 protein levels in wild-type and Spt5 ΔCTR cells was 
performed with total protein samples using an antibody against the N-terminus of Spt5 (yN-
20; Table 9) as well as the α-Tubulin antibody (3H3087; Table 9). The antibody signal was 
detected quantitatively using the Pierce® ECL Western Blotting Substrate and the LAS-3000 
camera (FUJIFILM, Tokyo, Japan). Spt5 protein signals were quantified relatively to the α-
Tubulin signals using the ImageQuant 5.0 software (Molecular Dynamics).  
 
 
 
3. Results 
3.1  Investigation of elongation factor recruitment by the Spt5 CTR 
To investigate whether the function of the yeast Spt5 CTR in recruiting Pol II-associated 
factors extends to elongation factors other than Paf1 (187, 343), we carried out ChIP analysis 
in strains lacking the Spt5 CTR. We generated a yeast strain with a CTR deletion (described 
in section V 2.1). As reported previously, CTR deletion led to 6-AU sensitivity and a slow-
growth phenotype at 16°C (187, 343). We also observed a slight growth defect at 30°C, but 
not at 37°C. In contrast to observations in S. pombe (271), the morphology of S. cerevisiae 
was not altered upon CTR deletion (not shown). Quantitative Western blot analysis revealed 
approximately two-fold higher Spt5 protein levels in cells lacking the CTR. 
 
For ChIP analysis, we fused a tandem affinity purification (TAP) tag to the C-terminus of 
elongation factors in the CTR deletion background. The occupancy levels of the elongation 
factors were determined by ChIP at different positions of genes ADH1, ILV5, PDC1, PMA1 
and TEF1. We chose these genes for several reasons. Firstly, these genes encode 
housekeeping proteins, are highly expressed (70), and are heavily occupied by Pol II in the 
mid-log phase of yeast growth (199). Secondly, their DNA elements, including the 
transcription start site (TSS) and the pA site, are well characterized (64, 155, 219). Thirdly, 
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the transcription unit is long enough to distinguish between different binding levels at distinct 
positions of the gene. The primers used are lited in Table 7. 
We performed ChIP analyses for eight Pol II elongation factors that belong to the three 
different groups described recently (199): (i) Spt4 and Spt6 (group 1), (ii) Elf1 and Spn1 
(group 2), (iii) Bur1, Ctk1, Paf1 and Spt16 (group 3). The results are shown in Figure 30. 
These data revealed strong factor binding at all tested genes. A severe decrease in Paf1 
occupancy to about 20% was detected at the ADH1 gene (Figure 30 b), consistent with 
previous reports (187, 343) and providing a positive control. The difference in Paf1 
occupancy was not due to a difference in Pol II occupancy, which was unaffected by CTR 
deletion (Figure 30 b). However, the other representative elongation factors tested did not 
show significant differences in their gene occupancies, showing that CTR deletions 
specifically reduce gene occupancy of Paf1. 
An overview of all factors that were analyzed by ChIP and ChIP-chip in this study is given in 
Table 22 and 23.  
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3.2  Spt5 CTR is required for recruitment of CFI in vivo 
Since Spt5 co-localizes with 3’-processing factors (155, 199, 311) and co-purifies with these 
factors (184), we tested whether it plays a role in the recruitment of 3’-processing and 
transcription termination factors. ChIP analysis revealed that all CFIA subunits, Clp1, Pcf11, 
Rna14, and Rna15, showed high occupancy at the 3’-end of protein-coding genes and the pA 
site (Figure 31). In Spt5 ∆CTR cells, occupancy of Clp1, Rna14, and Rna15 was reduced 
more than 50% at the ADH1 gene, and also markedly lower at other tested genes (Figure 1 
a,c). However, we observed no difference in the occupancy of Pcf11 between wild-type yeast 
and Spt5 ∆CTR cells (Figure 31 a). 
Figure 30: Spt5 CTR recruits Paf1 but no other 
Pol II transcription elongation factors investigated 
in this study. (A) ChIP analyses of group 1 (Spt4, 
Spt6), group II (Elf1, Spn1) and group III (Bur1, 
Ctk1, Spt16) transcription elongation factors. 
Although Spn1 occupancy seems to be slightly 
reduced towards the 3’-end of the ADH1 gene in Spt5 
∆CTR cells as compared to wild-type cells, the 
differences are within the standard deviation and 
therefore are not significant. (B) ChIP occupancies 
for the transcription elongation factor Paf1 and Pol II 
(Rpb3). The fold enrichments over a nontranscribed 
region that is located near the centromere of 
chromosome V are given for the transcription start 
site (TSS), the open reading frame (ORF) region, the 
polyadenylation (pA) site as well as for the region 3’ 
of the pA site of the ADH1 gene. The ChIP 
occupancies are indicated for wild-type and Spt5 
∆CTR cells as black and gray bars, respectively. The 
standard deviations refer to at least two independent 
ChIP experiments. 
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 Since CFIA is associated with CFIB/Hrp1, we investigated whether Hrp1 occupancy 
was affected by CTR deletion. Previous ChIP analyses have shown that Hrp1 crosslinks 
throughout the coding regions until the 3’-end of genes (155, 162). Our ChIP analysis 
revealed that Hrp1 shows strongest occupancy near the pA site, although it is recruited earlier 
than CFIA subunits (Figure 31 b). Similar to CFIA subunits, Hrp1 binding was markedly 
reduced in Spt5 ∆CTR cells (Figure 31 b). However, no occupancy difference could be 
observed for the poly(A) polymerase Pap1 (Figure 31 d), which is also required for 3’-end 
processing (195, 206). Taken together, the Spt5 CTR plays a crucial role in recruitment of 
CFI, but not of Pap1, to the 3’-end of protein-coding genes. 
 
 
 
 
 
Figure 31: ChIP analyses reveal that 
CFI (a-c) but not Pap1 (d) is markedly 
reduced in Spt5 ∆CTR cells. (a) 
Occupancy of CFIA subunits, except for 
Pcf11, as well as (b) CFIB (Hrp1) is 
strongly reduced at the ADH1 gene in 
Spt5 ∆CTR cells. (c) The CFIA core 
subunit Rna15 is also reduced at other 
genes, including ILV5, PDC1 and TEF1. 
(d) Pap1 occupancy is not altered in Spt5 
∆CTR cells. The color code is as in Figure 
3. The standard deviations refer to at least 
two independent ChIP experiments. 
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3.3  Spt5 CTR interacts with CFI in vitro 
Since CFI recruitment to genes was impaired upon CTR deletion, we asked whether there is a 
physical interaction between the Spt5 CTR and CFI. We performed pull-down experiments 
with a recombinantly expressed glutathione S-transferase (GST)-tagged version of the Spt5 
CTR and yeast cell lysates, prepared from an Rna14-TAP strain. Western blot analysis of the 
eluates with antibodies directed against the GST tag and the TAP tag of Rna14 revealed a co-
precipitation of the GST-tagged Spt5 CTR and the CFI subunit Rna14, but not with GST 
alone (Figure 32). Pull-down experiments in the presence and absence of phosphatase 
inhibitors and an excess of kinase substrate ATP revealed no differences in the amount of 
Rna14 that co-precipitated with Spt5 CTR (not shown). These experiments revealed an 
apparently phosphorylation-independent previously unobserved interaction between the Spt5 
CTR and CFI in vitro. Since the interaction was detected with the use of a lysate that naturally 
contains many non-specific competitor proteins, and since it was not observed with the GST 
tag alone, it must be regarded as being highly specific. It is however possible that the 
interaction is mediated by other proteins in the extract and thus indirect. 
 
 
 
 
 
 
 
3.4  RNA contributes to CFI recruitment 
Since deletion of the Spt5 CTR led to a marked reduction in the occupancy of CFI subunits, 
but not to a complete loss, we asked which factors contribute to the residual binding of CFI. 
Since Rna15 and Hrp1 contain RNA recognition motifs that are known to bind RNA 
sequences in vitro (150, 181, 233, 238), we reasoned that nascent RNA may contribute to CFI 
recruitment. To address this, we performed an RNase-ChIP assay (1). In this assay, RNA is 
digested before the immunoprecipitation step, leading to a drop in factor occupancy if factor 
recruitment in vivo involves RNA. 
We performed RNase-ChIP for Rna15 and Rna14 (Figure 33). Firstly, we observed a decrease 
in Rna15 occupancy after RNase treatment, indicating an important role of RNA in Rna15 
recruitment, both in wild-type and Spt5 ΔCTR cells (Figure 33 a). Secondly, Rna15 binding 
most strongly depended on RNA around the pA site of the ADH1 gene. Thirdly, the strongest 
reduction in Rna15 occupancy was observed when both the Spt5 CTR was deleted and when 
RNA was removed by RNAse treatment. The additional decrease of the Rna15 occupancy 
level was highly reproducible and could be observed in all four independent biological 
Figure 32: The Spt5 CTR interacts with Rna14 
in vitro. GST pull-down experiments were 
performed with a GST-Spt5 CTR fusion protein 
(GST-CTR), with GST alone (GST) and without 
protein (-), serving as negative control. Western 
Blotting was performed for the last washing 
fractions (W), the combined elution fractions (E) 
of the respective sample as well as for 1% of the 
Rna14-TAP lysate (Input) with antibodies against 
the TAP tag of Rna14 and the GST tag.  
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replicates. A similar RNA dependence could be observed for Rna14, although the additional 
decrease of Rna14 occupancy in Spt5 ∆CTR cells was not as prominent as for Rna15 (Figure 
33 b). These results indicate that RNA contributes to CFI recruitment in vivo and that this can 
explain residual recruitment of CFI in cells lacking the Spt5 CTR. 
 
 
 
 
Figure 33: RNAse-ChIP assays reveal that RNA contributes to CFI recruitment in Spt5 ∆CTR cells. RNA-dependent 
binding of (a) Rna15 and (b) Rna14 (same color code as in (a)) is given for the ORF region, the pA site and a region 3’ of the 
pA site of the ADH1 gene. The ChIP occupancy signal without RNase treatment (black) was set to 100%. The relative ChIP 
signals for wild-type (dark gray) and Spt5 ∆CTR cells (light gray) after RNase treatment are indicated as well. In case of 
Rna15, the corresponding percentages are given above the bars. The standard deviations refer to four independent RNase 
ChIP experiments.  
 
 
 
3.5  CFI co-localizes with the Ser2-phosphorylated CTD downstream of the pA site 
It was shown for mammalian cells that homologs of the yeast CFI complex are already 
recruited at the promoter region of genes (105, 299). One study in yeast showed that some 
RNA 3’-processing factors, including Rna14 and Rna15, also crosslinked to the promoter and 
the early coding region of the PMA1 gene, but not at other genes tested (155). However, our 
ChIP analysis (Figure 31) and published data in yeast (155, 182) suggested that CFI subunits 
crosslinked near the pA site at the 3’-end of genes. 
To investigate the preferred location of CFI subunits on a genome-wide level, we performed 
ChIP-chip analysis for Rna14 and Rna15. This revealed CFI recruitment at all protein-coding 
genes that are occupied by Pol II and its elongation factors (199). The ChIP-chip profiles 
showed sharp occupancy peaks for Rna14 and Rna15 105 (± 10) nucleotides and 108 (± 6) 
nucleotides downstream of the pA site, respectively (Figure 34 a). We also detected weak 
Rna14 and Rna15 binding over the transcribed region, with an increase towards the 3’-end. 
These profiles were independent of gene length (not shown). Comparison with previous 
profiles (199) revealed that peak occupancies of Rna15 and Rna14 coincided with Pcf11 
occupancy, which peaked 52 (± 7) nt downstream of the pA site (Figure 34 a). CFI subunit 
peak occupancies further occured in a region where the occupancies for Spt5 and the S2-
phosphorylated Pol II were high (Figure 34 b). The sharp occupancy drop-off of CFI subunits 
coincided with the drop-off for the ChIP signal of the S2-phosphorylated CTD, consistent 
with a role of the S2-phosphorylated CTD in CFI recruitment. 
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3.6  CTR deletion does not impair termination 
Previous studies showed that mutations in Pcf11, Rna14, and Rna15 can lead to defects in 
transcript cleavage and readthrough transcription beyond the termination site (10, 28, 249). 
We therefore investigated whether the reduced level of CFI recruitment observed in Spt5 
ΔCTR cells leads to Pol II readthrough transcription at the ACT1, PMA1 and RNA14 genes. 
To detect transcriptional readthrough, we chose a PCR-based method with a gene-specific 
forward primer and different reverse primers positioned downstream of the normal transcript 
termination site, as described (3) (Figure 35 a). In this assay, a prolonged transcript resulting 
from readthrough transcription would be detected by the generation of PCR products with a 
reverse primer that is located downstream of the termination site. As shown in Figure 35 b, no 
differences in the PCR products, and thus the length of the PMA1 transcripts, were observed 
between wild-type and ΔCTR cells. Similar results were obtained for the ACT1 and RNA14 
genes (not shown). Thus, deletion of the Spt5 CTR does not result in a termination defect that 
would be detected by transcriptional readthrough. 
Figure 34: Genome-wide ChIP-chip 
occupancy profiling of CFI subunits in 
yeast. (a) Gene-averaged profiles for the long 
gene length class (2,350 ± 750 nucleotides, 299 
genes, see methods) of Pcf11 (199), Rna14, 
and Rna15. (b) Gene-averaged profiles as in 
(a) for Pol II in wild-type and Spt5 ∆CTR 
cells, the Ser2-phosphorylated CTD form of 
Pol II (199) and the transcription elongation 
factor Spt5 (199). Occupancies and signal 
intensities are given for Spt5 and Pol II 
(including the Ser2-phosphorylated form) on 
the left and right y-axes, respectively. Dashed 
black lines indicate the TSS and pA site. 
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Although we did not detect readthrough transcription at tested single genes, it may still occur 
at other genes. To investigate this, we measured high-resolution ChIP-chip occupancy profiles 
for the Pol II core subunit Rpb3 in wild-type and mutant yeast cells lacking the CTR. The 
high correlation between the Pol II profiles (Pearson R = 0.89) and the high similarity of the 
gene-averaged profiles (Figure 34 b) however indicated no difference in Pol II occupancy 
between wild-type and mutant cells. In addition, a difference profile calculated from Rpb3 
occupancy in ∆CTR and wild-type cells did not reveal any clusters of altered occupancy. 
These results show that transcription readthrough does not occur in the ∆CTR strain. 
 
 
 
3.7  CTR deletion does not alter pA site usage 
Since mutations of 3’-end processing factors were also shown to result in the usage of 
alternative pA sites (194), we investigated whether CTR deletion and the resulting reduction 
in CFI recruitment lead to alternative pA site usage. To detect a possible change in the usage 
of pA sites in vivo, we used rapid amplification of cDNA 3’-ends (3’-RACE), which allows 
for a mapping of the 3’-ends of transcripts (89). We performed 3’-RACE for the ACT1 and 
PMA1 genes, which possess five and two pA sites, respectively (Figure 35 c; (155, 194)). The 
Figure 35: Spt5 CTR deletion provokes 
neither transcriptional readthrough of Pol II 
nor alternative pA site usage. (A) Schematic 
representation of the yeast PMA1 locus. The ORF 
region and the two pA sites according to (3) are 
indicated by a box and vertical arrows, 
respectively. The forward primer (fw) and 
different reverse primers (1 rev to 5 rev) that 
were used for Pol II readthrough detection are 
depicted as horizontal arrows. (B) Agarose 
gelelectrophoresis of the 5 PCR products as 
described in (A) for wild-type (wt) and Spt5 
∆CTR cells (∆CTR). No differences in the length 
of the PCR products could be detected between 
wild-type and Spt5 ∆CTR cells. The height of the 
marker lanes in base pairs (bp) are shown on the 
left. (C) The nucleotide sequence of the 3’-region 
of yeast ACT1 is shown. Key sequence elements 
are labeled. The RNA cleavage and pA sites as 
determined by 3’RACE map to the same region 
for wild-type (green boxes) and Spt5 ΔCTR cells 
(yellow boxes). 
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experiments revealed multiple pA sites for the ACT1 gene, which map to a distinct region at 
the 3’-end of the gene, 1508-1553 nucleotides from the TSS. However, no differences of the 
pA site pattern could be detected between wild-type and Spt5 ΔCTR cells (Figure 35 c). 
Similar results were obtained for the PMA1 gene (not shown). Thus a reduced level of CFI 
recruitment in Spt5 ∆CTR cells does not lead to altered pA site usage in vivo. 
 
 
 
4. Discussion 
Two major transitions occur during the Pol II transcription cycle, the initiation-elongation 
transition at the 5’-end of genes, and the elongation-termination transition at the 3’-end of 
genes, which is coupled to 3’-RNA processing. Whereas the first transition was extensively 
studied (243), less is known about the second transition. Studies of the second transition 
revealed a role of the Ser2-phosphorylated Pol II CTD in the recruitment of 3’-processing and 
termination factors (3). This transition also involves the Paf1 complex (135, 214, 225), 
elongation factor Spt6 (144), and the transcription regulator Sin1 (122). In this work we 
provide evidence for a role of the Spt5 CTR in the elongation-termination transition, in 
particular in the recruitment of the essential mRNA 3’-processing factor CFI. 
 
 
 
4.1  Paf1 complex-independent recruitment of CFI 
There is evidence that recruitment of RNA 3’-processing factors also involves the Paf1 
complex (Paf1C). Deletion of subunits of Paf1C reduces the recruitment of Pcf11 (214) and 
interferes with Pol II binding of Cft1 (225), a component of the yeast CPF complex. Since 
Paf1 occupancy levels are markedly reduced in Spt5 ∆CTR cells, it may be argued that 
recruitment of CFI may occur via Paf1C and the observed reduction of CFI subunit 
occupancy may result from a loss of Paf1C. However, several lines of evidence argue against 
this model and instead argue that CFI recruitment occurs via a direct interaction with the 
CTR. Firstly, Pcf11 occupancy is not altered in Spt5 ∆CTR cells, despite the loss of Paf1C 
(Figure 31). Secondly, despite extensive interactomics studies, physical interactions between 
Paf1C and CFI have never been observed. Thirdly, Paf1C clearly dissociates from the Pol II 
elongation complex upstream of the pA site (72, 155, 199), whereas CFI subunits are mainly 
recruited downstream of the pA site (Figure 34 a, (72, 155, 199)). These results argue for a 
Paf1C-independent mechanism of CFI recruitment in yeast. 
 
 
 
4.2  Spt5 CTR is not required for normal pA site usage and transcription 
termination 
The genes coding for the CFIA subunits Clp1, Pcf11, Rna14 and Rna15 are essential for 
viability in yeast (6, 99, 210). Therefore, deletion of these genes cannot be performed for 
functional studies. To circumvent this problem, temperature-sensitive rna14 and rna15 
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mutants were generated to reveal that Rna14 and Rna15 are required for RNA cleavage and 
polyadenylation, mRNA stability, poly(A) tail length, pA site choice and for the sequestration 
of small nucleolar ribonucleoproteins at discrete sites in the nucleus (3). Since the Rna14 and 
Rna15 occupancy levels were strongly reduced in cells lacking the CTR of Spt5, we asked 
whether this reduction could lead to similar 3’-end processing defects in vivo. However, our 
analyses have shown that neither the pA site usage nor transcription termination at selected 
genes or genome-wide is altered in yeast cells lacking the CTR of Spt5. This is consistent 
with the non-essential nature of the Spt5 CTR in yeast and may be due to residual CFI 
recruitment in Spt5 ∆CTR cells that likely results from binding of the CFI subunits to RNA 
and from the binding of  Pcf11 to the Pol II CTD. Pcf11 contains an essential CTD interaction 
domain (CID), which directly binds the Ser2-phosphorylated CTD (182, 201, 266), and may 
be responsible for normal recruitment of Pcf11 to genes upon CTR deletion. These 
observations indicate that CFI is recruited to a defined region downstream of the pA site by 
co-operative interactions with the Pol II CTD, the Spt5 CTR, and nascent RNA (Figure 36). 
This model is consistent with the reported binding of Rna14 and Rna15 to the phosphorylated 
CTD (15), and other published data. Rna15 can be cross-linked to RNA by UV light (150) 
and contains a RNA recognition motif (RRM) domain that binds GU-rich RNA in vitro (181, 
233). Hrp1 has two RRMs that bind to AU-containing RNAs (238). The recruitment of CFI 
within a narrow region downstream of the pA site and the absence at the promoter region of 
genes in yeast is in contrast to observations made in mammalian cells. In mammals, 3’-RNA 
processing factors, including homologs of yeast CFI, are already recruited at the promoter 
region of genes (61, 105, 299). It is currently not known what role, if any, 3’-RNA processing 
factors may play at the 5’-end of mammalian genes. 
 
 
 
Figure 36: Model of CFI recruitment in yeast. The complete yeast Pol II elongation complex with bound Spt4/5 is viewed 
from the back (198). Pol II and Spt4/5 are shown as molecular surfaces with key domains highlighted in color and labeled. 
Exiting RNA, the C-terminal KOW domains and the CTR of Spt5, and the Pol II CTD extend towards the same side around 
the Rpb4/7 subcomplex, providing the main interfaces for CFI recruitment. Rna14 may directly contact the Spt5 CTR, 
whereas the RNA is bound by the C-terminal RRM domain of Rna15 and by two internal RRM domains of Hrp1. The Pol II 
CTD is mainly bound by the N-terminal CID domain of Pcf11. CFI subunits are drawn to scale. Important protein domains 
are illustrated as extensions from the respective protein core. 
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4.3  A role of Spt5 in coupling transcription and translation 
Finally, our results have implications for understanding the evolution of transcription-coupled 
events. Spt5 represents the only known RNA polymerase-associated factor that is conserved 
in all three domains of life (320), and its bacterial homologue is called NusG (118). All Spt5 
homologues contain two conserved domains, the NusG N-terminal domain (NGN) and a C-
terminal KOW domain (124). Whereas the NGN domain binds to the polymerase clamp 
domain and closes the active center cleft to render transcription processive, the KOW domain 
extends from the polymerase surface towards exiting RNA (159, 198, 211) (Figure 36). In 
bacteria, the KOW domain interacts with the ribosome, thus coupling transcription to mRNA 
translation (38, 248). In eukaryotes, transcription and translation take place in different 
cellular compartments, and any coupling between these processes likely occurs via the mRNA 
that exits the nucleus (127, 197). Our data indicate that the CTR of Spt5 contributes to the 
coordination of transcription with 3’-RNA processing, which in turn is coupled to mRNA 
export (140, 192, 254). Since the CTR occurs only in eukaryotic Spt5 homologues, it is likely 
that it emerged in evolution to maintain coupling between transcription and translation after 
the spatial separation of these processes. Such coupling may be achieved by co-transcriptional 
Spt5-dependent loading of mRNA export factors onto the nascent RNA, before its maturation, 
nuclear export, and translation in the cytosol. 
 
 
 
5. Conclusions and Outlook 
This work reveals a new role of the Spt5 CTR in the Pol II transcription elongation-
termination transition, in particular in the recruitment of the essential 3’-RNA processing 
factor CFI. ChIP analyses in wild-type and Spt5 ∆CTR yeast cells detected a reduction in the 
occupancy of Paf1 as was already described by others, but also of CFI subunits, indicating 
impaired CFI recruitment to the 3’-end of genes in vivo. A pull-down assay additionally 
revealed an interaction between the CFI subunit Rna14 and the Spt5 CTR in vitro. RNA 
contributes to CFI recruitment, as RNAse treatment prior to ChIP further decreases CFI ChIP 
signals. Genome-wide profiling by ChIP-chip revealed a sharp occupancy peak of the CFI 
core subunits Rna14 and Rna15 around 100 nt downstream of the pA site, which coincides 
with high occupancy of Spt5 and the CTD Ser2-phosphorylated form of Pol II. These 
observations lead to a model, according to which CFI is recruited to a defined region 
downstream of the pA site of genes by cooperative binding to the Spt5 CTR, nascent RNA 
and the Ser2-phosphorylated CTD of Pol II. Consistent with this model, the CTR is not 
required for pA site recognition and transcription termination in vivo. 
 
Based on these findings new questions arise that can be tackled in follow-up studies. First, we 
confirmed that Paf1 interacts with the Spt5 CTR in vivo. However, Paf1 represents only one 
subunit of the Paf1 complex. The Paf1 complex consists of Paf1, Ctr9, Cdc73, Rtf1 and Leo1 
in yeast (135). It is currently not known which subunit(s) directly contact the Spt5 CTR. This 
question can be addressed by in vitro binding assays with CTR peptides. As soon as the 
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subunit of the Paf1 complex that mediates the interaction with the Spt5 CTR is identified, the 
binding interface can be characterized in more detail. For example this could be done by co-
crystallization trials with the respective subunit and CTR peptides.    
Second, our analysis revealed a new interaction between the CFI and the CTR of Spt5. 
However, the details of this interaction are not known. Since CFI also represents a 
multiprotein complex, the same approaches, as mentioned for the Paf1 complex, can be 
applied to characterize the binding interface between CFI and the Spt5 CTR. 
Third, our data provides strong evidence for CFI to bind to nascent RNA in vivo. One way to 
characterize the RNA binding interface on a genome-wide scale is by the application of NET-
seq and PAR-CLIP. These approaches bear the potential to identify preferred RNA sequence 
motifs that are bound by the protein of interest.   
Fourth, our study indentified CFI as a Spt5 CTR binding complex in vivo. It remains to be 
determined whether other factors also contact the CTR. An unbiased approach would be to 
combine an affinity-purification assay, for example with a GST-CTR construct, and mass 
spectrometry. The new interactions that may be discovered by this approach can in turn be 
investigated in a next round of follow-up projects. 
Fifth, the Spt5 CTR can be phosphorylated by the Pol II CTD kinase Bur1 (187). Currently, it 
is not known whether the CTR is phosphorylated in vivo and if so, what the biological 
implications of this modification are. One way to characterize the post-translational 
modification status of the Spt5 CTR is via mass spectrometry. Another way would be to 
generate an antibody that specifically recognizes the phospho-CTR. This antibody can then be 
used in ChIP experiments to reveal possible changes in the CTR-phosphorylation pattern in 
the course of the transcription cycle.    
The Spt5 CTR of yeast Saccharomyces cerevisiae (S. cerevisiae) consists of 15 hexapeptide 
repeats. However, many of those repeats differ strongly from the consensus sequence. 
Furthermore, the deletion of the Spt5 CTR has almost no phenotypic effects for S. cervisiae 
cells. However, in fission yeast Schizosaccharomyces pombe (S. pombe) the deletion of the 
Spt5 CTR leads to a slow-growth phenotype and an abnormal cell morphology (271). In 
fission yeast the CTR of Spt5 comprises 18 nonamer repeats. In contrast to S. cerevisiae, the 
repeats are much more consensus-like. Additionally, the capping enzyme binds to the Spt5 
CTR in S. pombe (236) but not in S. cerevisiae. Given the obvious differences of the Spt5 
CTR function in both model organisms, it would be very worthwhile to extend the analyses to 
S. pombe cells. To figure out the similarities and dissimilarities of the CTR function between 
budding and fission yeast, would shed light on the evolution of the CTR as well as the co-
evolution of CTR and its binding partners. 
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